Glycosylated kinamycins and methods of making and using them

ABSTRACT

The invention provides compositions, including pharmaceuticals, comprising glycosylated kinamycins. The compositions and methods of the invention can be used to treat infections, i.e., as antibiotics, and as anti-tumor agents. The compositions of the invention can also act as act as electrophilic azo-coupling agents in vitro or in vivo. The invention also provides enzymes capable of generating kinamycin, nucleic acids that encode them, antibodies that bind to them, and methods for making and using them.

TECHNICAL FIELD

[0001] This invention generally pertains to the fields of medicine and bacteriology. Specifically, the compositions of the invention comprise glycosylated kinamycins. The compositions and methods of the invention can be used to treat infections, i.e., as antibiotics, and as anti-tumor agents. The compositions of the invention can also act as act as electrophilic azo-coupling agents in vitro or in vivo. The invention also provides enzymes capable of generating kinamycin, nucleic acids that encode them, antibodies that bind to them, and methods for making and using them.

BACKGROUND

[0002] Kinamycins, a class of type II polyketides, are used to treat infections, as described, e.g., in “Structures and biological properties of Kinamycin A, B, C, and D,” Chem Pharm Bull (Tokyo), 1973 May;21(5):931-40; and, “A new antibiotic, kinamycin: fermentation, isolation, purification and properties,” J. Antibiot. (Tokyo). 1971 June, 24(6):353-9. The genes for most of the biosynthesis of kinamycin from Streptomyces murayamaensis have been cloned and heterologously expressed, see, e.g., Gould, et al., J. Antibiot. (Tokyo) 1998 January;51(1):50-7. It has been speculated that kinamycins owe their anti-tumor and antibiotic properties to their ability to act as electrophilic azo-coupling agents in vivo, see, e.g., Laufer, et al., J. Am. Chem. Soc. Mar. 6, 2002;124(9):1854-5.

SUMMARY

[0003] The invention provides glycosylated kinamycins and polyketides comprising glycosylated kinamycins. The compositions and methods of the invention can be used to treat infections, i.e., as antibiotics, and as anti-tumor agents. The compositions of the invention can also act as act as electrophilic azo-coupling agents in vitro or in vivo.

[0004] These compositions can be made using in vivo systems (e.g., in bacteria or using bacterial extracts, or equivalents) and then isolated, or, they can be partly or entirely made by synthetic procedures. In one aspect, the isolated or synthetically made glycosylated polyketide comprises least one saccharide moiety. The saccharide can comprise one or more polysaccharides. In one aspect, the saccharide comprises a 2, 6 dideoxysugar, such as a digitose, e.g., an L-digitose. The saccharide can also comprise an olivose, a lactose, a galactose, a glucose or a fructose. The polyketide can comprise a type II polyketide, such as a kinamycin. The kinamycin can comprise an aglycone kinamycin. The invention also provides isolated kinamycin molecules, wherein the kinamycin molecule comprises at least one saccharide moiety.

[0005] The invention provides pharmaceutical compositions comprising a polyketide, wherein the polyketide comprises a kinamycin comprising at least one saccharide moiety, and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a kinamycin, wherein the kinamycin comprises at least one saccharide moiety, and a pharmaceutically acceptable carrier. In the pharmaceutical compositions of the invention, any pharmaceutically acceptable carrier can be used, e.g., the pharmaceutically acceptable carrier and/or the pharmaceutical compositions can be solids or liquids. In one aspect of the pharmaceutical compositions, the saccharide comprises one or more polysaccharides. The saccharide can comprise a 2, 6 dideoxysugar, such as a digitose. The digitose can comprise an L-digitose. The saccharides can comprise an olivose, a lactose, a galactose, a glucose or a fructose. The polyketide can comprise a type II polyketide. The kinamycin can be an aglycone kinamycin.

[0006] The invention provides polyketides comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated polyketide comprising a glycosylated kinamycin. The process can further comprise isolating the glycosylated kinamycin. The polyketides can comprise a type II polyketide. The glycosylation can comprise a saccharide. The saccharide can further comprise a polysaccharide. The saccharide can comprise a 2, 6 dideoxysugar, such as a digitose, e.g., an L-digitose. The saccharide can comprise an olivose, a lactose, a galactose, a glucose or a fructose. The kinamycin can be an aglycone kinamycin. In the process, the Streptococcus sp. of step (b) can be a S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus, a S. violaceoruber, or a S. diversa. The Dactylosporangium sp. of step (b) can be a Dactylosporangium sp. ATCC 53693.

[0007] The invention provides an isolated glycosylated kinamycin made by a process comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin. In the process, the Streptococcus sp. of step (b) can be a S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus, a S. violaceoruber, or a S. diversa. The.Dactylosporangium sp. of step (b) can be a Dactylosporangium sp. ATCC 53693.

[0008] The invention provides a method for making a composition comprising a glycosylated kinamycin comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; (c) inserting the nucleic acid into the Streptococcus sp. of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin. In one aspect, the method further comprises isolating the glycosylated kinamycin. The polyketide can comprise a type II polyketide. The glycosylation can comprise a saccharide. The saccharide can further comprise a polysaccharide. The saccharide can comprise a 2, 6 dideoxysugar, such as a digitose, e.g., an L-digitose. The saccharide can comprise an olivose, a lactose, a galactose, a glucose or a fructose. The kinamycin can be an aglycone kinamycin. The Streptococcus sp. of step (b) can be a S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus or a S. violaceoruber, or extracts thereof, or equivalents thereof. The Dactylosporangium sp. of step (b) can be a Dactylosporangium sp. ATCC 53693, or extracts thereof, or equivalents thereof.

[0009] The invention provides an isolated composition comprising a compound having a general formula as set forth as DS2 in FIG. 3. The invention provides an isolated composition comprising a compound having a general formula as set forth as DS1a in FIG. 1. These compositions can further comprise a saccharide, such as a 2, 6 dideoxysugar, e.g., a digitose, such as an L-digitose. The saccharide also can comprise an olivose, a lactose, a galactose, a glucose or a fructose.

[0010] The invention provides an isolated composition comprising a compound having a general formula as set forth as DS1 in FIG. 1. The invention also provides compounds having a general formula as set forth as DS1 with different or more saccharide moieties, such as a 2, 6 dideoxysugar, e.g., a digitose, such as an L-digitose. The alternative saccharides also can comprise an olivose, a lactose, a galactose, a glucose or a fructose.

[0011] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence having 95% sequence identity to SEQ ID NO:1, wherein the nucleic acid, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus. The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence as set forth in SEQ ID NO:1, wherein the nucleic acid, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus.

[0012] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:2, wherein the sequence identity is at least 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:2; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:2; or (d) encoding a polypeptide as set forth in SEQ ID NO: 3. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:3, wherein the sequence identity is at least 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:3; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 1 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 594 residues in length.

[0013] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:4, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:4; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:4; or (d) encoding a polypeptide as set forth in SEQ ID NO:5. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:5, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:5; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 2 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 171, residues in length.

[0014] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:6, wherein the sequence identity is at least 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:6; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:6; or (d) encoding a polypeptide as set forth in SEQ ID NO:7. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:7, wherein the sequence identity is at least 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:7; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 3 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 132 residues in length.

[0015] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:8, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:8; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:8; or (d) encoding a polypeptide as set forth in SEQ ID NO:9. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:9, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:9; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 4 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 244 residues in length.

[0016] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:10, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:10; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:10; or (d) encoding a polypeptide as set forth in SEQ ID NO:11. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 11, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:11; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 5 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 121 residues in length.

[0017] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:12, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:12; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:12; or (d) encoding a polypeptide as set forth in SEQ ID NO:13. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 13, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:13; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 6 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 982 residues in length.

[0018] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:14, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:14; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:14; or (d) encoding a polypeptide as set forth in SEQ ID NO:15. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 15, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:15; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 7 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 197 residues in length.

[0019] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:16, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:16; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:16; or (d) encoding a polypeptide as set forth in SEQ ID NO:17. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 17, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:17; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 8 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 139 residues in length.

[0020] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:18, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:18; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:18; or (d) encoding a polypeptide as set forth in SEQ ID NO:19. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 19, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:19; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 9 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 148 residues in length.

[0021] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:20, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:20; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:20; or (d) encoding a polypeptide as set forth in SEQ ID NO:21. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 21, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:21; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 10 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 489 residues in length.

[0022] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:22, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:22; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:22; or (d) encoding a polypeptide as set forth in SEQ ID NO:23. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 23, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:23; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 11 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 229 residues in length.

[0023] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:24, wherein the sequence identity is at least 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:24; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:24; or (d) encoding a polypeptide as set forth in SEQ ID NO: 25. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:25, wherein the sequence identity is at least 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:25; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 12 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 109 residues in length.

[0024] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:26, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:26; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:26; or (d) encoding a polypeptide as set forth in SEQ ID NO: 27. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:27, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:27; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 13 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 424 residues in length.

[0025] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:28, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:28; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:28; or (d) encoding a polypeptide as set forth in SEQ ID NO:29. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:29, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:29; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 14 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 403 residues in length.

[0026] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:30, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:30; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:30; or (d) encoding a polypeptide as set forth in SEQ ID NO:31. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:31, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:31; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 15 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 88 residues in length.

[0027] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:32, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:32; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:32; or (d) encoding a polypeptide as set forth in SEQ ID NO: 33. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:33, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:33; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 16 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 261 residues in length.

[0028] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:34, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:34; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:34; or (d) encoding a polypeptide as set forth in SEQ ID NO:35. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:35, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:35; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 17 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 311 residues in length.

[0029] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:36, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:36; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:36; or (d) encoding a polypeptide as set forth in SEQ ID NO:37. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 37, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:37; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 18 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 490 residues in length.

[0030] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:38, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:38; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:38; or (d) encoding a polypeptide as set forth in SEQ ID NO:39. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 39, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:39; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 19 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 500 residues in length.

[0031] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:40, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:40; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:40; or (d) encoding a polypeptide as set forth in SEQ ID NO:41. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 41, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:41; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 20 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 292 residues in length.

[0032] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:42, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:42; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:42; or (d) encoding a polypeptide as set forth in SEQ ID NO:43. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 43, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:43; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 21 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 426 residues in length.

[0033] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:44, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:44; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:44; or (d) encoding a polypeptide as set forth in SEQ ID NO:45. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 45, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:45; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 22 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 191 residues in length.

[0034] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:46, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:46; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:46; or (d) encoding a polypeptide as set forth in SEQ ID NO: 47. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:47, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:47; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 23 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 526 residues in length.

[0035] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:48, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:48; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:48; or (d) encoding a polypeptide as set forth in SEQ ID NO:49. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:49, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:49; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 24 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 101 residues in length.

[0036] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:50, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:50; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:50; or (d) encoding a polypeptide as set forth in SEQ ID NO:51. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 51, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:51; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 25 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 260 residues in length.

[0037] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:52, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:52; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:52; or (d) encoding a polypeptide as set forth in SEQ ID NO:53. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:53, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:53; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 26 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 134 residues in length.

[0038] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:54, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:54; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:54; or (d) encoding a polypeptide as set forth in SEQ ID NO:55. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 55, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:55; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 27 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 432 residues in length.

[0039] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:56, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:56; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:56; or (d) encoding a polypeptide as set forth in SEQ ID NO:57. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 57, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:57; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 28 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 500 residues in length.

[0040] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:58, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:58; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:58; or (d) encoding a polypeptide as set forth in SEQ ID NO:59. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:59, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:59; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 29 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 461 residues in length.

[0041] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:60, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:60; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:60; or (d) encoding a polypeptide as set forth in SEQ ID NO:61. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:61, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:61; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 30 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 685 residues in length.

[0042] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:62, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:62; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:62; or (d) encoding a polypeptide as set forth in SEQ ID NO:63. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 63, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:63; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 31 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 133 residues in length.

[0043] The invention provides an isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:64, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:64; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:64; or (d) encoding a polypeptide as set forth in SEQ ID NO:65. The invention provides an isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO: 65, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:65; or (c) encoded by a nucleic acid of the invention as set forth above. In one aspect, the polypeptide functions an enzyme of the kinamycin biosynthetic pathway, in particular, this polypeptide can be gene 32 of the exemplary kinamycin biosynthetic pathway as set forth in FIG. 2. In one aspect, the polypeptide is 213 residues in length.

[0044] The invention provides a polyketide comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a plurality of nucleic acid coding sequences, wherein the nucleic acid coding sequences have at least 95% sequence identity to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO: 22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO: 44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62 and SEQ ID NO:64, wherein the plurality of nucleic acid coding sequences, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated polyketide comprising a glycosylated kinamycin.

[0045] The invention provides methods for making a glycosylated kinamycin comprising the following steps: (a) providing a plurality of nucleic acid coding sequences, wherein the nucleic acid coding sequences have at least 95% sequence identity to SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO: 24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO: 46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62 and SEQ ID NO:64, wherein the plurality of nucleic acid coding sequences, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin.

[0046] The invention provides a polyketide comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a plurality of polypeptides, wherein the polypeptide sequences have at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO: 25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ I D NO: 35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO: 47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63 and SEQ ID NO:65, wherein the plurality of polypeptides, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the polypeptides of step (a) into the bacillus of step (b) or contacting the polypeptides of step (a) with the intracellular extract of step (b) under conditions allowing synthesis of a glycosylated kinamycin.

[0047] In one aspect, one, some or all of the nucleic acids of the invention are assembled in one or more expression cassettes, e.g., vectors. In one aspect, the coding sequences of the, invention are under the control of transcriptional regulatory sequences, e.g., promoters and enhancers.

[0048] The invention provides methods for making a glycosylated kinamycin comprising the following steps: (a) providing a plurality of polypeptides, wherein the polypeptides he sequences at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO: 17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO: 39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO: 61, SEQ ID NO:63 and SEQ ID NO:65, wherein the plurality of polypeptides, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the polypeptides of step (a) into the bacillus of step (b) or contacting the polypeptides of step (a) with the intracellular extract of step (b) under conditions allowing synthesis of a glycosylated kinamycin.

[0049] The invention provides methods for making a glycosylated kinamycin that can comprise a combination of aspects of the invention, e.g., adding to a bacterial extract some coding sequences and some polypeptides to make a glycosylated kinamycin. The kinamycin or precursors of the kinamycin also can be completely or partially synthetically synthesized.

[0050] In all of the methods and processes of the invention, any appropriate Streptococcus sp. can be used, e.g., a S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus, a S. violaceoruber, or a S. diversa. The Dactylosporangium sp. of step (b) can be a Dactylosporangium sp. ATCC 53693.

[0051] The invention provides antibodies (e.g., monoclonal or polyclonal) that are capable of specifically binding to a polypeptide, wherein the polypeptide can have a sequence comprising at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO: 29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO: 51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63 and SEQ ID NO:65.

[0052] All publications, patents, patent applications, GenBank sequences and ATCC deposits, cited herein are hereby expressly incorporated by reference for all purposes.

[0053] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

[0054]FIG. 1 illustrates the general structure of an exemplary glycosylated kinamycin of the invention.

[0055]FIG. 2 is a schematic of the S. murayamaensis nucleic acid insert of ATCC 21414, and the 32 coding sequences encoded therein which, when expressed in a bacterial system, produces kinamycin.

[0056]FIG. 3 is a schematic of an exemplary biosynthetic pathway for making kinamycin and includes the structures of exemplary compounds of the invention.

[0057] Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

[0058] The compositions and methods of the invention can be used to treat infections, i.e., as antibiotics, and as anti-tumor agents. The compositions of the invention can also be used as electrophilic azo-coupling agents in vitro or in vivo. This invention provides novel glycosylated kinamycins that are useful as antibiotics and anti-tumor agents. Compositions of the invention comprise glycosylated kinamycins. The compositions and methods of the invention can be used to treat infections. In one aspect, the invention provides glycosylated polycyclic aromatic quinone antibiotics as shown in FIG. 1 and FIG. 3. These structures can be glycosylated in a variety of forms.

[0059] The invention also provides enzymes capable of generating kinamycin, nucleic acids that encode them, antibodies that bind to them, and methods for making and using them.

[0060] In one aspect, the compound of the invention is manufactured by first making a kinamycin and then glycosylating it. For example, the kinamycin can be made by growing a sample of Streptomyces murayamaensis as described, e.g., in J. Antibiotics, 23:315 (1970) and then isolating the kinamycin. Alternatively, the kinamycin can be made synthetically. The isolated or synthesized kinamycin can then be glycosylated, e.g., derivatized to form the compound in FIG. 1.

[0061] The compositions of the invention can be used as conventional antibiotics, e.g., as pharmaceuticals in the treatment of infections. For example, the compound can be given to a subject, e.g., a patient or other subject, suffering from a bacterial infection. Administration of the compound can be through any means, e.g., any conventional methods, e.g., oral, intravenous, intradermal, parenteral, transdermal or other methods.

[0062] In one aspect, the compound is used as a research tool to inhibit the growth of bacteria in vitro. For example, a bacterial colony can be plated onto agar that incorporates a growth-inhibiting quantity of a compound of the invention, e.g., the kinamycin derivative shown in FIG. 1. Bacteria that are resistant to the compound of the invention will continue to grow, while bacteria that are not resistant will be inhibited from growing.

[0063] The invention is not limited to the exemplary structure shown in FIG. 1. The invention provides similar structures that provide the antibacterial effects, as described herein.

[0064] One of ordinary skill in the art can test for antibacterial effects by growing (e.g., culturing) bacteria, such as Micrococcus luteus, in the presence and absence of a compound of the invention, e.g., a derivatized glycosylated kinamycin compound. Those compounds that inhibit the growth of the bacteria are selected for further tests, while those compounds that do not inhibit bacterial growth are not selected for further tests.

[0065] Definitions

[0066] To facilitate understanding the invention, a number of terms are defined below. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs.

[0067] The term “antibody” includes a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope, see, e.g. Fundamental Immunology, Third Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994) J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., “antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”

[0068] As used herein, “isolated,” when referring to a molecule or composition, such as, for example, a glycosylated kinamycin of the invention, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (e.g., RNAs, polypeptides, small compounds), or other contaminants with which it is associated in vivo or in its naturally occurring state. Thus, a compound is considered isolated when it has been isolated from any other component with which it is naturally associated, e.g., cell membrane, as in a cell extract, serum, and the like. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-PAGE) or high performance liquid chromatography (HPLC).

[0069] The term “expression cassette” as used herein refers to a nucleotide sequence which is capable of affecting expression of a structural gene (i.e., a protein coding sequence) in a host compatible with such sequences. Expression cassettes include at least a promoter operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used, e.g., enhancers. “Operably linked” as used herein refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence. Thus, expression cassettes also include plasmids, expression vectors, recombinant viruses, any form of recombinant “naked DNA” vector, and the like. A “vector” comprises a nucleic acid which can infect, transfect, transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid. The vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.). Vectors include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated. Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Pat. No. 5,217,879), and includes both the expression and non-expression plasmids. Where a recombinant microorganism or cell culture is described as hosting an “expression vector” this includes both extra-chromosomal circular and linear DNA and DNA that has been incorporated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host's genome.

[0070] The term “chemically linked” refers to any chemical bonding of two moieties, e.g., a kinamycin of the invention and a saccharide or polysaccharide. The saccharide and kinamycin moieties of the compounds of the invention can be chemically linked by any means known in the art.

[0071] The term “pharmaceutical composition” refers to a composition suitable for pharmaceutical use, e.g., as an antibiotic or an anti-cancer agent comprising a glycosylated kinamycin of the invention, in a subject. The pharmaceutical compositions of this invention are formulations that comprise a pharmacologically effective amount of a composition comprising, e.g., a glycosylated kinamycin of the invention, and a pharmaceutically acceptable carrier.

[0072] The term “promoter” is an array of nucleic acid control sequences which direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. A “constitutive” promoter is a promoter which is active under most environmental and developmental conditions. An “inducible” promoter is a promoter which is under environmental or developmental regulation. A “tissue specific” promoter is active in certain tissue types of an organism, but not in other tissue types from the same organism. The term “operably linked” refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence. The nucleic acids of the invention can be operatively linked to any type of promoter (or transcriptional regulatory sequence) alone or in an expression cassette, e.g., a vector.

[0073] The phrases “nucleic acid” or “nucleic acid sequence” as used herein refer to an oligonucleotide, nucleotide, polynucleotide, or to a fragment of any of these, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin. The term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides. The term also encompasses nucleic-acid-like structures with synthetic backbones, see e.g., Mata (1997) Toxicol. Appl. Pharmacol. 144:189-197; Strauss-Soukup (1997) Biochemistry 36:8692-8698; Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156.

[0074] “Amino acid” or “amino acid sequence” as used herein refer to an oligopeptide, peptide, polypeptide, or protein sequence, or to a fragment, portion, or subunit of any of these, and to naturally occurring or synthetic molecules.

[0075] The term “polypeptide” as used herein, refers to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids. The term “polypeptide” also includes peptides and polypeptide fragments, motifs and the like. The peptides and polypeptides of the invention also include all “mimetic” and “peptidomimetic” forms, as described in further detail, below.

[0076] The phrase “substantially identical” in the context of two nucleic acids or polypeptides, refers to two or more sequences that have at least 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% nucleotide or amino acid residue (sequence) identity (or as otherwise set forth herein), when compared and aligned for maximum correspondence, as measured using one any known sequence comparison algorithm or by visual inspection. In alternative aspects, the invention provides nucleic acid and polypeptide sequences having substantial identity to an exemplary sequence of the invention over a region of at least about 100 residues, 150 residues, 200 residues, 250 residues, 300 residues, 350 residues, or over a region ranging from between about 50 residues to the full length of the nucleic acid or polypeptide. Nucleic acid sequences of the invention can be substantially identical over the entire length of a polypeptide coding region. The invention provides polypeptides that are “substantially identical” to the exemplary amino acid sequences of the invention. “Substantially identical” can be a sequence that differs from a reference sequence by one or more conservative or non-conservative amino acid substitutions, deletions, or insertions, particularly when such a substitution occurs at a site that is not the active site of the molecule, and provided that the polypeptide essentially retains its functional properties. A conservative amino acid substitution, for example, substitutes one amino acid for another of the same class (e.g., substitution of one hydrophobic amino acid, such as isoleucine, valine, leucine, or methionine, for another, or substitution of one polar amino acid for another, such as substitution of arginine for lysine, glutamic acid for aspartic acid or glutamine for asparagine). One or more amino acids can be deleted resulting in modification of the structure of the polypeptide, without significantly altering its biological activity. For example, amino- or carboxyl-terminal amino acids that are not required for enzymatic activity can be removed. Modified polypeptide sequences of the invention can be assayed for activity by any number of methods, including contacting the modified polypeptide sequence with a substrate and determining whether the modified polypeptide decreases the amount of specific substrate in the assay or increases the bioproducts of the enzymatic reaction of a functional enzyme with the substrate, as discussed herein and illustrated in the Figures.

[0077] “Hybridization” refers to the process by which a nucleic acid strand joins with a complementary strand through base pairing. Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature, as described in detail, below.

[0078] General Synthetic Synthesis Methods

[0079] The present invention provides a novel genus of glycosylated kinamycin compounds that have antibiotic and anti-tumor activities. The skilled artisan will recognize that the compositions of the invention (and their precursors) can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature., e.g., Organic Syntheses Collective Volumes, Gilman et al. (Eds) John Wiley & Sons, Inc., NY; Venuti (1989) Pharm Res. 6:867-873. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

[0080] Generating and Manipulating Nucleic Acids

[0081] The invention provides nucleic acids, including expression cassettes such as expression vectors, encoding the polypeptides of the invention. The nucleic acids of the invention can be made, isolated and/or manipulated by, e.g., cloning and expression of cDNA libraries, amplification of message or genomic DNA by PCR, and the like. In practicing the methods of the invention, homologous genes can be modified by manipulating a template nucleic acid, as described herein. The invention can be practiced in conjunction with any method or protocol or device known in the art, which are well described in the scientific and patent literature.

[0082] General Techniques

[0083] The nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/generated recombinantly. Recombinant polypeptides generated from these nucleic acids can be individually isolated or cloned and tested for a desired activity. Any recombinant expression system can be used, including bacterial, mammalian, yeast, insect or plant cell expression systems.

[0084] Alternatively, these nucleic acids can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Pat. No. 4,458,066.

[0085] Techniques for the manipulation of nucleic acids, such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

[0086] Another useful means of obtaining and manipulating nucleic acids used to practice the methods of the invention is to clone from genomic samples, and, if desired, screen and re-clone inserts isolated or amplified from, e.g., genomic clones or cDNA clones. Sources of nucleic acid used in the methods of the invention can include genomic or cDNA libraries. The libraries, or any individual or collective nucleic acid sequences of the invention, can be contained in, e.g., mammalian artificial chromosomes (MACs), see, e.g., U.S. Pat. Nos. 5,721,118; 6,025,155; human artificial chromosomes, see, e.g., Rosenfeld (1997) Nat. Genet. 15:333-335; yeast artificial chromosomes (YAC); bacterial artificial chromosomes (BAC); P1 artificial chromosomes, see, e.g., Woon (1998) Genomics 50:306-316; P1-derived vectors (PACs), see, e.g., Kern (1997) Biotechniques 23:120-124; cosmids, recombinant viruses, phages or plasmids. For example, the nucleic acid sequences of the invention can be assembled in any of these expression systems as set forth in FIG. 2, or any other order, to express translation product and to generate a composition of the invention.

[0087] In one aspect, a nucleic acid encoding a polypeptide of the invention is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof. The invention also provides fusion proteins and nucleic acids encoding them. A polypeptide of the invention can be fused to a heterologous peptide or polypeptide, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification. Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, e.g., producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, to identify and isolate antibodies and antibody-expressing B cells, and the like. Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle Wash.). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego Calif.) between a purification domain and the motif-comprising peptide or polypeptide to facilitate purification. For example, an expression vector can include an epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34:1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-414). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.

[0088] Transcriptional and Translational Control Sequences

[0089] The invention provides DNA sequences of the invention operatively linked to expression (e.g., transcriptional or translational) control sequence(s),. e.g., promoters or enhancers, to direct or modulate RNA synthesis/expression. The expression control sequence can be in an expression vector. Exemplary bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, PL and trp. Exemplary eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein I.

[0090] Promoters suitable for expressing a polypeptide in bacteria include the E. coli lac or trp promoters, the lacI promoter, the lacZ promoter, the T3 promoter, the T7 promoter, the gpt promoter, the lambda PR promoter, the lambda PL promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter.

[0091] Expression Vectors and Cloning Vehicles

[0092] The invention provides expression vectors and cloning vehicles comprising nucleic acids of the invention. Expression vectors and cloning vehicles of the invention can comprise viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g., vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, Aspergillus and yeast). Vectors of the invention can include chromosomal, non-chromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. Exemplary vectors are include: bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (lambda-ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or other vector may be used so long as they are replicable and viable in the host. Low copy number or high copy number vectors may be employed with the present invention.

[0093] The expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Mammalian expression vectors can comprise an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking non-transcribed sequences. In some aspects, DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

[0094] In one aspect, the expression vectors contain one or more selectable marker genes to permit selection of host cells containing the vector. Such selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in E. coli, and the S. cerevisiae TRP1 gene. Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers.

[0095] Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, can be about 10 to about 300 bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers.

[0096] A DNA sequence may be inserted into a vector by a variety of procedures. In general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, blunt ends in both the insert and the vector may be ligated. A variety of cloning techniques are disclosed in Ausubel and Sambrook. Such procedures and others are deemed to be within the scope of those skilled in the art.

[0097] The vector may be in the form of a plasmid, a viral particle, or a phage. Other vectors include chromosomal, non-chromosomal and synthetic DNA sequences, derivatives of SV40; bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. A variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by, e.g., Sambrook.

[0098] Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), GEM1 (Promega Biotec, Madison, Wis., USA) pQE70, pQE60, pQE-9 (Qiagen), pD10, psiX174 pBluescript II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7. Particular eukaryotic vectors include pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other vector may be used as long as it is replicable and viable in the host cell.

[0099] Host Cells and Transformed Cells

[0100] The invention also provides a transformed cell comprising a nucleic acid sequence of the invention, including an expression cassette of the invention (e.g., a vector or BAC comprising a coding sequence of the invention). The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, such as bacterial cells, fungal cells, yeast cells, mammalian cells, insect cells, or plant cells. Exemplary bacterial cells include E. coli, Streptomyces, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus. Exemplary insect cells include Drosophila S2 and Spodoptera Sf9. Exemplary animal cells include CHO, COS or Bowes melanoma. The selection of an appropriate host is within the abilities of those skilled in the art.

[0101] The vector may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Particular methods include calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

[0102] Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.

[0103] Amplification of Nucleic Acids

[0104] In practicing the invention, nucleic acids encoding the polypeptides of the invention, or modified nucleic acids, can be reproduced by, e.g., amplification. Amplification reactions can also be used to quantify the amount of nucleic acid in a sample (such as the amount of message in a cell sample), label the nucleic acid (e.g., to apply it to an array or a blot), detect the nucleic acid, or quantify the amount of a specific nucleic acid in a sample. In one aspect of the invention, message isolated from a cell or a cDNA library are amplified. The skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (see, e.g., PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Innis, Academic Press, Inc., N.Y., ligase chain reaction (LCR) (see, e.g., Wu (1989) Genomics 4:560; Landegren (1988) Science 241:1077; Barringer (1990) Gene 89:117); transcription amplification (see, e.g., Kwoh (1989) Proc. Natl. Acad. Sci. USA 86:1173); and, self-sustained sequence replication (see, e.g., Guatelli (1990) Proc. Natl. Acad. Sci. USA 87:1874); Q Beta replicase amplification (see, e.g., Smith (1997) J. Clin. Microbiol. 35:1477-1491), automated Q-beta replicase amplification assay (see, e.g., Burg (1996) Mol. Cell. Probes 10:257-271) and other RNA polymerase mediated techniques (e.g., NASBA, Cangene, Mississauga, Ontario); see also Berger (1987) Methods Enzymol. 152:307-316; Sambrook; Ausubel; U.S. Pat. Nos. 4,683,195 and 4,683,202; Sooknanan (1995) Biotechnology 13:563-564.

[0105] Determining the Degree of Sequence Identity and Identifying Motifs

[0106] The invention provides nucleic acids and polypeptides having various % sequence identities (as set forth herein) to the exemplary nucleic acids and polypeptides of the invention. The extent of sequence identity (homology) may be determined using any computer program and associated parameters, including those described herein, such as FASTA version 3.0t78, or, BLAST, with the default parameters. Homologous sequences also include RNA sequences in which uridines replace the thymines in the nucleic acid sequences. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error. It will be appreciated that the nucleic acid sequences as set forth herein can be represented in the traditional single character format (see, e.g., Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York) or in any other format which records the identity of the nucleotides in a sequence.

[0107] To determine and identify sequence identities, structural homologies, motifs and the like in silico the sequence of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. Accordingly, the invention provides computers, computer systems, computer readable mediums, computer programs products and the like recorded or stored thereon the nucleic acid and polypeptide sequences of the invention. As used herein, the words “recorded” and “stored” refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid and/or polypeptide sequences of the invention. Another aspect of the invention is a computer readable medium having recorded thereon at least one nucleic acid and/or polypeptide sequence of the invention. Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art. Aspects of the invention include systems (e.g., internet based systems), particularly computer systems, which store and manipulate the sequences and sequence information.

[0108] Protein and/or nucleic acid sequence identities (homologies) may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are not limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-2448, 1988; Altschul et al., J. Mol. Biol. 215(3):403-410, 1990; Thompson et al., Nucleic Acids Res. 22(2):4673-4680, 1994; Higgins et al., Methods Enzymol. 266:383-402, 1996; Altschul et al., J. Mol. Biol. 215(3):403-410, 1990; Altschul et al., Nature Genetics 3:266-272, 1993). Homology or identity can be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches similar sequences by assigning degrees of homology to various deletions, substitutions and other modifications. The terms “homology” and “identity” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or designated region as measured using any number of sequence comparison algorithms or by manual alignment and visual inspection. For sequence comparison, one sequence can act as a reference sequence (an exemplary sequence of the invention) to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[0109] A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous residues. For example, in alternative aspects of the invention, continugous residues ranging anywhere from 20 to the full length of one or more exemplary sequences are compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. If the reference sequence has the requisite sequence identity to an exemplary sequence that sequence is within the scope of the invention. In alternative embodiments, subsequences ranging from about 20 to 600, about 50 to 200, and about 100 to 150 are compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of person & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection. Other algorithms for determining homology or identity include, for example, in addition to a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLocks IMProved Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las,Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi-sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-IF. Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences. A number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (Gibbs, 1995). Several genomes have been sequenced, e.g., M. genitalium (Fraser et al., 1995), M. jannaschii (Bult et al., 1996), H. influenzae (Fleischmann et al., 1995), E. coli (Blattner et al., 1997), and yeast (S. cerevisiae) (Mewes et al., 1997), and D. melanogaster (Adams et al., 2000).

[0110] One algorithm that can be used to determine if a sequence is within the scope of the invention is BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977, and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectations (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands. The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873, 1993). One measure of similarity provided by BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a references sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. In one aspect, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool (“BLAST”). For example, five specific BLAST programs can be used to perform the following task: (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database; (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database; (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and, (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database. The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as “high-scoring segment pairs,” between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., Science 256:1443-1445, 1992; Henikoff and Henikoff, Proteins 17:49-61, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation). The parameters used with the above algorithms may be adapted depending on the sequence length and degree of homology studied. In some embodiments, the parameters may be the default parameters used by the algorithms in the absence of instructions from the user.

[0111] Hybridization of Nucleic Acids

[0112] The invention provides isolated or recombinant nucleic acids that hybridize under stringent conditions to an exemplary sequence of the invention. The stringent conditions can be highly stringent conditions, medium stringent conditions and low stringent conditions. In alternative embodiments, nucleic acids of the invention as defined by their ability to hybridize under stringent conditions can be between about five residues and the full length of an exemplary sequence of the invention. For example, they can be at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 90, 100 and 150 residues in length. Nucleic acids shorter than full length are also included. These nucleic acids are useful as, e.g., hybridization probes, labeling probes, PCR oligonucleotide probes, sequences encoding antibody binding peptides (epitopes), motifs, active sites and the like.

[0113] In one aspect, hybridization under high stringency conditions is in about 50% formamide at about 37° C. to 42° C. Hybridization also can be under reduced stringency conditions in about 35% to 25% formamide at about 30° C. to 35° C. Alternatively, hybridization can be under high stringency conditions at 42° C. in 50% formamide, 5× SSPE, 0.3% SDS, and 200 n/ml sheared and denatured salmon sperm DNA. Hybridization can also be under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35° C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

[0114] By varying the stringency of the hybridization conditions used to identify nucleic acids, such as cDNAs or genomic DNAs, which hybridize to the detectable probe, nucleic acids having different levels of homology to the probe can be identified and isolated. Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes. The melting temperature, Tm, is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly complementary probe. Very stringent conditions are selected to be equal to or about 5° C. lower than the Tm for a particular probe. The melting temperature of the probe may be calculated using the following exemplary formulas. For probes between 14 and 70 nucleotides in length the melting temperature (Tm) is calculated using the formula: Tm=81.5+16.6(log [Na+])+0.41 (fraction G+C)−(600/N) where N is the length of the probe. If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation: Tm=81.5+16.6(log [Na+])+0.41(fraction G+C)−(0.63% formamide)−(600/N) where N is the length of the probe. Prehybridization may be carried out in 6× SSC, 5× Denhardt's reagent, 0.5% SDS, 100 μg denatured fragmented salmon sperm DNA or 6× SSC, 5× Denhardt's reagent, 0.5% SDS, 100 μg denatured fragmented salmon sperm DNA, 50% formamide. Formulas for SSC and Denhardt's and other solutions are listed, e.g., in Sambrook.

[0115] However, the selection of a hybridization format is not critical—it is the stringency of the wash conditions that set forth the conditions which determine whether a nucleic acid is within the scope of the invention. Wash conditions used to identify nucleic acids within the scope of the invention include, e.g.: a salt concentration of about 0.02 molar at pH 7 and a temperature of at least about 50° C. or about 55° C. to about 60° C.; or, a salt concentration of about 0.15 M NaCl at 72° C. for about 15 minutes; or, a salt concentration of about 0.2× SSC at a temperature of at least about 50° C. or about 55° C. to about 60° C. for about 15 to about 20 minutes; or, the hybridization complex is washed twice with a solution with a salt concentration of about 2X SSC containing 0. 1% SDS at room temperature for 15 minutes and then washed twice by 0.1X SSC containing 0.1% SDS at 68° C. for 15 minutes; or, equivalent conditions. See Sambrook, Tijssen and Ausubel for a description of SSC buffer and equivalent conditions.

[0116] Oligonucleotides Probes and Methods for Using Them

[0117] The invention also provides nucleic acid probes for identifying nucleic acids encoding a polypeptide of the invention. In one aspect, the probe comprises at least 10 consecutive bases of an exemplary sequence. Alternatively, a probe of the invention can be at least about 5, 6, 7, 8 or 9 to about 40, about 10 to 50, about 20 to 60 about 30 to 70, consecutive bases of an exemplary sequence. The probes identify a nucleic acid by binding or hybridization. The probes can be used in arrays, including, e.g., capillary arrays. The probes of the invention can also be used to isolate other nucleic acids or polypeptides.

[0118] The probes of the invention can be used to determine whether a biological sample, such as a soil sample, contains an organism having a nucleic acid sequence of the invention or an organism from which the nucleic acid was obtained. In such procedures, a biological sample potentially harboring the organism from which the nucleic acid was isolated is obtained and nucleic acids are obtained from the sample. The nucleic acids are contacted with the probe under conditions which permit the probe to specifically hybridize to any complementary sequences present in the sample. Where necessary, conditions which permit the probe to specifically hybridize to complementary sequences may be determined by placing the probe in contact with complementary sequences from samples known to contain the complementary sequence, as well as control sequences which do not contain the complementary sequence. Hybridization conditions, such as the salt concentration of the hybridization buffer, the formamide concentration of the hybridization buffer, or the hybridization temperature, may be varied to identify conditions which allow the probe to hybridize specifically to complementary nucleic acids (see discussion on specific hybridization conditions).

[0119] Polypeptides and Peptides

[0120] The invention provides polypeptides involved in the synthesis of polyketides, e.g., kinamycin, and subsequences thereof, e.g., peptides. This invention provides immunogenic peptides capable of generating an immune response, e.g., antibodies. Polypeptides and peptides of the invention can be isolated from natural sources (e.g., bacteria), be synthetic, or be recombinantly generated polypeptides. Peptides and proteins can be recombinantly expressed in vitro or in vivo. The peptides and polypeptides of the invention can be made and isolated using any method known in the art, and the invention provides a few exemplary means for generating such proteins.

[0121] The polypeptides of the invention include “mimetics” and “peptidomimetics,” which are synthetic chemical compounds that have substantially the same structural and/or functional characteristics of the polypeptides of the invention. The mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetics' structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond (“peptide bond”) linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds. Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N′-dicyclohexylcarbodiimide (DCC) or N,N′-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond (“peptide bond”) linkages include, e.g., ketomethylene (e.g., —C(═O)—CH₂— for —C(═O)—NH—), aminomethylene (CH₂—NH), ethylene, olefin (CH═CH), ether (CH₂—O), thioether (CH₂—S), tetrazole (CN₄—), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, “Peptide Backbone Modifications,” Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

[0122] Polypeptide and peptides of the invention can also be synthesized, whole or in part, using chemical methods well known in the art. See e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; Banga, A. K., Therapeutic Peptides and. Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, Pa. For example, peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. The skilled artisan will recognize that individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons, Inc., NY. Polypeptides incorporating mimetics can also be made using solid phase synthetic procedures, as described, e.g., by Di Marchi, et al., U.S. Pat. No. 5,422,426. Peptides and peptide mimetics of the invention can also be synthesized using combinatorial methodologies. Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, e.g., multipin, tea bag, and split-couple-mix techniques; see, e.g., al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234. Modified peptides of the invention can be further produced by chemical modification methods, see, e.g., Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896.

[0123] Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, e.g., producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, to identify and isolate antibodies and antibody-expressing B cells, and the like. Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle Wash.). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego Calif.) between the purification domain and GCA-associated peptide or polypeptide can be useful to facilitate purification. For example, an expression vector can include an epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34:1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-14). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.

[0124] Antibody Generation

[0125] The invention provides antibodies that specifically bind to the polypeptides of the invention. The polypeptides or peptide can be conjugated to another molecule or can be administered with an adjuvant. The coding sequence can be part of an expression cassette or vector capable of expressing the immunogen in vivo. (see, e.g., Katsumi (1994) Hum. Gene Ther. 5:1335-9). Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art and described in the scientific and patent literature, see, e.g., Coligan, CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY (1991); Stites (eds.) BASIC AND CLINICAL IMMUNOLOGY (7th ed.) Lange Medical Publications, Los Altos, Calif. (“Stites”); Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press,

[0126] New York, N.Y. (1986); Kohler (1975) Nature 256:495; Harlow (1988) ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publications, New York.

[0127] Antibodies also can be generated in vitro, e.g., using recombinant antibody binding site expressing phage display libraries, in addition to the traditional in vivo methods using animals. See, e.g., Huse (1989) Science 246:1275; Ward (1989) Nature 341:544; Hoogenboom (1997) Trends Biotechnol. 15:62-70; Katz (1997) Annu. Rev. Biophys. Biomol. Struct. 26:27-45.

[0128] Formulation and Administration of Pharmaceutical Compositions

[0129] In one embodiment, the compositions of the invention are combined with a pharmaceutically acceptable carrier (excipient) to form a pharmacological composition. The compositions of the invention can be used as antibiotics or as anti-tumor agents.

[0130] Pharmaceutically acceptable carriers can contain a physiologically acceptable compound that acts to, e.g., stabilize, or increase or decrease the absorption or clearance rates of the pharmaceutical compositions of the invention. Physiologically acceptable compounds can include, e.g., carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the peptides or polypeptides, or excipients or other stabilizers and/or buffers. Detergents can also used to stabilize or to increase or decrease the absorption of the pharmaceutical composition, including liposomal carriers. Pharmaceutically acceptable carriers and formulations for peptides and polypeptide are known to the skilled artisan and are described in detail in the scientific and patent literature, see e.g., the latest edition of Remington's Pharmaceutical Science, Mack Publishing Company, Easton, Pa. (“Remington's”).

[0131] Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, e.g., phenol and ascorbic acid. One skilled in the art would appreciate that the choice of a pharmaceutically acceptable carrier including a physiologically acceptable compound depends, for example, on the route of administration of the peptide or polypeptide of the invention and on its particular physio-chemical characteristics.

[0132] In one aspect, a solution of a composition of the invention is dissolved in a pharmaceutically acceptable carrier, e.g., an aqueous carrier if the composition is water-soluble. Examples of aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like. The formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilizers. For example, the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate. These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered. The resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The concentration of peptide in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

[0133] Solid formulations can be used for enteral (oral) administration. They can be formulated as, e.g., pills, tablets, powders or capsules. For solid compositions, conventional nontoxic solid carriers can be used which include, e.g., pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10% to 95% of active ingredient (e.g., peptide). A non-solid formulation can also be used for enteral administration. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. Suitable pharmaceutical excipients include e.g., starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol.

[0134] Compositions of the invention, when administered orally, can be protected from digestion. This can be accomplished either by complexing the composition with a compound to render it resistant to acidic and enzymatic hydrolysis or by packaging the peptide or complex in an appropriately resistant carrier such as a liposome. Means of protecting compounds from digestion are well known in the art, see, e.g., Fix (1996) Pharm Res. 13:1760-1764; Samanen (1996) J. Pharm. Pharmacol. 48:119-135; U.S. Pat. No. 5,391,377, describing lipid compositions for oral delivery of therapeutic agents (liposomal delivery is discussed in further detail, infra).

[0135] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents can be used to facilitate permeation. Transmucosal administration can be through nasal sprays or using suppositories. See, e.g., Sayani (1996) “Systemic delivery of peptides and proteins across absorptive mucosae” Crit. Rev. Ther. Drug Carrier Syst. 13:85-184. For topical, transdermal administration, the agents are formulated into ointments, creams, salves, powders and gels. Transdermal delivery systems can also include, e.g., patches.

[0136] The peptides and polypeptide complexes can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally. For example, biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a peptide can be included in the formulations of the invention (see, e.g., Putney (1998) Nat. Biotechnol. 16:153-157).

[0137] For inhalation, the peptide or polypeptide can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, e.g., Patton (1998) Biotechniques 16:141-143; product and inhalation delivery systems for polypeptide macromolecules by, e.g., Elan Pharmaceuticals (San Diego, Calif.), Aradigm (Hayward, Calif.), Aerogen (Santa Clara, Calif.), Inhale Therapeutic Systems (San Carlos, Calif.), and the like. For example, the pharmaceutical formulation can be administered in the form of an aerosol or mist. For aerosol administration, the formulation can be supplied in finely divided form along with a surfactant and propellant. In another embodiment, the device for delivering the formulation to respiratory tissue is an inhaler in which the formulation vaporizes. Other liquid delivery systems include, e.g., air jet nebulizers.

[0138] In preparing pharmaceuticals of the present invention, a variety of formulation modifications can be used and manipulated to alter pharmacokinetics and biodistribution. A number of methods for altering pharmacokinetics and biodistribution are known to one of ordinary skill in the art. Examples of such methods include protection of the complexes in vesicles composed of substances such as proteins, lipids (for example, liposomes, see below), carbohydrates, or synthetic polymers (discussed above). For a general discussion of pharmacokinetics, see, e.g., Remington's, Chapters 37-39.

[0139] The compositions used in the methods of the invention can be delivered alone or as pharmaceutical compositions by any means known in the art, e.g., systemically, regionally, or locally (e.g., directly into, or directed to, a tumor); by intra-arterial, intrathecal (IT), intravenous (IV), parenteral, intra-pleural cavity, topical, oral, or local administration, as subcutaneous, intra-tracheal (e.g., by aerosol) or transmucosal (e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa). Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in detail in the scientific and patent literature, see e.g., Remington's. For a “regional effect,” e.g., to focus on a specific organ, one mode of administration includes intra-arterial or intrathecal (IT) injections, e.g., to focus on a specific organ, e.g., brain and CNS (see e.g., Gurun (1997) Anesth Analg. 85:317-323). For example, intra-carotid artery injection if preferred where it is desired to deliver a peptide or polypeptide complex of the invention directly to the brain. Parenteral administration is a preferred route of delivery if a high systemic dosage is needed. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in detail, in e.g., Remington's,. See also, Bai (1997) J. Neuroimmunol. 80:65-75; Warren (1997) J. Neurol. Sci. 152:31-38; Tonegawa (1997) J. Exp. Med. 186:507-515.

[0140] In one aspect, the pharmaceutical formulations comprising compositions of the invention are incorporated in lipid monolayers or bilayers, e.g., liposomes, see, e.g., U.S. Pat. Nos. 6,110,490; 6,096,716; 5,283,185; 5,279,833. The invention also provides formulations in which water soluble peptides or complexes have been attached to the surface of the monolayer or bilayer. For example, compositions of the invention can be attached to peptides and peptides can be attached to hydrazide-PEG-(distearoylphosphatidyl) ethanolamine-containing liposomes (see, e.g., Zalipsky (1995) Bioconjug. Chem. 6:705-708). Liposomes or any form of lipid membrane, such as planar lipid membranes or the cell membrane of an intact cell, e.g., a red blood cell, can be used. Liposomal formulations can be by any means, including administration intravenously, transdermally (see, e.g., Vutla (1996) J. Pharm. Sci. 85:5-8), transmucosally, or orally. The invention also provides pharmaceutical preparations in which the peptides and/or complexes of the invention are incorporated within micelles and/or liposomes (see, e.g., Suntres (1994) J. Pharm. Pharmacol. 46:23-28; Woodle (1992) Pharm. Res. 9:260-265). Liposomes and liposomal formulations can be prepared according to standard methods and are also well known in the art, see, e.g., Remington's; Akimaru (1995) Cytokines Mol. Ther. 1:197-210; Alving (1995) Immunol. Rev. 145:5-31; Szoka (1980) Ann. Rev. Biophys. Bioeng. 9:467, U.S. Pat. Nos. 4, 235,871, 4,501,728 and 4,837,028.

[0141] Treatment Regimens: Pharmacokinetics

[0142] The pharmaceutical compositions of the invention can be administered in a variety of unit dosage forms depending upon the method of administration and objective, e.g., as an antibiotic or anti-tumor agent. Dosages for typical polyketide-comprising pharmaceutical compositions are well known to those of skill in the art. Such dosages are typically advisorial in nature and are adjusted depending on the particular therapeutic context, patient tolerance, etc. The amount of composition of the invention adequate to accomplish this is defined as a “therapeutically effective dose.” The dosage schedule and amounts effective for this use, i.e., the “dosing regimen,” will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age, pharmaceutical formulation and concentration of active agent, and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration. The dosage regimen must also take into consideration the pharmacokinetics, i.e., the pharmaceutical composition's rate of absorption, bioavailability, metabolism, clearance, and the like. See, e.g., the latest Remington's; Egleton (1997) “Bioavailability and transport of peptides and peptide drugs into the brain” Peptides 18:1431-1439; Langer (1990) Science 249:1527-1533.

[0143] In one aspect for therapeutic application, compositions of the invention can be administered to a subject suffering from an infection in an amount sufficient to at least partially arrest the infection and/or its complications. For example, in one aspect, a soluble pharmaceutical composition dosage for intravenous (IV) administration would be about 0.01 mg/hr to about 1.0 mg/hr administered over several hours (typically 1, 3, or 6 hours), which can be repeated for weeks with intermittent cycles. Considerably higher dosages (e.g., ranging up to about 10 mg/ml) can be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ, e.g., the cerebrospinal fluid (CSF).

EXAMPLES Example 1

[0144] Expression of Kinamycin Pathway in Streptococcus

[0145] Construction of a S. murayamaensis ATCC 21414 Library

[0146] The nucleic acid of ATCC 21414, when expressed in a bacterial system, produces kinamycin, a type II polyketide. The genomic DNA of ATCC 21414 was isolated and digested with Sau3A and ligated to the BamHI-cut pMF17 fosmid and lambda-packaged. The packaged library was transfected into an E. coli STR611. The fosmid was constructed by putting together the following sequences: a. FOS 1 replicon, for maintenance in E. coli; b. apramycin-resistance gene, for selection; c. Chloramphenicol resistance gene, for selection; d. attP, for integration; e. oriT, allows transfer from E. coli to Streptomyces.

[0147] Construction of the PKS probes

[0148] Primers were designed to identify and amplify PKS genes from Actinomycetes as described previously (see, e.g., M. Metsa-Ketela et al, FEMS Microbiology Letters, 180(1999)1-6). A 612 base pair (bp) PCR fragment was amplified from the genomic DNA of S. murayamaensis, which was then sequenced. The 612 bp DNA sequence showed high sequence similarity to jadomycin PKS genes from S. venezuelae. The PKS fragment was used as a probe for colony blot hybridization of the ATCC 21414 library. 18 clones were obtained that hybridized strongly to the PKS probe.

[0149] RFLP Data

[0150] All the clones which hybridized to the PKS probe shared common bands suggesting that contigs of the genomic DNA containing the PKS genes had been cloned.

[0151] DS4 is a S. diversa strain in which both chloramphenicol and jadomycin pathways have been knocked out. The PKS positive clones #1-18 were introduced into DS4 strain by E. coli-Streptomyces mating procedure. Clones 1-6 gave exconjugants which produced green diffusible pigment, with clones 5 and 6 producing a lighter green pigment. Clones 8, 11, 16, and 18 gave exconjugants that phenotypically looked similar to the exconjugants obtained using the fosmid alone, while clones 9, 12-15 failed to give any exconjugants. When the DS4 exconjugant clones were bioassayed against M. luteus, clones 1-6 (which produced the green diffusible pigment), showed bioactivity while all others were negative.

[0152] Mating into S. coelicolor M512

[0153]S. coelicolor M512 is a strain derived from S. coelicolor A3(2) in which the resident pathways actinorhodin, undecylprodigiosin, and methylenomycin have been eliminated/blocked. When E. coli clones containing the PKS positive fosmids #1 and #2 were mated into M512, exconjugants were obtained Which showed green diffusible pigment similar to that observed in S. diversa. These clones were not bioassayed.

[0154] Chemistry

[0155] One bioactive clone S. diversa kin-1 was chemically characterized to identify the nature of the active molecule. The structure of the novel glycosylated molecule is shown in FIG. 2.

[0156] Sequence Analysis

[0157] The insert present in the fosmid DNA (from one bioactive clone called kin-1) was sequenced. There are two gaps still remaining which are perhaps a few hundred base pairs each. The sequence analysis (BLAST) showed a similarity to jadomycin biosynthetic gene cluster in the organization of the PKS and other modifying genes. There were no sugar genes or glycosyltransferases detected in the kinamycin gene cluster. Therefore, the sugar moiety in the novel glycosylated molecule is most likely derived from an endogenous Streptococcus pathway.

[0158] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

1 65 1 36321 DNA Streptomyces murayamaensis ATCC 21414 misc_feature (1)...( 36321) n = A,T,C or G 1 cggtgaaaac ctggcctatt tccctaaagg gtttattgag aatatgtttt tcgtctcagc 60 caatccctgg gtgagtttca ccagttttga tttaaacgtg gccaatatgg acaacttctt 120 cgcccccgtt ttcaccatgg gcaaatatta tacgcaaggc gacaaggtgc tgatgccgct 180 ggcgattcag gttcatcatg ccgtttgtga tggcttccat gtcggcagaa tgcttaatga 240 attacaacag tactgcgatg agtggcaggg cggggcgtaa tttttttaag gcagttattg 300 gtgcccttaa acgcctggtt gctacgcctg aataagtgat aataagcgga tgaatggcag 360 aaattcgatg ataagctgtc aaacatgaga attggtcgac ggcccgggcg gccgcatacg 420 atttaggtga cactatagga tcaactcggc caaccccgag gagtgggacg ccatttacgg 480 ggaggtcgag cgcggcgaga ccgatgttct cctggtgagt ccggaacgtc tcaattccgt 540 ggacttccgc gaccaggtgc tgcccaagct cgcggccacc accggtctgc tggtggtgga 600 cgaggcgcac tgcatctccg actgggggca cgacttccgg ccggactacc ggcggttgcg 660 ggcgatgctg accgagctgc ccgccggggt gccggtgctg gccaccaccg cgaccgcgaa 720 cgcccgggtc accgccgacg tggccgaaca gctgggtacc ggggccggtg aggcgctggt 780 gctgcgcggc ccgctggagc gcgagagcct gcgcctgggc gtggtccggc tgccggacgc 840 cccacaccgc ctggcctggc tcgccgagca cctcgacgag cttcagggct ccgggatcat 900 ctacaccctc accgtggccg cggccgagga ggccaccgcc ttcctgcgcc agcgcggctt 960 caaggtgtcc tcgtacacgg ggcgcacgga gaacgccgac cgtctgcagg cggagaccga 1020 cctccaggag aaccaggtca aggcgctggt ggcgacctcc gcgctcggca tgggcttcga 1080 caagccggac ctcggcttcg tgatccacct cggctcgccg tcctcgccga tcgcctacta 1140 ccagcaggtc gggcgcgccg ggcgcggggt cgagcacgcc gacgtcctgc tgctgccggg 1200 caaggaggac gaagccatct ggcgctactt cgccgacacg gccttcccgc ccgaggtcca 1260 ggtccgccag accctgtcgg ccctcgccga cgcgggacgg ccgctgtccg taccggccct 1320 ggaggcggcg gtcgacctcc ggcgcagcag gctggagacg atgctgaagg tgctggacgt 1380 cgacggcgcc gtgaagcggg tgaagggcgg ctggacggcc acgggggcgg actgggtgta 1440 cgacgccgag cgctacgcct gggtggcccg gcagcgggcg gccgagcagc aggccatgcg 1500 cgattacgtg agcacgacgc ggtgccggat ggagttcctg cgccggcagc tggacgacga 1560 gggggcggcc ccgtgcggcc gctgcgacaa ctgcgcggga gcgtgggccg attccgccgt 1620 gtcggcggag acggtgacgg gggcggcgaa ggaactggac cgcccggggg tggaggtcga 1680 gccgcgccgg atgtggccga cggggatggc cgcgctgggc gtcgacctca aggggcgcat 1740 cccggccaag gagcagtgct ccaccggacg cgccctgggg cgcctgtcgg acatcggctg 1800 gggcaaccgg ctgcgcccgc tgctggccga gaacgcgccg gacggacccg tcccggacga 1860 cgtcctgcgg gccgcggtcg cggtcctcgc cgactgggcg cgctcgccgg gcggctgggc 1920 gcccgacgtc ccggacgccg tcgcccgtcc ggtgggagtc gtcgcgatgc cgtccctggc 1980 ccgcccccga ctggtcgcct ccctcgccga ggggatcgcg acggtcggcc gcctgccctt 2040 cctgggcacc ctgacgtaca cgggcccgga cgacgcgcac gcggcgcggc gcagcaactc 2100 cgcgcaacgc ctgcggacgc tgtcgggtgc cttcaccgtc tccgaggacc tggccaccgc 2160 gctggccgcc gcccccggcc ccgtcctgct ggtggacgac tacaccgact ccggctggac 2220 cctggcggta gccgcccgcc tactgcgccg cgcgggcagc gaccaggtcc tccccctggt 2280 cctggcggct acgggctgag cttggccgct ggggcgggac cgtcgtctag gatcacggga 2340 actcggcccg caggcgggcc acttagcaga ggatcaccgg tgccgagcca catacgctcc 2400 ttctgggtca cctccccggg acacggtgag atcgtgacct cggcccgcct gcccgcctgc 2460 ccgcctgccc gcctgcccgc ctgcccgcct gctaatgatg aggccgtagt ccggacgctg 2520 tattccggcg tcagccgtgg cacggaatcg ctcgttttcc acggccgggt acccgtcagt 2580 cagtacgccg tcatgcgtgc cccctttcag gaaggcgact ttcccggacc cgtcaagtac 2640 gggtatctca atgtcggccg ggtggaggag gggccggcgg agctcgtggg ccgggtcgtg 2700 ttcagtctgt atccgcacca gacccgttac cgcgtcgcgg ccgacgccct cgcggtggtg 2760 cccgacggcg tgccgccgga gcgtgccgtg ctggccggga ccgtcgagac cgcgctcaac 2820 gcgctgtggg acgcgccccc gcggatcggt gaccggatcg cggtggtggg cgcgggcatg 2880 gtcggctcct gtgtggccgc gctcctggct cggttccccg gtgtccgcgt gcagctcgtc 2940 gacgtcgaac cggcccgcca ggcggtcgcc gcgcggctcg gcgtcgcctt cgccccgccc 3000 gagcgggcca ctgacgactg cgatctcgtc ttccacgcca gcgccaccga ggcggggctg 3060 aggcgctccc tcgaactgct cgctcccgag ggctgtgtgg tcgatctgag ctggtacggc 3120 gaccggccgg tgacgctgcc gctgggggag ttcttccact cccggcggct gtcgctgcgc 3180 ggcagccagg tcggcgccat cgcgccggag cgccgcgcac gccacacgag ggccgatcgg 3240 ctcggcatgg cgctcgacct cctgcgggac ccggtcttcg acgtactgat caccggcgag 3300 tccgatttcg acgaccttcc gcaggtcatg gccgagatcg ccaccggcgc ccggcccggg 3360 ctctgccacc gcatccgcta cggccccggc tgaccgccgc agcacagccg cccgccgcca 3420 ccatcctttc ggagaagcca tgttcagcgt caccgtccgc gatcacctca tgatcgccca 3480 cagcttcagc ggcgaggtct tcggccccgc ccagcgcctg cacggagcga catacctggt 3540 cgacgcgacc ttccagcgac cggagctgga cgacgacaac atcgtcatcg acatgggcct 3600 ggcaggcagg gaagtgcgcg ggatcgtcgc ggcgctctcg taccgcaacc tcgacgagga 3660 ccccgacttc gccggaacca acaccaccac ggaattcctg gccaaggtca tcgccgaccg 3720 cctcgccgcc cggatacacg acggcgccct cggccccggc gcccagggcc tgaccggact 3780 caccgtacgg ctccatgaat cgcacatcgc gtgggccgac taccaccgca cgctctgacc 3840 gcccggtcat ggccatacgc ccgtacgtcg tgctgtccgc ggccgtctcc ctggacggcc 3900 ggctcgacga cacctcgcgc gaccggctcg tactctccaa ccggcgcgac ctcgaccgtg 3960 tcgacgatga acgcgccgcc gcggacgcca tcctggtcgg cgccaccacc ctgcgcaggg 4020 acaacccgcg cctgctggtg gcgagcgccg atcggcgggc ccggcgcgtc gccctcggca 4080 tgccggagca tccgctgaag gtcacggtca ccgggtccgc cgaggtgaac acgtcgtacg 4140 cgttctggca ttgcggcggc gagaagctgg tgttcacggt ggacggagcg ctcctgcggg 4200 cccgtcgcac cgtaggcgac ctcgccgacg tcgtcagcac cggccccgct ctcgactggc 4260 acctcctcct cgacgaactc gggcgacgtg gggtggaacg ccttctggtc gaaggcggcg 4320 ggacggtgca cacccagctg ctggcccagg acctggccga tgaactccac ctcgtcgtcg 4380 ccccgttgct ggtgggcgaa gccggtgcgc cggtgttcct gggcccggcg tcgtacccgg 4440 gtggtcccgc ggcccgtatg acgctgctcg aagcacgccc cgtcggtgat gtcgtgctgc 4500 tgcgctacgc cccgaaactc cgatcctgag acggtgagcc cgcacaagtc ggccagtgcc 4560 gagccgagtt gacgttccgt cggtatgctc ctcgggcgcg tggccggacg gtgtgcggac 4620 gagacggggg cgagtgtgga cgacgcggtg gaactggcgg agatgatcgg ccagttgcgg 4680 agcgagctga gccgggccat ggcggacggg gccgcgggcg gcgggctgcg gttccaggcg 4740 gagaagctgg agctcgaact caccgtgggc gtggagcgca gccgggagcc gggtgcgaag 4800 gtgcggttct gggtgctcga cgtccacggc tccgcccgct ccgcgcggac cgccacgcag 4860 cggatcaagc tcaccctgca accggtgctc ggcgacgcac ccgacagccc cgcgctgatc 4920 tcgggcgcgg agctgcccga tgagagctga accgtcggcc gacgggctcg acccgcaccg 4980 gatcgccgag atcatcgtcg agagccccga gggcagaagg cgcggttccg gctaccggat 5040 ctccaccacg acggtcctca ccgccgccca tgtggtcgcc gacgcgaccc gcacgctcgt 5100 acggtgcgac gccgaccagc ccgcggagtg gtcggctccg gccatggtga cctgggcgga 5160 tgcgggcagc gacctcgccg tgctgagcgt cggggcacct gcggccgccc ccgtggtcac 5220 cgcacccgcc cgcttcgcgc gcatcgccga cgaccggcac ggggtgatcg gggtgcacgc 5280 cgccgggttt ccgctgtgga aacgccgacg ccggtccgac ggcgcgtact tccgcgaact 5340 gcaccaggcg gacggcacgg tggcggcgct ctccaatctg cggaccggca cgctggagat 5400 gaccgtggca ccggccggaa ccgaccccga cccggcggcc tcgccgtggg cgggcatgtc 5460 gggcgcggcg gtgtgggccg gcagccgcat catcggcgtg gtcgccgagc accaccgcta 5520 cgagggcccc ggacggctca ccgcggtccg cctcgaccac gcgctgcgcg ggctcggcgc 5580 cgcgagacgg gcggagctgg cccggttgct cgcgctgccc gagaccgcgg atctgcccct 5640 cgccgtcccc gggcaaccgc acgacgaccg cgccccgggg gtgcgggtgg tcggcgtccc 5700 cgtcgcgcac ggcatcgagc tgttcaagaa ccgcacccgc gaaagcgacc tgatcgcccg 5760 tcacttgagc gatccggcca tccgtatggt gtccgtcgtc ggacggcgcg gcatcggcaa 5820 gagcgcgctc gccgcgaagg tcatggatct gctggaccgg ggggaatggc ccggcgcggc 5880 cgccggtccc ctcccgtccg gcctcgtcaa cctctccacc cgaacctccg gcatctccct 5940 ggagcggctc tacttcgact gcgtccggct gctcggcccc gagcacgagg agcggctgcg 6000 cggggtctgg gcgggcggcg gcagcgcgca ggaccgcctc gccgcactct tcgacgccat 6060 gggcgggcgg ctgatcgtca tcctcatgga caacttggag gaactgctcg gcgacgacgg 6120 cggcatcgag gacgaggagc tggccctctt cctggactgg ctgttccggg cccgcaccac 6180 cccacgtctg ctcgtcacca gccaggtgcc ggtgcgtctc gcgcccgaac tgcgccgctt 6240 cgccgccgag gtgccgctct ccgaggggct gcgccccacc gaggccgcgg ccctgctgcg 6300 cgaactcgac cgggacggca gcctcggcat cgccgacctg tccgacggcg aactcctcga 6360 cgccgcggtc cgggtgcacg gcgtcccgcg cgcgctcgaa ctcctcgtcg gcgcggtcgc 6420 cgaggagacg gtgctgctgc ccagcctgaa agacgtactg gaggacttca cccgccgcca 6480 cgacgtcgtc gcggacctcg cccaggaccg ctaccgtcgc ctcgacgagc cggcgcgtgc 6540 cgtcctcggt gtgctcgccg ccctgcgcac ccccgtggag cagggcgcgg tggcgcagat 6600 cgcgggcggg ctcgatccgg acctgcgggt ggtccccgtc ctcacggcgc tcgtccgggt 6660 ccgcctggtc tccgtggacc gggccagccg gacggtcgcc ctgcacccgt tggacgcgga 6720 catcgcccgt gaccagatgc cgtgggacgg acctttcggg aggcaagcgg tggaacggca 6780 gatcgcagcc tggtacgcgc ggcgggcgaa gccgcgcggc gcctggcgga cgctggagga 6840 cgtcgagccg cagcggcggc agttcgacca cctggtcggc gcgggcgacc acgacgcggc 6900 cgcgcgggtg ctggccgaga tcagcgaatg gctcgtctgg cacggctcgg tgctcgccgc 6960 ggtcacgatg cacctggcgg tcgacggaca cctccgcgac gagcgggtac gcctcgccca 7020 caccgtcgcg tacgggcacg cccggctcag tgcgggtccc atggagcagg cggtcgagct 7080 gttcaccgag gccgcggccc tcgccgaacg cctcggcgac cggcccgcgc tgcagaacgc 7140 gctgttcggc ctgggcgacg cccaccggca gctgggcgat cagggcgcca ccgtcgaacc 7200 gctcgcccgc gccgccgagt tggcgcgtga actgggcgac accgagcgcg aggcgcacgc 7260 gctgctctcc ctcagcctcg cgcacagcta cctcggcgac ggcgagcgcg cgctggaggg 7320 ggccgaccgg ctggccgcgc tcgccgaggc gggcggcgac ccgctcgcgc tcgcccgcgc 7380 cggcaacgcg cgcaccatcg cgctgctcac cctgggccgc tggcaggaga ccgccgaggc 7440 gggcgccgag acggcccgcg cctatcgcgc cgccggcagt caggaagcgg tcgcgtacgc 7500 gctgaacgcg cagggcctgg ccctgctggc cctggacgac ccggcgcggg cggccgcggt 7560 gctcgaagag gcccgccacg aggcctcact gatggagagc ccccgggccg agggcgtctg 7620 cctgctcaac ctgtcctggg cgtactggtg cgacggccgc cgggacgagt gcgcggccac 7680 cgccgaacgc gcctcgaccg ccctccagat cgccggagcg acccaggcgg cggcggcccg 7740 ttcgctggcc gaggccgccc gcgtcctgcc cggcgaccct ggggccgccg ccgacgccct 7800 gatccgcgcg gcggccgcgc tggacggcaa cgccgaggtc atcgcccccg cccggctcac 7860 cgccgaggca cgccgactgc tggactgacc cgctggggtg cgccgctagg acgtggcgcg 7920 gtcggagcgc aatccgtcga gcacgatgtc gatgtagcgc cgccagtcgc cgctgcgccg 7980 gtgcacgatc gaggtgagac cgcaggtcag cgcgaggatg tcggcgcccg cgatatcggt 8040 gcggatggag ccggccgcct ggcccttgcc gaccaggtcc accagctcgt cctccaggtc 8100 ggcccgcatg gtgctgggcg gcccctcgga gccgagcgtc ccgccgacga cgctggcgaa 8160 gccgcggtcc cgggcctcca cctcgccgac ccgggtgagc agcatctgga gtgcttccag 8220 cggctcggcc gactcccggc agaccgtgcg gtagtacgtg aggatctcgc cgaagcgctg 8280 ctgggaggcc gcgacgacca tggcttcctt ggtggggaag tggcggtaga gcgtccccac 8340 gccgacctcg gcgcggcggg ccacctcgtc catggacacg ttggcgccgc gttccgcgaa 8400 gagctccctg gccgcgttca gcacccgggc ccggttgcgc tccgcgtcgg cccggagccg 8460 gcggggaccg ttctcggtga ctggcgttga cgtaggcata cggaacctcc ctccgtttga 8520 ctctactatg ccctgccgtt acctactgaa ccagccctga cttcgcgcca gttggggtat 8580 gcggttcgca gttgcccagt cggttacgcg gtgcggcccg gggtgttgac aatggcctgg 8640 tcgtacagtg aaacggaagg acgaacacga tgtcgttgcc cctggggcgt acgagtgcgc 8700 cggaggtgtc ggcgtcggtg gaggcattcc tgacccagac gccgcacatc ggcgtgctga 8760 ccaccatccg gcccgacggg tccccgcatg tggcgccggt gcggttcacc tgggacgcgg 8820 aggcgggtct cgcccgggtg atgacggtgt cctcgtcccg caaggcgcgc aatctgatcg 8880 ccgcgcccgg cagccgggtc gccatatgcc aggtggccgg gttcgcctgg gtcaccctcg 8940 aaggctccgc cgtggtggcc gacgacccgg tgcgggtcac cgagggagcg cgccgctaca 9000 cccgccgcta ccgctccggg ccgcccaacc cgcccggccg ggtggtcgtg gagatctcgg 9060 tcgaccgggt catgagcctc aacgtctgaa ccgggttccg caccgagttc cgcgcaaagg 9120 cggaacaagg gcggaacaac ggcagagcgc gnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 9180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnctctttt cgtgctgtcc 9240 cggcggtcgc ccgcgtcagc ccttgcgggg cgcggtgccg gtcacccaga tcatgcgcag 9300 ggacagcagg ctgagccgcc agccctccgg ggtgcggcgg gcctcggcgg tcaccaggct 9360 tccgttggcg aatatcggat cgcggtcggc gtcctccgga tggtcggacg ggtggtgcac 9420 atgggtggag acgatgttgc accgcaaaga ggcccggtcg ccgtcgattt ccacgacggc 9480 gggcgaaccg atgtgctgcg tgcgcgcgaa ggccgcgagc gccgtgctgt ggtactcggc 9540 gagtccggcg atcccctcgt gccggctcat cgggaactcg acgaccgcgt cctcggtgaa 9600 cagcccccgg gcccaggcgt cgtcgagctt gtcgtcgtcc agattgatca ggtaacggtc 9660 cagaagtccc gcgacatcgg cggtggattg gcttgaggtc atggttgagg atgctccgga 9720 acaagccgct gaccaagact ccttgtagca gacctgacgt acttgtcaga ggtctgtact 9780 agcggctatt tacgcccgct ggacccctcg ggatactggt gaaacgccag tcggaagagg 9840 gtagatggat aactttgacg cggacgtaat tatcgcggga gccggcccca ctggactcat 9900 gctcgcaggc gaactgcgcc tgaacggcgt gtccgtgatt gtcgtcgatc gccttgccga 9960 gccgatacag cagtcgcgtg cgctgggatt ttcggcccgt accatcgagg aattcggcca 10020 gcgcggactg ctgtcccgtt tcggtgaagt cgacgtcatt ccggtcggtc atttcggcgg 10080 agtgtccatc gattaccgtc tggtcgaggg cggttcgtac ggagcgcgcg gcattcccca 10140 gtcgcgcacc gagggcgtgc tggcgggctg ggccggacag ctcggcgccg aggtgcggcg 10200 cggggtcgag gtcacgggcc tggacaacgg cgccgacggc gtgagcgtgg aggtcagcac 10260 cgccgagggg cccgccacgc tgcgcggccg ctacctggtg ggcgcggacg gcgcccgcag 10320 tgcggtgcgc aagctcgcgg gcatcgactt cccgggcacc gacccggcca tcgagctccg 10380 gttcgccgac atcagcgggg tgccgttgcg cccgcgcttc agcggcgagc gggtgcccgg 10440 cggcatggtc atggtgctgc cgctcggccc ggagcgctgc cggatcgtct acttcgaccg 10500 cagcgagccg ttgcgcaaga gcccggaccc gatcaccttc gacgaggtgg ccgaggcgtt 10560 caagcggctg tccggcgagg acatcagcgg cgccaccgtg cactgggtct ccaccaccac 10620 cgatgtgagc cggcaggccg ccgagtaccg caggggccgg gtcttcctgg ccggcgacgc 10680 cgcccacatc catctgccca tcggcgccca gggaatgagc gccggcgtgc aggacgcggt 10740 caacctcggc tggaagctcg ccctggagat caagggccag gctcccgagg gcctgctcga 10800 cacgtaccac tccgagcggc acccggtcgg cgcgcgggtc ctcaccaaca cgctcgccca 10860 gcggatcctc tacctcggcg gcgacgagat caccccgctg ctcgatgtgt tcaccgagct 10920 caccgggttc gaggacgtcc agaagacgct gatcggcatg gtcaccggcc tggacatccg 10980 ccatgacgtg ggcgagggcg accatccgct cctcggccgc cgtctcaagg acgaggagct 11040 ggtggtcgac ggcaagaaga ccaccaactt cgaactcctc gcggccggca aggccgttct 11100 gttcaacctc accgatgacc cccacctgcg ggagctcgcc gcgggctggg ccgaccgtgt 11160 caccacggtc accgccgagc agcacgactg cgacaacggt ctggacgcct tcctggtccg 11220 tcccgacggc tatgtcgcct gggtcgcccc ttccgcgtcg cgcacggagg ggctcgccga 11280 agcactcaac cgatggttcg gccggcccaa ctgagccggg cctgactccc tttcacatcc 11340 gtagacccga aggaagcgaa gaacatgccc aagatttcct ctgatgacaa gcacctgacc 11400 gtcctcaacc tgttctccac ggacgccccg gagaagcagg agggtctgct cggcgcgatg 11460 cgcgagatcg tcgacgcggc cgcctacccg ggctggatgt cgtccaccgt gcacgccggc 11520 gtggacaagc cgggcacggc caacttcatc cagtggcgca gccgcgcgga ccttgaggac 11580 cgctacgacg gcgaggagtt caagcaccgc acgctccccc tcttcggcga gctgaccacc 11640 tcgatccggc tgctccagaa cgaggtcgcg tactcgcaga ccaagtcggg cgacagcgtc 11700 gagatctccc cggcccgcac cgacttcacc gtcatcgcgg tcttcggtgt cgaggagaag 11760 aaccaggacg acctggtcga cgcgctcggc ccgtcgatga agttcctcag cgacgttccc 11820 ggctacgtct cgcacaccgt cctgaagggc atcgcggccc gtggccttga gggctccttc 11880 gtggtctcct actcgcagtg ggagagccag gaggccttcg tcgcctacca ggccgtcgcg 11940 caggccgaca agcccgccgc ccgccaggac gcggagaagc gcaccggctc gctcctgacg 12000 tcggtggact ccaacaccta ccgcgtggtc cacacccgcg cggccggcga gtaacgagac 12060 ggagcgttcc gctccagcac gacacgtacg cacggacgcc cgactcccct cgcggagccg 12120 ggcgttccgg cgttttgggg cccggtcgcg cccctttccg ccgccaagac ggtccggttc 12180 gcgacctgac ggcacctgac gcccacgtga caattccgcg ccgactcgct gctcttcgct 12240 gcgagttctc tgacatggct gcgggacatt tgcggaacct gaccgaaccg gacgtagacc 12300 tgaaccgggg cgccttgaaa ggacatgccc gctcagcgga cccttgaatg catgatccgg 12360 ggcgtggttc gccaccgctg atcctctcgc tcaactcccg ctcatggccc tcgcattcgg 12420 gcgcgtccga cgtcgtacgc gcaagaggcg gagccagtgc cggatcaacc gcaaccgctg 12480 aggagcgaat acgtatgcac agcacgctca tcgtcgcccg catggaaccc ggttcgagca 12540 ccgacgtcgc caagctcttc gccgagttcg acgcgacgga gatgccgcac cggatgggaa 12600 cgctgcgccg ccagctgttc tcctaccggg gcctctactt ccacctgcag gacttcgacg 12660 cggacaacgg cggtgagctg atcgaggccg cgaagaacga cccgcggttc atcgggatca 12720 gcaacgacct gaagccgttc atccaggcgt acgacccggc cacctggcgc tcgcccgccg 12780 acgccatggc cacgcgcttc tacaactggg aggggcgcgc gtgacaacgc ctcgcagggt 12840 ggtcatcacc gggatggagg tcctcgcccc cggtggcatc ggcaccaaga acttctggag 12900 cctcctcagc gagggccgca cggcgacccg ggggatcacg ttcttcgacc ccacgccgtt 12960 ccgctcgcgg gtggccgccg agatcgactt cgacccgtac gagcacggtc tgagcccgca 13020 ggaggtccgc cgcatggacc gggccggcca gttcgcggtc gtcgcctcgc gcggcgcggt 13080 cgccgacagc ggtctggagc tcgccggcct cgacccgtac cgggtcggtg tcacggtcgg 13140 cagcgcggtc ggcgccacca tgggcctgga cgaggagtac cgggtcgtca gcgacggcgg 13200 ccggctcgac ctcgtggacc accagtacgc ggccccgcac ctctacaacc acctggtgcc 13260 gagctcgttc gcggccgagg tggcctgggc ggtcggcgcc gagggcccca gcaccgtggt 13320 ctccacgggc tgcacctccg gcatcgactc ggtcggctac gccgtcgagc tgatccgcga 13380 gggctccgcc gacgtcatga tcgccggatc ctcggacgcg ccgatctcgc cgatcaccat 13440 ggcgtgcttc gacgcgatca aggccacgac gaaccgttac gacgagcccg agacggcctc 13500 gcggccgttc gacaactcgc gcaacggctt cgtcctgggc gagggcaccg cgttcttcgt 13560 cctggaggag ctggagagcg ccgtcaagcg aggcgcccac atctacgcgg agatcgccgg 13620 ctacgccacg cgctccaacg cgtaccacat gaccggactg cgccccgacg gcgcggagat 13680 ggccgaggcg atccgcgtgg cgctggacga ggcgcggatg aacggcgacg agatcgacta 13740 catcaacgcc cacggctccg gcaccaagca gaacgaccgc cacgagacgg cggcggtcaa 13800 gcggatcctc ggtgaccacg cctaccggac gccgatgagc tccatcaagt cgatggtggg 13860 gcactcgctc ggcgcgatcg gctccatcga gatcgccgcg tccgcgctcg ccatggagta 13920 caacgtcgta ccgcccacgg ccaacctgca cacgcccgac cccgagtgcg acctggacta 13980 cgtcccgttg accgcccgcg accgcaagac cgacgcggtc ctctcggtcg gcagcggctt 14040 cggtggattc cagagtgccg tggtgctcgc ccgtcccgag aggaagctcg catgacgtcg 14100 tccgtggtgg tcaccggcct gggggtggcg tcccccaacg gactcggcat ccaggactac 14160 tgggcggcga ccgtcggtgg caagagcggc atcggccgta tcacccgctt cgacccgtcg 14220 tcctacccgg ccaagctggc cggcgaggtc ccgggcttcg tcgcggagga cctgctgccc 14280 agccgcctgc tcccgcagac cgaccgggtc acccggctgg cgctcgtcgc cgccgactgg 14340 gcgctcgccg acgcgggcat caccccctcc gaactcggcg agttcgacat gggcgtggtg 14400 accgcgagcg cggccggcgg cttcgagttc ggccagggcg agctccaggc gctgtggtcc 14460 aagggcagcc agtacgtctc ggcgtaccag tccttcgcct ggttctacgc ggtcaacagc 14520 ggccagatct ccatccgcaa cgggatgaag ggccccagcg gcgtggtcgt cagcgaccag 14580 gccggcgggc tcgacgcggt ggcgcaggcc cggcggcaga tccgcaaggg caccagcgtg 14640 atcgtgtccg gcgccatcga cgcctcggtc tgcccgtggg gctgggtggc gcagctggcc 14700 agcgaccggc tctccaccag cgacgagccg acccgcgcct atctgccgtt cgaccgcgac 14760 gcctcgggct atgtggcggg cgagggcggc gcgatcctga tcatggagga cgccgagtcg 14820 gcccgcgccc gtggcgcccg tgtctacggc gagatctccg gctacggctc gaccatcgac 14880 ccgaaggccg gctccggccg cccgccgggg ctgcgcaagg ccatcgaact cgccctggcg 14940 gacgcggggg tcgccccggg tgaggtggac gtggtcttcg ccgacgcggc cgccgacccc 15000 gagctcgacc ggcaggaggc cgaggccatc aacgccgtgt tcggcacccg cggcgtgccg 15060 gtcaccgctc ccaagacgat gaccggacgg ctctactcgg gcgccgcccc gctggacctg 15120 gccgccgcct tcctcgccat gaaggacggt ctgatcccgc cgaccgtgca catcgatccg 15180 gccgccgagt acgacctgga tctggtcacc ggcgagccgc gcaccgccga ggtgcgcacc 15240 gcgctggtcg tggcccgcgg ctacggcggg ttcaactccg cggtggtcgt gcgcgccgcg 15300 tagcgctccg cgggagtgcg ttgttcgact gcaggccgtc tgtggctggt cgcgcagttc 15360 cccgcgcccc ttcggggcgc ggtacttacc taggaaaggg aaatcccatg gccaccacgt 15420 tcaccctcga cgacctcaag cgcatcctcc ttgaggcagc cggcgccgac gagggcgtcg 15480 acctggacgg cgacattctg gacaccgagt tcgaggtcct gggatacgag tcgctcgccc 15540 tgctggagac cggcggccgc atcgagcgcg agtacggcat ctcgctggac gacgacgcgc 15600 tgaccgacgc ggtcaccccg cgcgccctca tcgaggtcgt caacgcccag ctgtccgccg 15660 cgtccgccgc ctgagccgct cgaacaagga agaggaatca tgaccgagaa caccgcacgg 15720 gtcgcgctgg tcacgggtgc cacgagcggc atcgggctct ccgtcgcccg gctgctcggc 15780 tcgcagggcc acaaggtctt catcggcgcg cgcaacgccg acaacgtcgc cgagacggtc 15840 aagcagctcc agggcgaggg cctggaggcc gacggctcgg cgctcgacgt caccgacgcc 15900 gccagcgtca aggccttcgt ccaggcggcc gtcgaccgct tcggcaccgt cgacgtgctg 15960 gtgaacaacg ccggccgctc cggtggcggc gtcaccgccg acatcgagga cgagctgtgg 16020 gacgccgtca tcgacaccaa cctgaacagc gtcttccggg tcacccgtga ggtcctgaac 16080 accggtggca tgcgccacaa ggaccgcggc cggatcatca acatcgcctc caccgcgggc 16140 aagcagggcg tggtgctcgg cgccccgtac tcggcctcca agcacggtgt ggtcggcttc 16200 accaaggccc tgggcaacga gctcgcgccc accggcatca cggtcaacgc cgtctgcccc 16260 ggctacgtcg agacgccgat ggcgcagcgc gtgcgccagg gctacgcggc cgcgtactcc 16320 acctccgagg acgcgatcct ggagaagttc cagtccaaga tcccgctcgg ccgctactcc 16380 accccggacg aggtcgccgg tctggtcggc tacctcgcct cggacacggc cgcgtccatc 16440 accgcgcagg cgctcaacgt ctgcggcggc ctcggcaact tctagcccac gtacccgaag 16500 gagcagcgga tatgacgacc cgcgaggtcg agcacgagat caccatcgag gcccccgccg 16560 ccgccgtgta ccggctgctg gcggaggtca ccaactggcc gcggatcttc ccgccgacga 16620 tctacgtcga ccaggtgggc gagcacgaca accacgagcg catccggatc tgggccaccg 16680 ccaacggcga ggccaagaac tggacctcgc accgtgagct cgaccccgag gcgctgcgga 16740 tcaccttccg ccaggaggtc accacgccgc cggtcgccgc gatgggcggc acctggatca 16800 tcgagaccct gggcgagacc acctcgcggg tccggctgct ccacgactac cgggcgatcg 16860 acgacgaccc cgaggggctg gcctggatcg acgaggcggt cgacaagaac agccgctcgg 16920 agctggccgc gctgaagcag aacgtcgaac tggcccacgc gaccgaggag gtgacgttct 16980 cgttcaccga caccgtcatc gtccagggct cgcccaagga cctgtacgac ttcatcaacg 17040 aggcgaacct gtggtccgag cggctgccgc acgtggccgt cgtccggctc accgaggaca 17100 ccccggggct gcagaccctg gagatggaca cccgcgccaa ggacggctcg gtgcacacca 17160 ccaagtcgta ccgggtgacc ttcccgcacc acaagatcgc gtacaagcag gtcacgctgc 17220 ccgcgctgat gaccctgcac accgggatct ggacgttcga ggagacgccc gagggcacgg 17280 ccgcctcctc gcagcacacc gtcacgctca acacggacaa catcgcgaag atcctcggcc 17340 ccgaggccac cgtcgcggac gcccgtgagt acgtgcacac cgcgctgtcc accaacagca 17400 cggcgacgct caaccacgcc aagacgtacg ccgagtcgaa gggctgagcc acagatgacc 17460 ccggaccgcc tggacacaca ggtcatcgtc gtcggcgccg gccccgtcgg gcttctgctc 17520 gccggtgagc tgcgtcttgg cggcgccgac gtggtcgtac tggaacaacg ggccacgccc 17580 accacggagt cgagggcctc cacgctgcac gcccgcacca tggagctcct tgacagccgc 17640 ggcctgctcg acctgttcgg gacgccgccg aacgagccgc gcggccactt cggcggcatc 17700 ccgatggacc tcacgctgcc cagccccttc ccggggcagt ggaagatgcc ccagacccgg 17760 accgaggcgc tgctccagga gtgggcgctg tcgctgggcg cggacatccg gcgcggccac 17820 gagctggtcg ccgtgtccga cgagggcgac ttcgtcgagg cccgggcggc cgggccggag 17880 ggcacggtcg tggtgcgcgg gcggttcctc gtcgggtgcg acggcgagga gtcggccgtg 17940 cgccgcctga cgggcgccga gttcccgggc aacgacgccg gccgcgagct gctgcgcgcg 18000 gacgtggccg gtgtcaccat cccgggccgc cgcttcgagc ggctgcccgc cgggctcgcc 18060 atcgcggcga cccgcgacgg ggtgacccgg gtgatggtgc acgagttcgg ctcccaggcc 18120 gaaccccgca ccggcgaccc ggagttcggc gagatcgcgg cggtctggaa gcgcgtcacc 18180 ggcgaggaca tcagcggcgg aaccccgctg tgggcgaact cgttcggcga cgccaaccgc 18240 cagctcacgc actaccgcga cggccggatc ctgttcgccg gcgacgcggc ccaccggcag 18300 atgccgatcg gcggccaggc cctcaacctg ggcctccagg acgccttcaa cctgggctgg 18360 aagctggctc tgcacctcgg cgagtcggcc cccgagggcc tgctcgacac gtaccacagc 18420 gagcggcacg aggtcggccg gcgggtgctt tccaacatca gggcacaggc catgctgctg 18480 ctcggcggcc aggaggtcga gccgctgcgc gcggtgctga ccgagctcct gccgtacgac 18540 gacgtccggg cgcacctcgc cgggatgatc agcggcctcg acatccgtta cgacgtgggc 18600 ggccccgagc acccgctgct cggcgcacgg ctgccggacg ccggtctcac caccggcgaa 18660 ggcccgctga gcaccgccca gttgctgcgc accgcacgcg gtgtgctcct cgacctgtcc 18720 ggtggcagtg cggtgctgtc ggacgccgcc ggctgggcgg accgggtcac cgctctgccc 18780 gccgtgccgg agaagggcgg cgccctcgac tcggtgggcg ccgtcctggt ccggcccgac 18840 ggccatgtgg cctgggccgg cgccccggac accgacggcg ccgggctgcg ggaggccctg 18900 gagcgctggt tcggcccctc gcactgagct cccgtaccgc gagaaacccc ccacccccgc 18960 gcacgaccgt acgactccac ctcacagcac gacagggcac gtccaggaaa gggaacacta 19020 tggaggggac agccgtggac accgatgtga tcatcgtcgg cgcgggtccg accggcctca 19080 tgctcgccgg ggaactgcgc ctcggcgggg cggacgtcgt cgtcgtcgaa cggctgacga 19140 agcccaccgg ccagtcccgg ggcctgggct tcaccgcccg cgccatggag atcttcgacc 19200 agcgcgggct gctgccccgg ttcggccagg gcgagacgct ggagatcagc ccgctcggtc 19260 acttcggcgg tgtgcagttc gactacaccg tcctggaggg cgcccacttc ggggcgcgcg 19320 gcattcccca gaacatcacc gagacggtcc ttgaggagtg ggcgaccgag ctcggcgtgg 19380 acatccggcg cggctgggac ttcctggaga tagccgacgg ctacctcgac ggcgacagcg 19440 tcgagatcaa ggtgcagacg cccaactcgg tacggaagct gcgcgcttcc tacctcgtgg 19500 gcgccgacgg cggccgcagc gtggtgcgcg aggcggccgg gttcgacttc ccgggcacct 19560 cggccacccg ggcgatgttc ctggccgatg tgaccggctg caacctcaag ccgcgcttcc 19620 tcggtgagcg gctgaacaac ggcatggtga tggcggcccc gctcgccgag ggcgtcgacc 19680 gcatcatcgt ctgcccggac ggcacgcccg cgcgcgccag cggcgacacg gtcagcttcg 19740 aggaggtcgc cgccgcctgg cagtcgatca ccggcgagga catctcgcac ggcggcgccg 19800 agtgggtcag cttcttcagc gacgccaccc gccaggcctc cgagtaccgg cgcggccggg 19860 tcctgctggt cggcgacgcc gcccacatcc acctcccggc cggcggccag ggcctgagca 19920 ccggcgtcca ggacgcggcc aacctcggct ggaagctggc cgcggcggtc gccgggaccg 19980 cgcccgaggg gctgctcgac acgtaccacg gcgagcgcca ccccgtgggt gcccggctgc 20040 tgatgaacac ccgcgcccag ggcatggtgt tcctcggcgg acccgaggcc gagccgctgc 20100 gccagctctt cggcgagctc atccagtacg acgacgtgaa gcgccatctc gccgggatcg 20160 tcagtggtct ggacatccgg tacgagctgg gtgacgcgca cccgctggtg gggcgccgga 20220 ttccgcctcg gcggctggtg ggggcggcgg gggagaccag caccgtcgcg ctgctgcacg 20280 cggcgcgggg tgtgctgctc gacttcgccg acgacgcggc ggtgcgggac gcggccgccg 20340 ggtggtcggg gcgcgtcgac gtcgtcacgg cggcgccgaa gccggtcgac ggcggtaccg 20400 atccgctcgc gggtgcggct gccgtgctcg tacggcccga tggatatgtg gcgtgggccg 20460 cggacacggc cgaaggcctt gctccggctc ttgagcgctg gttcggtccg gccggggtgt 20520 gacgcccact cactcggtcc cgaaggcggt ttcgcgtctg cgagccgtcc cgggttgctc 20580 gcgcccacgc ggcgaagccg cacatgtcac agccccgcgc cccttcgggc gcggggcagg 20640 cggcccactc aacagtcaac gcaaacgggg gcattgatgg aaagcacgct cgcaccgggc 20700 gcggtctccc agggcgttcg caggatcacc ctggacgccg ggggagtcac gctgtccgcg 20760 ctgctgtgcg agccggaagg gaccccccgc gccaccgtcg tcgccgtgca cggcggcggg 20820 atgagcgccg ggtacttcga cggtcaggcg caccccgagc tgtccctgct caccctcggc 20880 gcccggctcg gctacaccgt gctcgcggtg gaccggcccg gctacggccg ttccgccgcc 20940 cagctgccgg acgggctcac cgtcgccgag cagaccgagg tgctgcgggc cgggatcgac 21000 gacttcacct ccaagtaccc gacgggcgcg ggggtgttgc tggtcgccca ctccttcggc 21060 ggcaagctcg ccctgtcggc cgccgcgcac tgcaccggcg acggcctgct cggcatcgac 21120 atctccggct gcggccaccg ctacgccgtc accccgggcg tgctgcgcaa gggcctcaag 21180 cacatcgccc ggcactgggg cccgctgcgg ctctacccgc cggacacctt ccgcagcagc 21240 ggctccctgg tggcgccgat gccggagcgc gaggcgagtg aactcaagcg ctggcccgag 21300 ctgttcgcgg ccctcgcgcc gcgcgtgcgg atcccggtcc ggctcacctt cgccgagcac 21360 gagggctggt ggctgcacgg cgagcaggac ctcgccgacc tcgccgccca gctgaccgcc 21420 tcgccccgta tcgtcgtcga ccgccagccg gacgccggtc acaacatcag cctcggctgg 21480 gcggcccgct cctaccacct gcgcaccctc gcgttcctgg aggactgcat cacgcgggcg 21540 ggacgcgatg ggtgatccga gcctatgacc agcactctgg caaccccttt ccgttccctg 21600 tccgtacgga acttccggct gttcgcggcc gggcaggtgg tctccgtcgc gggcacctgg 21660 atgatggtcg tggcccagga ctggatcgtc ctgagcctgg ccgacaactc cggtacggcg 21720 ctgggcgtgg tgaccgcgct gcagttcacc ccgctgctgc tgctcaccct gtacggcggg 21780 cgcctcgccg accgctacga caagcgcttc ctgctgacct gtgccaatct cgcgtccggc 21840 gcgctggctc tggtgctcgc gctgctcgcg ttcgcggacg cggtgcagct gtggcacatc 21900 tggctgtgcg cgttcggcct cgggatggtg aacgccgtcg aggtgccgac ccggatggcg 21960 ttcgtcagcg agctggtcgg ccccgaactg ctgcccaacg cctccgcatt gagcgccgcg 22020 tacttcaaca ccgcccgggt cgtcggcccg gcgctggccg ggctgctcat caccggcttc 22080 ggcaccggct gggtcatgct gttcaactcc gtcagctatc tggccacggt ggccgggctg 22140 cggatgatgc ggccggacga actgctgcgc ggcgcacggc aggacacccg tccccgggtg 22200 atcgacgggc tgcggtacat ccgcagccgc cccgatctga agctgccgct cgccctgatc 22260 ggggtgatct cgctcgtcgg gctcaacttc cagctgacgc tgccgctgta tgccaaaacg 22320 gttttccacg ccgacgcggc ctcgttcggg ctgctgacca ccggcttcgc ggcgggctcc 22380 ctggtcgccg cgttcgtcac cacggcgcgc cgcggccgcc cctccagccg tctggtggtc 22440 gcctcggcga tcgcgttcgc ggccttggag acggtggcgg gctgggcgcc caacttcgcc 22500 tcggcgatcg tgctgctctc gctcaccggc ggggcgacca tctacttcgt ccaggcggcc 22560 aaccatcgcg tccagctcgg cagcgacccg cagtaccggg gccgggtgat ggcgctctac 22620 acgctcatcg tccagggctc caccccgctg ggatcgctcc tcatcggctg gctcgccgaa 22680 cacctgggcg cccgctcggg gttctacgtg ggcggcctgg tctcgctggc ggccgccctg 22740 acggcgctgg ccttcgaccg gcgtacggga caggaggcgt ccgacgacgt gacgacggcg 22800 acgaaggccg cgcccgaggg cgagcccgag gcggtgagcc ggtgaacgcg accgtgacac 22860 cggtgaacgc caccgtgacg ccgctgaagg cgccgcccgg ggcgggcctg ctgcatctgg 22920 tcgtcttccg gccgcccgtc gaggacgcgg cgccggtgtg cccgctgatg caggccctgg 22980 acgagctgga ggcggcccgc gcggccacct tcgtccacga cagggaccgc cgccagtacg 23040 tggcggcgca cgccaccctg cggcgcgtgc tcgccgagta caccgggcac gagcccagcc 23100 gggtgccgct cggccgggcc gaagggccct acgggaagcc gcagttgatc ggttcgccgg 23160 tcccgctgca cttcaacctc tcgcacagcc acggcctgat cgccatcggg gtcgcggcgg 23220 acccggtggg cgtcgacgtc cagcgcgtcc cgtcgcccga ggcggtcgag gtggtcctgc 23280 ccaggctgca tccgcgcgag cgcgaggaac tgcgcgctct gcccgcatcg gagcgcccgg 23340 aggcgttcgc gcggctgtgg acccgcaagg aggcctacct caagggcctg ggcaccggcc 23400 tcacccgctc gcccgcggcg gactatctgg gcgagacggc cgcggcccgc ccggccggct 23460 ggacggtgcg caacgtgccg gtacagccgg gctacgcggc cgcggccgcg ctccgccacc 23520 acccgacctg atcgagaagg cagtcgattc cgctccagga ttccgcaacc acacaggggg 23580 aaaacgaacc atgccgacca cgccgaccac acagtcctcc gccgaggtct ccgaccggct 23640 ggacgaactc agcgaacgca aggaacaggc cgtacgcggt cccagcgaca aggcgaccga 23700 ggcgcagcac gccaagggca agctgaccgc acgcgagcgg atcgaactcc tcctggacaa 23760 gggcagcttc accgaggtcg agcagctgcg gcggcaccgc gccaccgggt tcggcctgga 23820 ggccaagaag ccgtacacgg acggtgtcat caccggctgg ggcacggtcg agggccgtac 23880 ggtcttcgtc tacgcccatg acttccgcat cttcggcggc gcgctcggcg aggcccacgc 23940 gaccaagatc cacaagatca tggacatggc gctggcggcg ggcgcgccgc tggtctcgct 24000 gaacgacggc gcgggcgccc ggatccagga gggcgtctcg gcgctcgccg gttacggcgg 24060 catcttccag cgcaacacgc gggcctcggg tgtcatcccg cagatctccg tgatgctcgg 24120 cccgtgcgcg ggcggcgcgg cgtactcgcc ggcgctgacc gacttcgtgt tcatggtccg 24180 cgagacctcg cagatgttca tcaccggccc ggacgtcgtc caggccgtga cgggcgagga 24240 gatcagccag aacggactcg gcggcgccga tgtgcacgcc gggacctcgg gcgtggcgca 24300 cttcgcgtac gacgacgagg agagctgcct cgccgaggtg cgctatctgc tctccctgct 24360 gccgtccaac aaccgggaga tgccgccgct ggcgcagacc tcggacccgg tggaccgcga 24420 gggcaccgcc ctgctcgatc tggtgccggc cgacggcaac cgctcgtacg acgtgcgcgg 24480 ggtgatcgag gagctcgtcg acgacggcga gtacatggag atccacgcca actgggcgcc 24540 caacctggtg gtggccctgg cccggctgga cggccatgtc gtcggcgtcg tcgccaacca 24600 gccgtccgcc atggccggcg tcctggacat caaggcgagc gagaagggcg cccggttcgt 24660 ccagttctgc gactccttca gcatcccgct gatcaccctc gtcgacgtgc ccgggttcct 24720 gccgggcgtc gaccaggagc acgacggcat catccggcgc ggcgcgaagc tgctctacgc 24780 ctactgcaac gcgaccgtgc ctcgtatctc ggtggtgctg cgcaaggcgt acggcggtgc 24840 ctacatcgtg atggactcgc gttccatcgg agccgacctg tcgttcgcct ggcccaccaa 24900 cgagatcgcg gtgatgggcg ccgagggcgc ggcgaacgtg gtgttccggc gggagatcgc 24960 cgcggccgag gacccggacg cgatgcgcaa gcagaagatc gacgagtaca agaacgagct 25020 ggtgcacccc tacttcgcgg ccgagcgcgg tctggtcgac gacgtcatcg acccgcgcga 25080 gacccgctcg gtgctgtgcc gctcggtcac gatgctcatc gccaaggacg ccgagctgcc 25140 ccgccgcaag cacggcaacc cgccccagta gacccgacga ccacagagag gtgcacgaca 25200 tgagcgagat gacccagttc accgagcccg ccgagcccgc cgccgagtcc gccgggatga 25260 ccctggagca ctgccgcgag ctgttgcggg tcgagcgggg caaccccgat ccggaggaac 25320 tcgcggcgct ggcggcgctg ttcttcgccc acttctccgc gatcgaggcg cggcgggagg 25380 ccgcccgtgt cctgatcccg cggcagcggc gctccgcgag ctggcgccgc accgagcggg 25440 cacccggctt cgacggcccg cgcacctggc gcgcgggcgg tcccgcactc gtttgacgat 25500 gcgtcaattg ccgtaggaat acggcgattt acccaccacg acagtaagcg cgcaccccgt 25560 gcgggccgcc ccggcagggc ggcaccgccc ggggtgcgcc cctgttcggg ccctgcgggc 25620 tttacttgac acgcgctcgg ccggacgacc attctgtgcg gtgaatgggg gtcttcgtca 25680 tgcaggtgtt gccgtactgc aagctactgc ccgatcacac ggagcgccgg ggcgctccgg 25740 cggcgcccga ctgaggcgca ggcaggcgaa attcagccaa cggccatcat ggcgccactt 25800 ggacacccgt tatttaacac gccgtcagca gacccgccgg aattctgtat acgggcaggc 25860 cgatgtggcg aacgtcatgt catgactctg ccaacatcag agctgcgcca agatggccgg 25920 tttatgcgag tcgcggcgag ttacgcttgg ttgaatcgtc agttgtgccg gtcttccgct 25980 tccgcatggc ggggactggt tgacgagggc tcctgatcgt gatcacgtat ggaaacgagc 26040 aggcagcctg tccgatcccg ctcaataacc gacacagttt atttgttatt tgctcgaacc 26100 tctttgaatt ccgtagcagc ggtctgtagg ttcgtcggtg agatctggat cggatctcat 26160 attggactca ctcagatggg ggagggacat gactcgcggg ggaggcatga ctcagagttc 26220 gtcagaggca gtgctggagc ctcatatacc tgtccagcgt ggtcccggtg gaccacacct 26280 gatcgaagag ggcgtgtcgg aagcggtgcg cagggtggcc ggcctctcgc ggggccggcg 26340 gatcctcgtg gtcgacagcg acgtcgacgg cgcggagtcc ctggtgtgcc ggctgcgcag 26400 gcacggccac gaggccatcg gcgtgaagag cggtagcacc gcgctgcagg cgtacgagga 26460 cgtggacctt gtcctcctcg acctcgaact cccggacctg gacgggctgg aggtgtgccg 26520 ggccatccgc tccgtgagcg gcatccctgt gatcatcgtc accgcccggg gctccgagct 26580 cgactgtgtg ctcggcctac aggccggtgc agacgactat gtggtcaagc cctatggctt 26640 ccgggaatta atggcacgga tcgaagccgt catgcgtcgc gccaggttcc aaccgcctgt 26700 tgccagagag atcttgcacg ggcggttgcg cattgacgtg agctcccgcg aggtgagcct 26760 ggacggccgc gaggtggggc tgacccgcaa ggaattcgat ctgctctgcc tgctcgcgtc 26820 ccatccggac acggtcattc cgcgaaagcg cctgctccag caggtctggg gggactcctg 26880 gtcccgccgt actgtcgaca cccatgtcag cagccttcgc ggaaaactcg gcgacagcgg 26940 ctggatcatt actgtgcgcg gggtcggttt caagctgggc aacgggtgaa tttccgtctt 27000 tccgcccggt gtgcgcaacg gaaaaacaag ttgaacaacc gtcttatatc cgaagaattc 27060 tttggtgccg cagccggtaa atgattgccg agtgtgagac gggttttcgg gcggggttcc 27120 gggggtattg tttctcccct ggggccccgc cttctttatc agtaaccgca gtaaatatca 27180 attccgtgca acatgccgtc tcgcacacct tggcaggccc ctgaacaaca cactgaacac 27240 agcgaaaagg ccccccgcgg ccggccggga agccgggccg cgggggcctt ttcgtgaact 27300 gccgtcgtcg ccctacgggt tgagcaccca ggcggagttg tgctgggtga agccgatgtg 27360 cgggtagtac tccaccgccg ccggcgccga caggagaatg atcttcgcct gcggggcctc 27420 cttctgcgtg gcgtcgatga gcgcgcggcc gatgcccgag cgctggtagt cgccgctcac 27480 cgcgatgtcc gagaggtacg tcgcgtagga gaagtcggag atgctgcggg cgatgccgat 27540 gagcctgccc tccgcgtccc gcgccaccac cacgaggttg gcgttgcgga ccatggcggc 27600 gaaccgctcc acgtcctcga tgggacggcg ctcgccgagc ccggagctgc ggtagacgtc 27660 gaggaccgcc tccaggtcca ggtcggcgcc ctccacccgc tcagtcgtcc aggtcacgaa 27720 gctgctccaa tcgcttgaga atcacaccgt ggttgacgag gaaacgctcc gggcggagct 27780 ggccgatgtc catgccctcc tgccgcagcg tgtccccgaa gtgctcgccg gtcgcgatgg 27840 tgcggttggc ggcggactgg acggcccggt aggccttctc ccgctccacc ccgtcggcca 27900 gcagatcggc gagtacggca gagctgaaca caagaccgtc ggtctggtcg atccccgccc 27960 gcatccgctc cgggaacacc ttgaggttac ggaccaggtc ggccgccatc gtggcctgga 28020 agtgccccac cgacagcgcg tccggcagga tcacccgctc caccgactgg tgggccagat 28080 cccgctcgtg ccacagcgcc acgttctcca gggccgtggt cgcgtaaccg cgcagcagcc 28140 gggccagacc cgtcagacgc tcgctggtgg tcgggttgcg cttgtggggc atggcgctgg 28200 agccctggta cgccgaggtg cgctgctcct cgacctcgcg gacctcggtg cgctgcagca 28260 gccgcagctc cagggcgatc tgctcgacgc tcgcgccgag cacggcgacg gcctggatca 28320 gctgggcgtg ccggtcgcgg gcgacgacct ggctcggggc cggctccacc cccaggtcca 28380 gctcctcgca gacgtacgcc tcgacggagg ggtcgatcag cgcgtacgtg ccgaccgagc 28440 cggagatcgt gcccaccgcc acggccttgc gcgccgcgcg cagccgggtg atcgagcggt 28500 ccaccgcgaa cgcgaactgc gccagcttgt ggccgaagga cgtcggctcg gcgtggacgc 28560 cgtgggtgcg gccgacgatg accgtctccc agtgctccag ggcccgttcg accaggacct 28620 tgcgcagctc gaccgcggcc gcgatcacca ggtcggtggc gcgggccagg ttgtagccca 28680 gcgaggtgtc gacgaggtcg tagctggtca tgccgaggtg gacccagcgg gccgactcgt 28740 ccgggatgtc ctcgcagtac gcggcgagga acgagagcac ttcgtggtcg cgctcgcgct 28800 cgatctcctg cacccgctcg ggcgtcggga ccttggcccg ccgcatgtcc tcgaccgcgt 28860 cctcgggcac ccgtcccagg cgcgcctgcg cctcggaagc caggatctcc acccggaccc 28920 aggtcgcgta ccgcgcctgg tccgagaaga tgtccgccat cgcgggcagg gtatagcggg 28980 gaatcatgtg ggccagcacc cccagggtga gcttgtcgac aagtggatcg gacggaccgg 29040 cagtggtgca cgggccgtcg tgaggggacg ggccgtcatc agaaggcctc gaagtattcg 29100 cgctgctccc actcggtgac ctggccgtcg gcgggccgct cggccgcgcg ccaggcctcg 29160 tagcgggaca gctcgctctc cttcagcttg gccagggtgg cggccagcgg cttgccgagc 29220 agttcggcgg cctgaccggc ccggaaggcc tccagcgcct cgccgaggtc ctgcggcagc 29280 gtctcgtatg actcctcgcc gctctcccgc gtgctcgcgc cgacctcggt ggccatgccg 29340 tcgaacccgg cggagagctg ggcggcgatg ttgaggtacg ggttggcggt gggctcgccc 29400 acccggttct cgatgtgcgt gccggcgccg ccgccgacca cccggatcat cgcgctgcgg 29460 tcctcgtagc tccagccgag acgggtcggc gagagcgaga agtccgcgcc catgcggcgg 29520 tagccgttga cggtggggac cgagagcaga cacaggtcgc gggcgcggga gagcagcccg 29580 tcgatgtacg ccttgccctg gtccgagatg ccgccgccgt cggccgcgaa gaggttgcgc 29640 ccgttcgtgc tgtccatcac cgactggtgc agatgccagc cgcacgggtc gaagctgtcg 29700 acgcggggca gcgccatgaa ggaggcgtgg tagccctggc gcgcggcggt ctgcttgacc 29760 acggtgcgga acaggagcat cgcgtcggcg gtgtccagcg cgtgcatcgg gttgaaggtc 29820 gtctcgatct ggcccgggcc cgactcgtgc tcgatcgagc gcagcggcag gccgagttcg 29880 agcagcttca tcgccagcgg gctggtgaag tgggccaccg agtcgtagtt ggcgtccagg 29940 ttgaactggt agcccgagtt catcgcctcg accttggggg ccgcgccctg gaggccgaag 30000 ccgttgcccg cgttcccggg cggacccgcg agcttgcggg tcaggtacca ctcgacctcc 30060 aggccgagca ccggggtgag gtcgcgggcc gcgtaccggg cgacgacctg gcgcagcacg 30120 ttccgcgcgg agagcgggtg cggggagccg tcgcgcagat actcgtcacc gagcacccac 30180 gcggtgcgcg gtccctcgtg ggggagcacc tggaacgtca gcgggtccgg gaccagcacg 30240 aagctgcccg cgcccgcgat ctcgtcgacg ccgacgcccg ggtcggcgag gaagtccagg 30300 gcggccgcgt ggccggtgtc gaagatgaac gggcccgagc tgaagtccat gccgttgcgc 30360 aggaccgagc ggaacgcgtc cacggtcagc gtcttggagc gggccagccc gtgcgggtcg 30420 gcgaaggcga ggcggaccag gtcgatctcg tcgagcgagg cctcgatctg ctcggccgca 30480 gcggcctgtt cgtcggtcca caggccgaac tcggtgacga acgcgggacg tcctgtgccg 30540 cccgcctcgg agaaggggct ggaccacgac cgggagtaca tgggttacag gatcctttcg 30600 gttactcggt ccggtgcggc cggcagcggc ccgaggtccg cctccagacg gcgtgcggcg 30660 gacaggacca gatcgtccgc gccgaagggg cccacgagtt ggagccccac cgggagaccg 30720 gcgcgggtga gtccggccgg gagcgaaacg gccggctggc cagtcatatt gaagggatac 30780 gcggcgggtg tccacgccag ccagagcagg tcctccggac ggctggccca gtcagggccg 30840 atcgcgtggg gatcgatcgg ctcgatgggc acggtggcca tcgcgagcag gtcgtaccgg 30900 tcgaagatct ggtgcagtgt ggtgcgcagc gccagacgca cctcctcggc ccgcatcacg 30960 gtggccgcgc tgagcgtgcg gccgtgccgc acgatcgcga ggcggcccgg gtcgcaccac 31020 tcctcgtcgg cgggcgaggt acccgccgcg tcgctcgcgg cgaggatgtc gacgagcgcc 31080 ggatacgggt cgcggaacgg cacctcgatc cgctcgacgc ggtgcccctg cgcggcgagc 31140 gcgtccagac cctgctcgct gacccggcgg acctccggcg aggtgcccgg gaactcgatc 31200 cagccgatgc gcaaccgccg ccgctggcgg ggcagttcat gcacgccgag catcgagtcc 31260 gggtcctgcg gatgcccgcc ggtgatcacc gaggcgagct cgatgacgtc cggcacggtg 31320 cgcgcgatcg gcccctggtg ggagagccgg tcggcgcagg cgggcacata cggcaccttg 31380 gcgaacgacg gcttgtagcc gaccacaccg cagaacgccg acgggatacg gatcgagccc 31440 gcgccgtcgg tgccgagcgc ccccgagccg agccccgccg cgaccgcggc cgcggcgccg 31500 ccgctggagc cgccggcgga gagttccaga tcccacgggt tacgggtggg cggggccacc 31560 cggctcaccg tggaggcgct ccacccgtac tccgacgtcg tggtcttgcc gatgacgatg 31620 gccccggcgg cccgcagccg cgcgaccgag ggcgcgtcgg cccggggccg ccggttctcc 31680 aggagggacc cacgggcagt gggcaggtcc ccggtctgga tgaggtcctt caccgagacc 31740 gtgatcccga gcagcggctg ccggtcgaag acggccgggc cctcctcgcg gatccgggcg 31800 tcggccagtt cggcctcccg cacggcctcg tcgcccgcga ccgagacgaa ggcgccgagc 31860 tcgatgtcgg tcttctggat cgcggtgagg accgactgca catggtcggc ggcggacagc 31920 tctccccggg cgaggaggtc gcgtatgtcg ccaatggacg ctgaggtcaa cggagcagct 31980 cctcgtcaga acggggtggg ccgccggtca cgagacctgc tgcggctgct tggcgcgcgc 32040 cgccgcggcc tggaccgact tgaggtgcca ctcggagtcg aaggcggtga cctcgatctc 32100 ctcgcccgcg gccaccagcg cggcggcggc gctcatggcg ccggcgatga accccgaggt 32160 gcggtgcgcg gcgagcaggt cggactcgtc gaacggggtg ccgtcgcagc gcagcagacg 32220 caggtccatg aacccgttga acctctggcc cagcacctcg accgactgcg ggctgcggat 32280 gctgaaccgc accttcgacg ccacatggcc gtggtggtgc tggtcggagt agaaggcgac 32340 gtcggggatg gtcggcggga tgaagtggtc gcgctccacc acggcgggca ccttgggcag 32400 gttcccggcg atgaagtgcc aggagttgta ctgcatgcgg gacgacatcg cccaggcgtt 32460 gtcggccagt tgcagcaccg agtcctcgta gtggcgcttg gccgacgggg cgggcaccac 32520 gcagcagaag aagtcggtga tgtcccactt ggtgatctcg gcgtagctct gctcccgcag 32580 ggcgcgcatc agttcgggga tcgaacgcat gccccggctc atggcgaagt cggcctcgaa 32640 gacctccgtc gccccggcca ccgtctcgta caccagggcc tcaagtccgg taccgaactc 32700 gccgtacggc cgggcgagcc aggaggggga cgcggccagg ctcgcgcgga gctcggcgaa 32760 ggtggcgccg gtgaccggga gacgctcgct cagcagggcg gcgagctccg cctcgcgctg 32820 ctgcgacttc tccccgtacg gaccggccag gcgctcgatc ttgtgcatca gcgcgccgtg 32880 gatctcgcgg tagagctggg cgttggggat gacatggccc atgcggcgct cgcgcagcgc 32940 catggcgagg gcgttcagcg cctcgacgcg gtgcgtggga gcgggcggga cgagctcgcc 33000 gccggggacc gcgttgtagt tgccgcgggt gcgctccagc atgtacgcga tgtgatccag 33060 cgtcagctgg gtgccgttgg cctcctcgat gcgcccggcg cccgcggagc gcaccagcag 33120 cgtgaggcag acgaccatca ccgcgtcgtg gtccgaccac tgctccatgg agacgcccat 33180 cagacggctg aacgtctcgt tggggtggcc cgcccacagc gtcttgccga tgacgttgtt 33240 ggtctcgcgg aagttggtgt agagcttccc ctcctggtgc agcacgaagg gggcggtccg 33300 cagcgcggac tcccgcagca tctccaggag ttcgtcacgg gcctgggtgc cgagcgccgc 33360 cagccactgg cggcagtcga cgacctggtc ggcgaagcgg gcggccgcgc ggtcgacctc 33420 gctctcgtag tcgagcaggt cctgcgccga ccacggcacg ctcatgacgc cctcgaccag 33480 cttctcctcg tcctccaacg gcccctgcga gggcacgcgg acgacgatgc ggccggtcgt 33540 ggtcaggccc agctcgccga ggaacgcggg gcgctccttg acgtcgcgca cgggcgtcgg 33600 caggttctcc tcgcgccacg agatgccgca gagcaccttg agcgcggcct cgtcggcggt 33660 gcgcagggcg cgcagctgga cctcggcggg gacgtggccg tccagggtga gcagggcgtt 33720 caccgcgccg cgcaggtccg gggccgcggt cgcgcgctcc caggcgcgct tgagcagagt 33780 ggggaaaccg gcctcctcgt ctttgaggcg gtccggcttc ggcgtggccc cggccaccgc 33840 gccctggcgg ctcggccggc ggctctgccg cttcttggcg ttgatggccc ggcgggaggt 33900 gccgttgcgc tcggcggaac ttgtcatgac acaccctcag cggtaagccc gatgtgcttc 33960 cacatctcgt cggtcgtggg cgtccagtcc tcgtcgacgt agatgcagtc gaccgggcac 34020 tccaggacgc acttggggca gccggagcac agttcgggga tgatgacgac gtcgagtccg 34080 ttgtcgaaga tcgcgttgaa ctcgggcggg caggcacgca ggcaggtgtc gcaggtgatg 34140 cactccgcgc gctcgatacg gcgtggcggc ttcttccacg tttcgctgcg ggtccgctcg 34200 gcgatcagct tgtcgcgccc ggacaccgag ccttccactg tctcgtccag cgagtcgtcc 34260 gaagtgttcg tgggcattcg gcccccctct tgtcctgttt cgctcgtgcc acggtaagag 34320 agcattaata actgcgccgc agtgcggcga cgacggccag aattacacgc ggccccgctc 34380 catgggaacg gcggacgagc ggtgtgcaga cgcggatttc atggctgcgg tggattcctg 34440 ctagagggaa tcttgaaccc gcgggcttct gataatccac cgttccgcaa ggggacgcaa 34500 tatgctcaag tcaccgcgcc gacgtccgtc acaagacggc gcgggggatc cgtgtcggtt 34560 tcgttgatac ccgctctgac ctgctgcgat tgggtgatcc gggcttcggc ttcgcccccg 34620 cgggccggac cggggcgggc cccgtcgggc gacggtatac gcgaacggcg gccgtgcaac 34680 cgcggaactc acgcagtcga acaccgcgac cgggtgcact ccggtttgtc aactccgtgc 34740 acggaaaccc actggagtca ccctaccgtt ttactggtgt tgtgtccgtc atcggatacg 34800 cgtgtatatc gcacgcggtg aatgctccct aaacggagat atccgcgtta tggccggggg 34860 aaagggaatc cattgtgcgg gaacagcagc agtgcgttgg aacctggcgc gacgcatgac 34920 ggnttcgatc cgtnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 34980 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ncggcggcgc cactggtgtt gggggcgtgt 35040 cacctcaagt tccgtcgccg taagcccagt tcatgagggg gactggggga gtcatggcgc 35100 ggaagggggc acacgcgggc cgctcggcgg ccggccctca gtcgttcagg atcgtcagat 35160 cgagccggtc cagccgctcg ggcgcggccc gcatgtcgat cccggtgatc ttctcgtcca 35220 cgacggtgaa cccgaagacg accctcggcc gcccgcgcgg cgcccacacc gccccgacga 35280 cgccgtcgac cagcgccagc ttggcgtact tggcgcgccc cgagaacgcg tccgccaccg 35340 agcccgcgcc ccgcacctcc gtcggcgccc ccaccgccac cgcctccggg tcggcgcgga 35400 gcaccacgtc cggggcgagc agcgcggtca gggtggcgaa gtcgccgccg cgcgaggcgg 35460 tcaggaacgc gtcgacgatc cggcgcagcc gcgtcgtacc gtcgtccggc agcggatcga 35520 cccgccgcac ccgcgcccgg gcccggtcgg ccagctcgca cgcctcctcg gcgccggtcc 35580 ccacgatcgg cgccacctcg tcatagggga ggccgaacag atcgtgcagg acgaacgcca 35640 tccgctcggc cgggtccagc gtctccagga cgacaaggag ggcgaggccc accgagtccg 35700 ccagcacctc ctcgtgcgcg gggcccatcg aggcgagttt ggcggccagt tcggccggga 35760 ccgggtcggc cagatccaag cttttcgatc agaaacttct cgacagacgt atatcaggct 35820 tcccgggtgt ctcgctacgc cgctacgtct tccgtgccgt cctgggcgtc gtcttcgtcg 35880 tcgtcggtcg gcggcttcgc ccacgtgatc gaagcgcgct tctcgatggg cgttccctgc 35940 cccctgcccg tagtcgactt cgtgacaacg atcttgtcta cgaagagccc gacgaacacg 36000 cgcttgtcgt ctactgacgc gcgcccccac cacgacttag ggccggtcgg gtcagcgtcg 36060 gcgtcttcgg ggaaccattg gtcaagggga agcttcgggg cttcggcggc ttcaagttcg 36120 gcaagccgct cttccgcccc ttgctgccgg agcgtcagcg ctgcctgttg cttccggaag 36180 tgcttcctgc caacgggtcc gtcgtacgcg cctgccgcgc ggtcttcgta cagctcttca 36240 agggcgttca gggcgtcggc gcgctccgca acaaggttcg cccgttcgcc gctcttctca 36300 ggcgcctcag tgagcctgcc g 36321 2 1785 DNA Streptomyces murayamaensis ATCC 21414 2 gtgagtccgg aacgtctcaa ttccgtggac ttccgcgacc aggtgctgcc caagctcgcg 60 gccaccaccg gtctgctggt ggtggacgag gcgcactgca tctccgactg ggggcacgac 120 ttccggccgg actaccggcg gttgcgggcg atgctgaccg agctgcccgc cggggtgccg 180 gtgctggcca ccaccgcgac cgcgaacgcc cgggtcaccg ccgacgtggc cgaacagctg 240 ggtaccgggg ccggtgaggc gctggtgctg cgcggcccgc tggagcgcga gagcctgcgc 300 ctgggcgtgg tccggctgcc ggacgcccca caccgcctgg cctggctcgc cgagcacctc 360 gacgagcttc agggctccgg gatcatctac accctcaccg tggccgcggc cgaggaggcc 420 accgccttcc tgcgccagcg cggcttcaag gtgtcctcgt acacggggcg cacggagaac 480 gccgaccgtc tgcaggcgga gaccgacctc caggagaacc aggtcaaggc gctggtggcg 540 acctccgcgc tcggcatggg cttcgacaag ccggacctcg gcttcgtgat ccacctcggc 600 tcgccgtcct cgccgatcgc ctactaccag caggtcgggc gcgccgggcg cggggtcgag 660 cacgccgacg tcctgctgct gccgggcaag gaggacgaag ccatctggcg ctacttcgcc 720 gacacggcct tcccgcccga ggtccaggtc cgccagaccc tgtcggccct cgccgacgcg 780 ggacggccgc tgtccgtacc ggccctggag gcggcggtcg acctccggcg cagcaggctg 840 gagacgatgc tgaaggtgct ggacgtcgac ggcgccgtga agcgggtgaa gggcggctgg 900 acggccacgg gggcggactg ggtgtacgac gccgagcgct acgcctgggt ggcccggcag 960 cgggcggccg agcagcaggc catgcgcgat tacgtgagca cgacgcggtg ccggatggag 1020 ttcctgcgcc ggcagctgga cgacgagggg gcggccccgt gcggccgctg cgacaactgc 1080 gcgggagcgt gggccgattc cgccgtgtcg gcggagacgg tgacgggggc ggcgaaggaa 1140 ctggaccgcc cgggggtgga ggtcgagccg cgccggatgt ggccgacggg gatggccgcg 1200 ctgggcgtcg acctcaaggg gcgcatcccg gccaaggagc agtgctccac cggacgcgcc 1260 ctggggcgcc tgtcggacat cggctggggc aaccggctgc gcccgctgct ggccgagaac 1320 gcgccggacg gacccgtccc ggacgacgtc ctgcgggccg cggtcgcggt cctcgccgac 1380 tgggcgcgct cgccgggcgg ctgggcgccc gacgtcccgg acgccgtcgc ccgtccggtg 1440 ggagtcgtcg cgatgccgtc cctggcccgc ccccgactgg tcgcctccct cgccgagggg 1500 atcgcgacgg tcggccgcct gcccttcctg ggcaccctga cgtacacggg cccggacgac 1560 gcgcacgcgg cgcggcgcag caactccgcg caacgcctgc ggacgctgtc gggtgccttc 1620 accgtctccg aggacctggc caccgcgctg gccgccgccc ccggccccgt cctgctggtg 1680 gacgactaca ccgactccgg ctggaccctg gcggtagccg cccgcctact gcgccgcgcg 1740 ggcagcgacc aggtcctccc cctggtcctg gcggctacgg gctga 1785 3 594 PRT Streptomyces murayamaensis ATCC 21414 3 Val Ser Pro Glu Arg Leu Asn Ser Val Asp Phe Arg Asp Gln Val Leu 1 5 10 15 Pro Lys Leu Ala Ala Thr Thr Gly Leu Leu Val Val Asp Glu Ala His 20 25 30 Cys Ile Ser Asp Trp Gly His Asp Phe Arg Pro Asp Tyr Arg Arg Leu 35 40 45 Arg Ala Met Leu Thr Glu Leu Pro Ala Gly Val Pro Val Leu Ala Thr 50 55 60 Thr Ala Thr Ala Asn Ala Arg Val Thr Ala Asp Val Ala Glu Gln Leu 65 70 75 80 Gly Thr Gly Ala Gly Glu Ala Leu Val Leu Arg Gly Pro Leu Glu Arg 85 90 95 Glu Ser Leu Arg Leu Gly Val Val Arg Leu Pro Asp Ala Pro His Arg 100 105 110 Leu Ala Trp Leu Ala Glu His Leu Asp Glu Leu Gln Gly Ser Gly Ile 115 120 125 Ile Tyr Thr Leu Thr Val Ala Ala Ala Glu Glu Ala Thr Ala Phe Leu 130 135 140 Arg Gln Arg Gly Phe Lys Val Ser Ser Tyr Thr Gly Arg Thr Glu Asn 145 150 155 160 Ala Asp Arg Leu Gln Ala Glu Thr Asp Leu Gln Glu Asn Gln Val Lys 165 170 175 Ala Leu Val Ala Thr Ser Ala Leu Gly Met Gly Phe Asp Lys Pro Asp 180 185 190 Leu Gly Phe Val Ile His Leu Gly Ser Pro Ser Ser Pro Ile Ala Tyr 195 200 205 Tyr Gln Gln Val Gly Arg Ala Gly Arg Gly Val Glu His Ala Asp Val 210 215 220 Leu Leu Leu Pro Gly Lys Glu Asp Glu Ala Ile Trp Arg Tyr Phe Ala 225 230 235 240 Asp Thr Ala Phe Pro Pro Glu Val Gln Val Arg Gln Thr Leu Ser Ala 245 250 255 Leu Ala Asp Ala Gly Arg Pro Leu Ser Val Pro Ala Leu Glu Ala Ala 260 265 270 Val Asp Leu Arg Arg Ser Arg Leu Glu Thr Met Leu Lys Val Leu Asp 275 280 285 Val Asp Gly Ala Val Lys Arg Val Lys Gly Gly Trp Thr Ala Thr Gly 290 295 300 Ala Asp Trp Val Tyr Asp Ala Glu Arg Tyr Ala Trp Val Ala Arg Gln 305 310 315 320 Arg Ala Ala Glu Gln Gln Ala Met Arg Asp Tyr Val Ser Thr Thr Arg 325 330 335 Cys Arg Met Glu Phe Leu Arg Arg Gln Leu Asp Asp Glu Gly Ala Ala 340 345 350 Pro Cys Gly Arg Cys Asp Asn Cys Ala Gly Ala Trp Ala Asp Ser Ala 355 360 365 Val Ser Ala Glu Thr Val Thr Gly Ala Ala Lys Glu Leu Asp Arg Pro 370 375 380 Gly Val Glu Val Glu Pro Arg Arg Met Trp Pro Thr Gly Met Ala Ala 385 390 395 400 Leu Gly Val Asp Leu Lys Gly Arg Ile Pro Ala Lys Glu Gln Cys Ser 405 410 415 Thr Gly Arg Ala Leu Gly Arg Leu Ser Asp Ile Gly Trp Gly Asn Arg 420 425 430 Leu Arg Pro Leu Leu Ala Glu Asn Ala Pro Asp Gly Pro Val Pro Asp 435 440 445 Asp Val Leu Arg Ala Ala Val Ala Val Leu Ala Asp Trp Ala Arg Ser 450 455 460 Pro Gly Gly Trp Ala Pro Asp Val Pro Asp Ala Val Ala Arg Pro Val 465 470 475 480 Gly Val Val Ala Met Pro Ser Leu Ala Arg Pro Arg Leu Val Ala Ser 485 490 495 Leu Ala Glu Gly Ile Ala Thr Val Gly Arg Leu Pro Phe Leu Gly Thr 500 505 510 Leu Thr Tyr Thr Gly Pro Asp Asp Ala His Ala Ala Arg Arg Ser Asn 515 520 525 Ser Ala Gln Arg Leu Arg Thr Leu Ser Gly Ala Phe Thr Val Ser Glu 530 535 540 Asp Leu Ala Thr Ala Leu Ala Ala Ala Pro Gly Pro Val Leu Leu Val 545 550 555 560 Asp Asp Tyr Thr Asp Ser Gly Trp Thr Leu Ala Val Ala Ala Arg Leu 565 570 575 Leu Arg Arg Ala Gly Ser Asp Gln Val Leu Pro Leu Val Leu Ala Ala 580 585 590 Thr Gly 4 516 DNA Streptomyces murayamaensis ATCC 21414 4 atggtcggct cctgtgtggc cgcgctcctg gctcggttcc ccggtgtccg cgtgcagctc 60 gtcgacgtcg aaccggcccg ccaggcggtc gccgcgcggc tcggcgtcgc cttcgccccg 120 cccgagcggg ccactgacga ctgcgatctc gtcttccacg ccagcgccac cgaggcgggg 180 ctgaggcgct ccctcgaact gctcgctccc gagggctgtg tggtcgatct gagctggtac 240 ggcgaccggc cggtgacgct gccgctgggg gagttcttcc actcccggcg gctgtcgctg 300 cgcggcagcc aggtcggcgc catcgcgccg gagcgccgcg cacgccacac gagggccgat 360 cggctcggca tggcgctcga cctcctgcgg gacccggtct tcgacgtact gatcaccggc 420 gagtccgatt tcgacgacct tccgcaggtc atggccgaga tcgccaccgg cgcccggccc 480 gggctctgcc accgcatccg ctacggcccc ggctga 516 5 171 PRT Streptomyces murayamaensis ATCC 21414 5 Met Val Gly Ser Cys Val Ala Ala Leu Leu Ala Arg Phe Pro Gly Val 1 5 10 15 Arg Val Gln Leu Val Asp Val Glu Pro Ala Arg Gln Ala Val Ala Ala 20 25 30 Arg Leu Gly Val Ala Phe Ala Pro Pro Glu Arg Ala Thr Asp Asp Cys 35 40 45 Asp Leu Val Phe His Ala Ser Ala Thr Glu Ala Gly Leu Arg Arg Ser 50 55 60 Leu Glu Leu Leu Ala Pro Glu Gly Cys Val Val Asp Leu Ser Trp Tyr 65 70 75 80 Gly Asp Arg Pro Val Thr Leu Pro Leu Gly Glu Phe Phe His Ser Arg 85 90 95 Arg Leu Ser Leu Arg Gly Ser Gln Val Gly Ala Ile Ala Pro Glu Arg 100 105 110 Arg Ala Arg His Thr Arg Ala Asp Arg Leu Gly Met Ala Leu Asp Leu 115 120 125 Leu Arg Asp Pro Val Phe Asp Val Leu Ile Thr Gly Glu Ser Asp Phe 130 135 140 Asp Asp Leu Pro Gln Val Met Ala Glu Ile Ala Thr Gly Ala Arg Pro 145 150 155 160 Gly Leu Cys His Arg Ile Arg Tyr Gly Pro Gly 165 170 6 399 DNA Streptomyces murayamaensis ATCC 21414 6 atgttcagcg tcaccgtccg cgatcacctc atgatcgccc acagcttcag cggcgaggtc 60 ttcggccccg cccagcgcct gcacggagcg acatacctgg tcgacgcgac cttccagcga 120 ccggagctgg acgacgacaa catcgtcatc gacatgggcc tggcaggcag ggaagtgcgc 180 gggatcgtcg cggcgctctc gtaccgcaac ctcgacgagg accccgactt cgccggaacc 240 aacaccacca cggaattcct ggccaaggtc atcgccgacc gcctcgccgc ccggatacac 300 gacggcgccc tcggccccgg cgcccagggc ctgaccggac tcaccgtacg gctccatgaa 360 tcgcacatcg cgtgggccga ctaccaccgc acgctctga 399 7 132 PRT Streptomyces murayamaensis ATCC 21414 7 Met Phe Ser Val Thr Val Arg Asp His Leu Met Ile Ala His Ser Phe 1 5 10 15 Ser Gly Glu Val Phe Gly Pro Ala Gln Arg Leu His Gly Ala Thr Tyr 20 25 30 Leu Val Asp Ala Thr Phe Gln Arg Pro Glu Leu Asp Asp Asp Asn Ile 35 40 45 Val Ile Asp Met Gly Leu Ala Gly Arg Glu Val Arg Gly Ile Val Ala 50 55 60 Ala Leu Ser Tyr Arg Asn Leu Asp Glu Asp Pro Asp Phe Ala Gly Thr 65 70 75 80 Asn Thr Thr Thr Glu Phe Leu Ala Lys Val Ile Ala Asp Arg Leu Ala 85 90 95 Ala Arg Ile His Asp Gly Ala Leu Gly Pro Gly Ala Gln Gly Leu Thr 100 105 110 Gly Leu Thr Val Arg Leu His Glu Ser His Ile Ala Trp Ala Asp Tyr 115 120 125 His Arg Thr Leu 130 8 735 DNA Streptomyces murayamaensis ATCC 21414 8 atgaatcgca catcgcgtgg gccgactacc accgcacgct ctgaccgccc ggtcatggcc 60 atacgcccgt acgtcgtgct gtccgcggcc gtctccctgg acggccggct cgacgacacc 120 tcgcgcgacc ggctcgtact ctccaaccgg cgcgacctcg accgtgtcga cgatgaacgc 180 gccgccgcgg acgccatcct ggtcggcgcc accaccctgc gcagggacaa cccgcgcctg 240 ctggtggcga gcgccgatcg gcgggcccgg cgcgtcgccc tcggcatgcc ggagcatccg 300 ctgaaggtca cggtcaccgg gtccgccgag gtgaacacgt cgtacgcgtt ctggcattgc 360 ggcggcgaga agctggtgtt cacggtggac ggagcgctcc tgcgggcccg tcgcaccgta 420 ggcgacctcg ccgacgtcgt cagcaccggc cccgctctcg actggcacct cctcctcgac 480 gaactcgggc gacgtggggt ggaacgcctt ctggtcgaag gcggcgggac ggtgcacacc 540 cagctgctgg cccaggacct ggccgatgaa ctccacctcg tcgtcgcccc gttgctggtg 600 ggcgaagccg gtgcgccggt gttcctgggc ccggcgtcgt acccgggtgg tcccgcggcc 660 cgtatgacgc tgctcgaagc acgccccgtc ggtgatgtcg tgctgctgcg ctacgccccg 720 aaactccgat cctga 735 9 244 PRT Streptomyces murayamaensis ATCC 21414 9 Met Asn Arg Thr Ser Arg Gly Pro Thr Thr Thr Ala Arg Ser Asp Arg 1 5 10 15 Pro Val Met Ala Ile Arg Pro Tyr Val Val Leu Ser Ala Ala Val Ser 20 25 30 Leu Asp Gly Arg Leu Asp Asp Thr Ser Arg Asp Arg Leu Val Leu Ser 35 40 45 Asn Arg Arg Asp Leu Asp Arg Val Asp Asp Glu Arg Ala Ala Ala Asp 50 55 60 Ala Ile Leu Val Gly Ala Thr Thr Leu Arg Arg Asp Asn Pro Arg Leu 65 70 75 80 Leu Val Ala Ser Ala Asp Arg Arg Ala Arg Arg Val Ala Leu Gly Met 85 90 95 Pro Glu His Pro Leu Lys Val Thr Val Thr Gly Ser Ala Glu Val Asn 100 105 110 Thr Ser Tyr Ala Phe Trp His Cys Gly Gly Glu Lys Leu Val Phe Thr 115 120 125 Val Asp Gly Ala Leu Leu Arg Ala Arg Arg Thr Val Gly Asp Leu Ala 130 135 140 Asp Val Val Ser Thr Gly Pro Ala Leu Asp Trp His Leu Leu Leu Asp 145 150 155 160 Glu Leu Gly Arg Arg Gly Val Glu Arg Leu Leu Val Glu Gly Gly Gly 165 170 175 Thr Val His Thr Gln Leu Leu Ala Gln Asp Leu Ala Asp Glu Leu His 180 185 190 Leu Val Val Ala Pro Leu Leu Val Gly Glu Ala Gly Ala Pro Val Phe 195 200 205 Leu Gly Pro Ala Ser Tyr Pro Gly Gly Pro Ala Ala Arg Met Thr Leu 210 215 220 Leu Glu Ala Arg Pro Val Gly Asp Val Val Leu Leu Arg Tyr Ala Pro 225 230 235 240 Lys Leu Arg Ser 10 366 DNA Streptomyces murayamaensis ATCC 21414 10 atgctcctcg ggcgcgtggc cggacggtgt gcggacgaga cgggggcgag tgtggacgac 60 gcggtggaac tggcggagat gatcggccag ttgcggagcg agctgagccg ggccatggcg 120 gacggggccg cgggcggcgg gctgcggttc caggcggaga agctggagct cgaactcacc 180 gtgggcgtgg agcgcagccg ggagccgggt gcgaaggtgc ggttctgggt gctcgacgtc 240 cacggctccg cccgctccgc gcggaccgcc acgcagcgga tcaagctcac cctgcaaccg 300 gtgctcggcg acgcacccga cagccccgcg ctgatctcgg gcgcggagct gcccgatgag 360 agctga 366 11 121 PRT Streptomyces murayamaensis ATCC 21414 11 Met Leu Leu Gly Arg Val Ala Gly Arg Cys Ala Asp Glu Thr Gly Ala 1 5 10 15 Ser Val Asp Asp Ala Val Glu Leu Ala Glu Met Ile Gly Gln Leu Arg 20 25 30 Ser Glu Leu Ser Arg Ala Met Ala Asp Gly Ala Ala Gly Gly Gly Leu 35 40 45 Arg Phe Gln Ala Glu Lys Leu Glu Leu Glu Leu Thr Val Gly Val Glu 50 55 60 Arg Ser Arg Glu Pro Gly Ala Lys Val Arg Phe Trp Val Leu Asp Val 65 70 75 80 His Gly Ser Ala Arg Ser Ala Arg Thr Ala Thr Gln Arg Ile Lys Leu 85 90 95 Thr Leu Gln Pro Val Leu Gly Asp Ala Pro Asp Ser Pro Ala Leu Ile 100 105 110 Ser Gly Ala Glu Leu Pro Asp Glu Ser 115 120 12 2949 DNA Streptomyces murayamaensis ATCC 21414 12 atgagagctg aaccgtcggc cgacgggctc gacccgcacc ggatcgccga gatcatcgtc 60 gagagccccg agggcagaag gcgcggttcc ggctaccgga tctccaccac gacggtcctc 120 accgccgccc atgtggtcgc cgacgcgacc cgcacgctcg tacggtgcga cgccgaccag 180 cccgcggagt ggtcggctcc ggccatggtg acctgggcgg atgcgggcag cgacctcgcc 240 gtgctgagcg tcggggcacc tgcggccgcc cccgtggtca ccgcacccgc ccgcttcgcg 300 cgcatcgccg acgaccggca cggggtgatc ggggtgcacg ccgccgggtt tccgctgtgg 360 aaacgccgac gccggtccga cggcgcgtac ttccgcgaac tgcaccaggc ggacggcacg 420 gtggcggcgc tctccaatct gcggaccggc acgctggaga tgaccgtggc accggccgga 480 accgaccccg acccggcggc ctcgccgtgg gcgggcatgt cgggcgcggc ggtgtgggcc 540 ggcagccgca tcatcggcgt ggtcgccgag caccaccgct acgagggccc cggacggctc 600 accgcggtcc gcctcgacca cgcgctgcgc gggctcggcg ccgcgagacg ggcggagctg 660 gcccggttgc tcgcgctgcc cgagaccgcg gatctgcccc tcgccgtccc cgggcaaccg 720 cacgacgacc gcgccccggg ggtgcgggtg gtcggcgtcc ccgtcgcgca cggcatcgag 780 ctgttcaaga accgcacccg cgaaagcgac ctgatcgccc gtcacttgag cgatccggcc 840 atccgtatgg tgtccgtcgt cggacggcgc ggcatcggca agagcgcgct cgccgcgaag 900 gtcatggatc tgctggaccg gggggaatgg cccggcgcgg ccgccggtcc cctcccgtcc 960 ggcctcgtca acctctccac ccgaacctcc ggcatctccc tggagcggct ctacttcgac 1020 tgcgtccggc tgctcggccc cgagcacgag gagcggctgc gcggggtctg ggcgggcggc 1080 ggcagcgcgc aggaccgcct cgccgcactc ttcgacgcca tgggcgggcg gctgatcgtc 1140 atcctcatgg acaacttgga ggaactgctc ggcgacgacg gcggcatcga ggacgaggag 1200 ctggccctct tcctggactg gctgttccgg gcccgcacca ccccacgtct gctcgtcacc 1260 agccaggtgc cggtgcgtct cgcgcccgaa ctgcgccgct tcgccgccga ggtgccgctc 1320 tccgaggggc tgcgccccac cgaggccgcg gccctgctgc gcgaactcga ccgggacggc 1380 agcctcggca tcgccgacct gtccgacggc gaactcctcg acgccgcggt ccgggtgcac 1440 ggcgtcccgc gcgcgctcga actcctcgtc ggcgcggtcg ccgaggagac ggtgctgctg 1500 cccagcctga aagacgtact ggaggacttc acccgccgcc acgacgtcgt cgcggacctc 1560 gcccaggacc gctaccgtcg cctcgacgag ccggcgcgtg ccgtcctcgg tgtgctcgcc 1620 gccctgcgca cccccgtgga gcagggcgcg gtggcgcaga tcgcgggcgg gctcgatccg 1680 gacctgcggg tggtccccgt cctcacggcg ctcgtccggg tccgcctggt ctccgtggac 1740 cgggccagcc ggacggtcgc cctgcacccg ttggacgcgg acatcgcccg tgaccagatg 1800 ccgtgggacg gacctttcgg gaggcaagcg gtggaacggc agatcgcagc ctggtacgcg 1860 cggcgggcga agccgcgcgg cgcctggcgg acgctggagg acgtcgagcc gcagcggcgg 1920 cagttcgacc acctggtcgg cgcgggcgac cacgacgcgg ccgcgcgggt gctggccgag 1980 atcagcgaat ggctcgtctg gcacggctcg gtgctcgccg cggtcacgat gcacctggcg 2040 gtcgacggac acctccgcga cgagcgggta cgcctcgccc acaccgtcgc gtacgggcac 2100 gcccggctca gtgcgggtcc catggagcag gcggtcgagc tgttcaccga ggccgcggcc 2160 ctcgccgaac gcctcggcga ccggcccgcg ctgcagaacg cgctgttcgg cctgggcgac 2220 gcccaccggc agctgggcga tcagggcgcc accgtcgaac cgctcgcccg cgccgccgag 2280 ttggcgcgtg aactgggcga caccgagcgc gaggcgcacg cgctgctctc cctcagcctc 2340 gcgcacagct acctcggcga cggcgagcgc gcgctggagg gggccgaccg gctggccgcg 2400 ctcgccgagg cgggcggcga cccgctcgcg ctcgcccgcg ccggcaacgc gcgcaccatc 2460 gcgctgctca ccctgggccg ctggcaggag accgccgagg cgggcgccga gacggcccgc 2520 gcctatcgcg ccgccggcag tcaggaagcg gtcgcgtacg cgctgaacgc gcagggcctg 2580 gccctgctgg ccctggacga cccggcgcgg gcggccgcgg tgctcgaaga ggcccgccac 2640 gaggcctcac tgatggagag cccccgggcc gagggcgtct gcctgctcaa cctgtcctgg 2700 gcgtactggt gcgacggccg ccgggacgag tgcgcggcca ccgccgaacg cgcctcgacc 2760 gccctccaga tcgccggagc gacccaggcg gcggcggccc gttcgctggc cgaggccgcc 2820 cgcgtcctgc ccggcgaccc tggggccgcc gccgacgccc tgatccgcgc ggcggccgcg 2880 ctggacggca acgccgaggt catcgccccc gcccggctca ccgccgaggc acgccgactg 2940 ctggactga 2949 13 982 PRT Streptomyces murayamaensis ATCC 21414 13 Met Arg Ala Glu Pro Ser Ala Asp Gly Leu Asp Pro His Arg Ile Ala 1 5 10 15 Glu Ile Ile Val Glu Ser Pro Glu Gly Arg Arg Arg Gly Ser Gly Tyr 20 25 30 Arg Ile Ser Thr Thr Thr Val Leu Thr Ala Ala His Val Val Ala Asp 35 40 45 Ala Thr Arg Thr Leu Val Arg Cys Asp Ala Asp Gln Pro Ala Glu Trp 50 55 60 Ser Ala Pro Ala Met Val Thr Trp Ala Asp Ala Gly Ser Asp Leu Ala 65 70 75 80 Val Leu Ser Val Gly Ala Pro Ala Ala Ala Pro Val Val Thr Ala Pro 85 90 95 Ala Arg Phe Ala Arg Ile Ala Asp Asp Arg His Gly Val Ile Gly Val 100 105 110 His Ala Ala Gly Phe Pro Leu Trp Lys Arg Arg Arg Arg Ser Asp Gly 115 120 125 Ala Tyr Phe Arg Glu Leu His Gln Ala Asp Gly Thr Val Ala Ala Leu 130 135 140 Ser Asn Leu Arg Thr Gly Thr Leu Glu Met Thr Val Ala Pro Ala Gly 145 150 155 160 Thr Asp Pro Asp Pro Ala Ala Ser Pro Trp Ala Gly Met Ser Gly Ala 165 170 175 Ala Val Trp Ala Gly Ser Arg Ile Ile Gly Val Val Ala Glu His His 180 185 190 Arg Tyr Glu Gly Pro Gly Arg Leu Thr Ala Val Arg Leu Asp His Ala 195 200 205 Leu Arg Gly Leu Gly Ala Ala Arg Arg Ala Glu Leu Ala Arg Leu Leu 210 215 220 Ala Leu Pro Glu Thr Ala Asp Leu Pro Leu Ala Val Pro Gly Gln Pro 225 230 235 240 His Asp Asp Arg Ala Pro Gly Val Arg Val Val Gly Val Pro Val Ala 245 250 255 His Gly Ile Glu Leu Phe Lys Asn Arg Thr Arg Glu Ser Asp Leu Ile 260 265 270 Ala Arg His Leu Ser Asp Pro Ala Ile Arg Met Val Ser Val Val Gly 275 280 285 Arg Arg Gly Ile Gly Lys Ser Ala Leu Ala Ala Lys Val Met Asp Leu 290 295 300 Leu Asp Arg Gly Glu Trp Pro Gly Ala Ala Ala Gly Pro Leu Pro Ser 305 310 315 320 Gly Leu Val Asn Leu Ser Thr Arg Thr Ser Gly Ile Ser Leu Glu Arg 325 330 335 Leu Tyr Phe Asp Cys Val Arg Leu Leu Gly Pro Glu His Glu Glu Arg 340 345 350 Leu Arg Gly Val Trp Ala Gly Gly Gly Ser Ala Gln Asp Arg Leu Ala 355 360 365 Ala Leu Phe Asp Ala Met Gly Gly Arg Leu Ile Val Ile Leu Met Asp 370 375 380 Asn Leu Glu Glu Leu Leu Gly Asp Asp Gly Gly Ile Glu Asp Glu Glu 385 390 395 400 Leu Ala Leu Phe Leu Asp Trp Leu Phe Arg Ala Arg Thr Thr Pro Arg 405 410 415 Leu Leu Val Thr Ser Gln Val Pro Val Arg Leu Ala Pro Glu Leu Arg 420 425 430 Arg Phe Ala Ala Glu Val Pro Leu Ser Glu Gly Leu Arg Pro Thr Glu 435 440 445 Ala Ala Ala Leu Leu Arg Glu Leu Asp Arg Asp Gly Ser Leu Gly Ile 450 455 460 Ala Asp Leu Ser Asp Gly Glu Leu Leu Asp Ala Ala Val Arg Val His 465 470 475 480 Gly Val Pro Arg Ala Leu Glu Leu Leu Val Gly Ala Val Ala Glu Glu 485 490 495 Thr Val Leu Leu Pro Ser Leu Lys Asp Val Leu Glu Asp Phe Thr Arg 500 505 510 Arg His Asp Val Val Ala Asp Leu Ala Gln Asp Arg Tyr Arg Arg Leu 515 520 525 Asp Glu Pro Ala Arg Ala Val Leu Gly Val Leu Ala Ala Leu Arg Thr 530 535 540 Pro Val Glu Gln Gly Ala Val Ala Gln Ile Ala Gly Gly Leu Asp Pro 545 550 555 560 Asp Leu Arg Val Val Pro Val Leu Thr Ala Leu Val Arg Val Arg Leu 565 570 575 Val Ser Val Asp Arg Ala Ser Arg Thr Val Ala Leu His Pro Leu Asp 580 585 590 Ala Asp Ile Ala Arg Asp Gln Met Pro Trp Asp Gly Pro Phe Gly Arg 595 600 605 Gln Ala Val Glu Arg Gln Ile Ala Ala Trp Tyr Ala Arg Arg Ala Lys 610 615 620 Pro Arg Gly Ala Trp Arg Thr Leu Glu Asp Val Glu Pro Gln Arg Arg 625 630 635 640 Gln Phe Asp His Leu Val Gly Ala Gly Asp His Asp Ala Ala Ala Arg 645 650 655 Val Leu Ala Glu Ile Ser Glu Trp Leu Val Trp His Gly Ser Val Leu 660 665 670 Ala Ala Val Thr Met His Leu Ala Val Asp Gly His Leu Arg Asp Glu 675 680 685 Arg Val Arg Leu Ala His Thr Val Ala Tyr Gly His Ala Arg Leu Ser 690 695 700 Ala Gly Pro Met Glu Gln Ala Val Glu Leu Phe Thr Glu Ala Ala Ala 705 710 715 720 Leu Ala Glu Arg Leu Gly Asp Arg Pro Ala Leu Gln Asn Ala Leu Phe 725 730 735 Gly Leu Gly Asp Ala His Arg Gln Leu Gly Asp Gln Gly Ala Thr Val 740 745 750 Glu Pro Leu Ala Arg Ala Ala Glu Leu Ala Arg Glu Leu Gly Asp Thr 755 760 765 Glu Arg Glu Ala His Ala Leu Leu Ser Leu Ser Leu Ala His Ser Tyr 770 775 780 Leu Gly Asp Gly Glu Arg Ala Leu Glu Gly Ala Asp Arg Leu Ala Ala 785 790 795 800 Leu Ala Glu Ala Gly Gly Asp Pro Leu Ala Leu Ala Arg Ala Gly Asn 805 810 815 Ala Arg Thr Ile Ala Leu Leu Thr Leu Gly Arg Trp Gln Glu Thr Ala 820 825 830 Glu Ala Gly Ala Glu Thr Ala Arg Ala Tyr Arg Ala Ala Gly Ser Gln 835 840 845 Glu Ala Val Ala Tyr Ala Leu Asn Ala Gln Gly Leu Ala Leu Leu Ala 850 855 860 Leu Asp Asp Pro Ala Arg Ala Ala Ala Val Leu Glu Glu Ala Arg His 865 870 875 880 Glu Ala Ser Leu Met Glu Ser Pro Arg Ala Glu Gly Val Cys Leu Leu 885 890 895 Asn Leu Ser Trp Ala Tyr Trp Cys Asp Gly Arg Arg Asp Glu Cys Ala 900 905 910 Ala Thr Ala Glu Arg Ala Ser Thr Ala Leu Gln Ile Ala Gly Ala Thr 915 920 925 Gln Ala Ala Ala Ala Arg Ser Leu Ala Glu Ala Ala Arg Val Leu Pro 930 935 940 Gly Asp Pro Gly Ala Ala Ala Asp Ala Leu Ile Arg Ala Ala Ala Ala 945 950 955 960 Leu Asp Gly Asn Ala Glu Val Ile Ala Pro Ala Arg Leu Thr Ala Glu 965 970 975 Ala Arg Arg Leu Leu Asp 980 14 594 DNA Streptomyces murayamaensis ATCC 21414 14 atgcctacgt caacgccagt caccgagaac ggtccccgcc ggctccgggc cgacgcggag 60 cgcaaccggg cccgggtgct gaacgcggcc agggagctct tcgcggaacg cggcgccaac 120 gtgtccatgg acgaggtggc ccgccgcgcc gaggtcggcg tggggacgct ctaccgccac 180 ttccccacca aggaagccat ggtcgtcgcg gcctcccagc agcgcttcgg cgagatcctc 240 acgtactacc gcacggtctg ccgggagtcg gccgagccgc tggaagcact ccagatgctg 300 ctcacccggg tcggcgaggt ggaggcccgg gaccgcggct tcgccagcgt cgtcggcggg 360 acgctcggct ccgaggggcc gcccagcacc atgcgggccg acctggagga cgagctggtg 420 gacctggtcg gcaagggcca ggcggccggc tccatccgca ccgatatcgc gggcgccgac 480 atcctcgcgc tgacctgcgg tctcacctcg atcgtgcacc ggcgcagcgg cgactggcgg 540 cgctacatcg acatcgtgct cgacggattg cgctccgacc gcgccacgtc ctag 594 15 197 PRT Streptomyces murayamaensis ATCC 21414 15 Met Pro Thr Ser Thr Pro Val Thr Glu Asn Gly Pro Arg Arg Leu Arg 1 5 10 15 Ala Asp Ala Glu Arg Asn Arg Ala Arg Val Leu Asn Ala Ala Arg Glu 20 25 30 Leu Phe Ala Glu Arg Gly Ala Asn Val Ser Met Asp Glu Val Ala Arg 35 40 45 Arg Ala Glu Val Gly Val Gly Thr Leu Tyr Arg His Phe Pro Thr Lys 50 55 60 Glu Ala Met Val Val Ala Ala Ser Gln Gln Arg Phe Gly Glu Ile Leu 65 70 75 80 Thr Tyr Tyr Arg Thr Val Cys Arg Glu Ser Ala Glu Pro Leu Glu Ala 85 90 95 Leu Gln Met Leu Leu Thr Arg Val Gly Glu Val Glu Ala Arg Asp Arg 100 105 110 Gly Phe Ala Ser Val Val Gly Gly Thr Leu Gly Ser Glu Gly Pro Pro 115 120 125 Ser Thr Met Arg Ala Asp Leu Glu Asp Glu Leu Val Asp Leu Val Gly 130 135 140 Lys Gly Gln Ala Ala Gly Ser Ile Arg Thr Asp Ile Ala Gly Ala Asp 145 150 155 160 Ile Leu Ala Leu Thr Cys Gly Leu Thr Ser Ile Val His Arg Arg Ser 165 170 175 Gly Asp Trp Arg Arg Tyr Ile Asp Ile Val Leu Asp Gly Leu Arg Ser 180 185 190 Asp Arg Ala Thr Ser 195 16 420 DNA Streptomyces murayamaensis ATCC 21414 16 atgtcgttgc ccctggggcg tacgagtgcg ccggaggtgt cggcgtcggt ggaggcattc 60 ctgacccaga cgccgcacat cggcgtgctg accaccatcc ggcccgacgg gtccccgcat 120 gtggcgccgg tgcggttcac ctgggacgcg gaggcgggtc tcgcccgggt gatgacggtg 180 tcctcgtccc gcaaggcgcg caatctgatc gccgcgcccg gcagccgggt cgccatatgc 240 caggtggccg ggttcgcctg ggtcaccctc gaaggctccg ccgtggtggc cgacgacccg 300 gtgcgggtca ccgagggagc gcgccgctac acccgccgct accgctccgg gccgcccaac 360 ccgcccggcc gggtggtcgt ggagatctcg gtcgaccggg tcatgagcct caacgtctga 420 1 139 PRT Streptomyces murayamaensis ATCC 21414 17 Met Ser Leu Pro Leu Gly Arg Thr Ser Ala Pro Glu Val Ser Ala Ser 1 5 10 15 Val Glu Ala Phe Leu Thr Gln Thr Pro His Ile Gly Val Leu Thr Thr 20 25 30 Ile Arg Pro Asp Gly Ser Pro His Val Ala Pro Val Arg Phe Thr Trp 35 40 45 Asp Ala Glu Ala Gly Leu Ala Arg Val Met Thr Val Ser Ser Ser Arg 50 55 60 Lys Ala Arg Asn Leu Ile Ala Ala Pro Gly Ser Arg Val Ala Ile Cys 65 70 75 80 Gln Val Ala Gly Phe Ala Trp Val Thr Leu Glu Gly Ser Ala Val Val 85 90 95 Ala Asp Asp Pro Val Arg Val Thr Glu Gly Ala Arg Arg Tyr Thr Arg 100 105 110 Arg Tyr Arg Ser Gly Pro Pro Asn Pro Pro Gly Arg Val Val Val Glu 115 120 125 Ile Ser Val Asp Arg Val Met Ser Leu Asn Val 130 135 18 447 DNA Streptomyces murayamaensis ATCC 21414 18 atgacctcaa gccaatccac cgccgatgtc gcgggacttc tggaccgtta cctgatcaat 60 ctggacgacg acaagctcga cgacgcctgg gcccgggggc tgttcaccga ggacgcggtc 120 gtcgagttcc cgatgagccg gcacgagggg atcgccggac tcgccgagta ccacagcacg 180 gcgctcgcgg ccttcgcgcg cacgcagcac atcggttcgc ccgccgtcgt ggaaatcgac 240 ggcgaccggg cctctttgcg gtgcaacatc gtctccaccc atgtgcacca cccgtccgac 300 catccggagg acgccgaccg cgatccgata ttcgccaacg gaagcctggt gaccgccgag 360 gcccgccgca ccccggaggg ctggcggctc agcctgctgt ccctgcgcat gatctgggtg 420 accggcaccg cgccccgcaa gggctga 447 19 148 PRT Streptomyces murayamaensis ATCC 21414 19 Met Thr Ser Ser Gln Ser Thr Ala Asp Val Ala Gly Leu Leu Asp Arg 1 5 10 15 Tyr Leu Ile Asn Leu Asp Asp Asp Lys Leu Asp Asp Ala Trp Ala Arg 20 25 30 Gly Leu Phe Thr Glu Asp Ala Val Val Glu Phe Pro Met Ser Arg His 35 40 45 Glu Gly Ile Ala Gly Leu Ala Glu Tyr His Ser Thr Ala Leu Ala Ala 50 55 60 Phe Ala Arg Thr Gln His Ile Gly Ser Pro Ala Val Val Glu Ile Asp 65 70 75 80 Gly Asp Arg Ala Ser Leu Arg Cys Asn Ile Val Ser Thr His Val His 85 90 95 His Pro Ser Asp His Pro Glu Asp Ala Asp Arg Asp Pro Ile Phe Ala 100 105 110 Asn Gly Ser Leu Val Thr Ala Glu Ala Arg Arg Thr Pro Glu Gly Trp 115 120 125 Arg Leu Ser Leu Leu Ser Leu Arg Met Ile Trp Val Thr Gly Thr Ala 130 135 140 Pro Arg Lys Gly 145 20 1470 DNA Streptomyces murayamaensis ATCC 21414 20 atggataact ttgacgcgga cgtaattatc gcgggagccg gccccactgg actcatgctc 60 gcaggcgaac tgcgcctgaa cggcgtgtcc gtgattgtcg tcgatcgcct tgccgagccg 120 atacagcagt cgcgtgcgct gggattttcg gcccgtacca tcgaggaatt cggccagcgc 180 ggactgctgt cccgtttcgg tgaagtcgac gtcattccgg tcggtcattt cggcggagtg 240 tccatcgatt accgtctggt cgagggcggt tcgtacggag cgcgcggcat tccccagtcg 300 cgcaccgagg gcgtgctggc gggctgggcc ggacagctcg gcgccgaggt gcggcgcggg 360 gtcgaggtca cgggcctgga caacggcgcc gacggcgtga gcgtggaggt cagcaccgcc 420 gaggggcccg ccacgctgcg cggccgctac ctggtgggcg cggacggcgc ccgcagtgcg 480 gtgcgcaagc tcgcgggcat cgacttcccg ggcaccgacc cggccatcga gctccggttc 540 gccgacatca gcggggtgcc gttgcgcccg cgcttcagcg gcgagcgggt gcccggcggc 600 atggtcatgg tgctgccgct cggcccggag cgctgccgga tcgtctactt cgaccgcagc 660 gagccgttgc gcaagagccc ggacccgatc accttcgacg aggtggccga ggcgttcaag 720 cggctgtccg gcgaggacat cagcggcgcc accgtgcact gggtctccac caccaccgat 780 gtgagccggc aggccgccga gtaccgcagg ggccgggtct tcctggccgg cgacgccgcc 840 cacatccatc tgcccatcgg cgcccaggga atgagcgccg gcgtgcagga cgcggtcaac 900 ctcggctgga agctcgccct ggagatcaag ggccaggctc ccgagggcct gctcgacacg 960 taccactccg agcggcaccc ggtcggcgcg cgggtcctca ccaacacgct cgcccagcgg 1020 atcctctacc tcggcggcga cgagatcacc ccgctgctcg atgtgttcac cgagctcacc 1080 gggttcgagg acgtccagaa gacgctgatc ggcatggtca ccggcctgga catccgccat 1140 gacgtgggcg agggcgacca tccgctcctc ggccgccgtc tcaaggacga ggagctggtg 1200 gtcgacggca agaagaccac caacttcgaa ctcctcgcgg ccggcaaggc cgttctgttc 1260 aacctcaccg atgaccccca cctgcgggag ctcgccgcgg gctgggccga ccgtgtcacc 1320 acggtcaccg ccgagcagca cgactgcgac aacggtctgg acgccttcct ggtccgtccc 1380 gacggctatg tcgcctgggt cgccccttcc gcgtcgcgca cggaggggct cgccgaagca 1440 ctcaaccgat ggttcggccg gcccaactga 1470 21 489 PRT Streptomyces murayamaensis ATCC 21414 21 Met Asp Asn Phe Asp Ala Asp Val Ile Ile Ala Gly Ala Gly Pro Thr 1 5 10 15 Gly Leu Met Leu Ala Gly Glu Leu Arg Leu Asn Gly Val Ser Val Ile 20 25 30 Val Val Asp Arg Leu Ala Glu Pro Ile Gln Gln Ser Arg Ala Leu Gly 35 40 45 Phe Ser Ala Arg Thr Ile Glu Glu Phe Gly Gln Arg Gly Leu Leu Ser 50 55 60 Arg Phe Gly Glu Val Asp Val Ile Pro Val Gly His Phe Gly Gly Val 65 70 75 80 Ser Ile Asp Tyr Arg Leu Val Glu Gly Gly Ser Tyr Gly Ala Arg Gly 85 90 95 Ile Pro Gln Ser Arg Thr Glu Gly Val Leu Ala Gly Trp Ala Gly Gln 100 105 110 Leu Gly Ala Glu Val Arg Arg Gly Val Glu Val Thr Gly Leu Asp Asn 115 120 125 Gly Ala Asp Gly Val Ser Val Glu Val Ser Thr Ala Glu Gly Pro Ala 130 135 140 Thr Leu Arg Gly Arg Tyr Leu Val Gly Ala Asp Gly Ala Arg Ser Ala 145 150 155 160 Val Arg Lys Leu Ala Gly Ile Asp Phe Pro Gly Thr Asp Pro Ala Ile 165 170 175 Glu Leu Arg Phe Ala Asp Ile Ser Gly Val Pro Leu Arg Pro Arg Phe 180 185 190 Ser Gly Glu Arg Val Pro Gly Gly Met Val Met Val Leu Pro Leu Gly 195 200 205 Pro Glu Arg Cys Arg Ile Val Tyr Phe Asp Arg Ser Glu Pro Leu Arg 210 215 220 Lys Ser Pro Asp Pro Ile Thr Phe Asp Glu Val Ala Glu Ala Phe Lys 225 230 235 240 Arg Leu Ser Gly Glu Asp Ile Ser Gly Ala Thr Val His Trp Val Ser 245 250 255 Thr Thr Thr Asp Val Ser Arg Gln Ala Ala Glu Tyr Arg Arg Gly Arg 260 265 270 Val Phe Leu Ala Gly Asp Ala Ala His Ile His Leu Pro Ile Gly Ala 275 280 285 Gln Gly Met Ser Ala Gly Val Gln Asp Ala Val Asn Leu Gly Trp Lys 290 295 300 Leu Ala Leu Glu Ile Lys Gly Gln Ala Pro Glu Gly Leu Leu Asp Thr 305 310 315 320 Tyr His Ser Glu Arg His Pro Val Gly Ala Arg Val Leu Thr Asn Thr 325 330 335 Leu Ala Gln Arg Ile Leu Tyr Leu Gly Gly Asp Glu Ile Thr Pro Leu 340 345 350 Leu Asp Val Phe Thr Glu Leu Thr Gly Phe Glu Asp Val Gln Lys Thr 355 360 365 Leu Ile Gly Met Val Thr Gly Leu Asp Ile Arg His Asp Val Gly Glu 370 375 380 Gly Asp His Pro Leu Leu Gly Arg Arg Leu Lys Asp Glu Glu Leu Val 385 390 395 400 Val Asp Gly Lys Lys Thr Thr Asn Phe Glu Leu Leu Ala Ala Gly Lys 405 410 415 Ala Val Leu Phe Asn Leu Thr Asp Asp Pro His Leu Arg Glu Leu Ala 420 425 430 Ala Gly Trp Ala Asp Arg Val Thr Thr Val Thr Ala Glu Gln His Asp 435 440 445 Cys Asp Asn Gly Leu Asp Ala Phe Leu Val Arg Pro Asp Gly Tyr Val 450 455 460 Ala Trp Val Ala Pro Ser Ala Ser Arg Thr Glu Gly Leu Ala Glu Ala 465 470 475 480 Leu Asn Arg Trp Phe Gly Arg Pro Asn 485 22 690 DNA Streptomyces murayamaensis ATCC 21414 22 atgcccaaga tttcctctga tgacaagcac ctgaccgtcc tcaacctgtt ctccacggac 60 gccccggaga agcaggaggg tctgctcggc gcgatgcgcg agatcgtcga cgcggccgcc 120 tacccgggct ggatgtcgtc caccgtgcac gccggcgtgg acaagccggg cacggccaac 180 ttcatccagt ggcgcagccg cgcggacctt gaggaccgct acgacggcga ggagttcaag 240 caccgcacgc tccccctctt cggcgagctg accacctcga tccggctgct ccagaacgag 300 gtcgcgtact cgcagaccaa gtcgggcgac agcgtcgaga tctccccggc ccgcaccgac 360 ttcaccgtca tcgcggtctt cggtgtcgag gagaagaacc aggacgacct ggtcgacgcg 420 ctcggcccgt cgatgaagtt cctcagcgac gttcccggct acgtctcgca caccgtcctg 480 aagggcatcg cggcccgtgg ccttgagggc tccttcgtgg tctcctactc gcagtgggag 540 agccaggagg ccttcgtcgc ctaccaggcc gtcgcgcagg ccgacaagcc cgccgcccgc 600 caggacgcgg agaagcgcac cggctcgctc ctgacgtcgg tggactccaa cacctaccgc 660 gtggtccaca cccgcgcggc cggcgagtaa 690 23 229 PRT Streptomyces murayamaensis ATCC 21414 23 Met Pro Lys Ile Ser Ser Asp Asp Lys His Leu Thr Val Leu Asn Leu 1 5 10 15 Phe Ser Thr Asp Ala Pro Glu Lys Gln Glu Gly Leu Leu Gly Ala Met 20 25 30 Arg Glu Ile Val Asp Ala Ala Ala Tyr Pro Gly Trp Met Ser Ser Thr 35 40 45 Val His Ala Gly Val Asp Lys Pro Gly Thr Ala Asn Phe Ile Gln Trp 50 55 60 Arg Ser Arg Ala Asp Leu Glu Asp Arg Tyr Asp Gly Glu Glu Phe Lys 65 70 75 80 His Arg Thr Leu Pro Leu Phe Gly Glu Leu Thr Thr Ser Ile Arg Leu 85 90 95 Leu Gln Asn Glu Val Ala Tyr Ser Gln Thr Lys Ser Gly Asp Ser Val 100 105 110 Glu Ile Ser Pro Ala Arg Thr Asp Phe Thr Val Ile Ala Val Phe Gly 115 120 125 Val Glu Glu Lys Asn Gln Asp Asp Leu Val Asp Ala Leu Gly Pro Ser 130 135 140 Met Lys Phe Leu Ser Asp Val Pro Gly Tyr Val Ser His Thr Val Leu 145 150 155 160 Lys Gly Ile Ala Ala Arg Gly Leu Glu Gly Ser Phe Val Val Ser Tyr 165 170 175 Ser Gln Trp Glu Ser Gln Glu Ala Phe Val Ala Tyr Gln Ala Val Ala 180 185 190 Gln Ala Asp Lys Pro Ala Ala Arg Gln Asp Ala Glu Lys Arg Thr Gly 195 200 205 Ser Leu Leu Thr Ser Val Asp Ser Asn Thr Tyr Arg Val Val His Thr 210 215 220 Arg Ala Ala Gly Glu 225 24 330 DNA Streptomyces murayamaensis ATCC 21414 24 atgcacagca cgctcatcgt cgcccgcatg gaacccggtt cgagcaccga cgtcgccaag 60 ctcttcgccg agttcgacgc gacggagatg ccgcaccgga tgggaacgct gcgccgccag 120 ctgttctcct accggggcct ctacttccac ctgcaggact tcgacgcgga caacggcggt 180 gagctgatcg aggccgcgaa gaacgacccg cggttcatcg ggatcagcaa cgacctgaag 240 ccgttcatcc aggcgtacga cccggccacc tggcgctcgc ccgccgacgc catggccacg 300 cgcttctaca actgggaggg gcgcgcgtga 330 25 109 PRT Streptomyces murayamaensis ATCC 21414 25 Met His Ser Thr Leu Ile Val Ala Arg Met Glu Pro Gly Ser Ser Thr 1 5 10 15 Asp Val Ala Lys Leu Phe Ala Glu Phe Asp Ala Thr Glu Met Pro His 20 25 30 Arg Met Gly Thr Leu Arg Arg Gln Leu Phe Ser Tyr Arg Gly Leu Tyr 35 40 45 Phe His Leu Gln Asp Phe Asp Ala Asp Asn Gly Gly Glu Leu Ile Glu 50 55 60 Ala Ala Lys Asn Asp Pro Arg Phe Ile Gly Ile Ser Asn Asp Leu Lys 65 70 75 80 Pro Phe Ile Gln Ala Tyr Asp Pro Ala Thr Trp Arg Ser Pro Ala Asp 85 90 95 Ala Met Ala Thr Arg Phe Tyr Asn Trp Glu Gly Arg Ala 100 105 26 1275 DNA Streptomyces murayamaensis ATCC 21414 26 gtgacaacgc ctcgcagggt ggtcatcacc gggatggagg tcctcgcccc cggtggcatc 60 ggcaccaaga acttctggag cctcctcagc gagggccgca cggcgacccg ggggatcacg 120 ttcttcgacc ccacgccgtt ccgctcgcgg gtggccgccg agatcgactt cgacccgtac 180 gagcacggtc tgagcccgca ggaggtccgc cgcatggacc gggccggcca gttcgcggtc 240 gtcgcctcgc gcggcgcggt cgccgacagc ggtctggagc tcgccggcct cgacccgtac 300 cgggtcggtg tcacggtcgg cagcgcggtc ggcgccacca tgggcctgga cgaggagtac 360 cgggtcgtca gcgacggcgg ccggctcgac ctcgtggacc accagtacgc ggccccgcac 420 ctctacaacc acctggtgcc gagctcgttc gcggccgagg tggcctgggc ggtcggcgcc 480 gagggcccca gcaccgtggt ctccacgggc tgcacctccg gcatcgactc ggtcggctac 540 gccgtcgagc tgatccgcga gggctccgcc gacgtcatga tcgccggatc ctcggacgcg 600 ccgatctcgc cgatcaccat ggcgtgcttc gacgcgatca aggccacgac gaaccgttac 660 gacgagcccg agacggcctc gcggccgttc gacaactcgc gcaacggctt cgtcctgggc 720 gagggcaccg cgttcttcgt cctggaggag ctggagagcg ccgtcaagcg aggcgcccac 780 atctacgcgg agatcgccgg ctacgccacg cgctccaacg cgtaccacat gaccggactg 840 cgccccgacg gcgcggagat ggccgaggcg atccgcgtgg cgctggacga ggcgcggatg 900 aacggcgacg agatcgacta catcaacgcc cacggctccg gcaccaagca gaacgaccgc 960 cacgagacgg cggcggtcaa gcggatcctc ggtgaccacg cctaccggac gccgatgagc 1020 tccatcaagt cgatggtggg gcactcgctc ggcgcgatcg gctccatcga gatcgccgcg 1080 tccgcgctcg ccatggagta caacgtcgta ccgcccacgg ccaacctgca cacgcccgac 1140 cccgagtgcg acctggacta cgtcccgttg accgcccgcg accgcaagac cgacgcggtc 1200 ctctcggtcg gcagcggctt cggtggattc cagagtgccg tggtgctcgc ccgtcccgag 1260 aggaagctcg catga 1275 27 424 PRT Streptomyces murayamaensis ATCC 21414 27 Val Thr Thr Pro Arg Arg Val Val Ile Thr Gly Met Glu Val Leu Ala 1 5 10 15 Pro Gly Gly Ile Gly Thr Lys Asn Phe Trp Ser Leu Leu Ser Glu Gly 20 25 30 Arg Thr Ala Thr Arg Gly Ile Thr Phe Phe Asp Pro Thr Pro Phe Arg 35 40 45 Ser Arg Val Ala Ala Glu Ile Asp Phe Asp Pro Tyr Glu His Gly Leu 50 55 60 Ser Pro Gln Glu Val Arg Arg Met Asp Arg Ala Gly Gln Phe Ala Val 65 70 75 80 Val Ala Ser Arg Gly Ala Val Ala Asp Ser Gly Leu Glu Leu Ala Gly 85 90 95 Leu Asp Pro Tyr Arg Val Gly Val Thr Val Gly Ser Ala Val Gly Ala 100 105 110 Thr Met Gly Leu Asp Glu Glu Tyr Arg Val Val Ser Asp Gly Gly Arg 115 120 125 Leu Asp Leu Val Asp His Gln Tyr Ala Ala Pro His Leu Tyr Asn His 130 135 140 Leu Val Pro Ser Ser Phe Ala Ala Glu Val Ala Trp Ala Val Gly Ala 145 150 155 160 Glu Gly Pro Ser Thr Val Val Ser Thr Gly Cys Thr Ser Gly Ile Asp 165 170 175 Ser Val Gly Tyr Ala Val Glu Leu Ile Arg Glu Gly Ser Ala Asp Val 180 185 190 Met Ile Ala Gly Ser Ser Asp Ala Pro Ile Ser Pro Ile Thr Met Ala 195 200 205 Cys Phe Asp Ala Ile Lys Ala Thr Thr Asn Arg Tyr Asp Glu Pro Glu 210 215 220 Thr Ala Ser Arg Pro Phe Asp Asn Ser Arg Asn Gly Phe Val Leu Gly 225 230 235 240 Glu Gly Thr Ala Phe Phe Val Leu Glu Glu Leu Glu Ser Ala Val Lys 245 250 255 Arg Gly Ala His Ile Tyr Ala Glu Ile Ala Gly Tyr Ala Thr Arg Ser 260 265 270 Asn Ala Tyr His Met Thr Gly Leu Arg Pro Asp Gly Ala Glu Met Ala 275 280 285 Glu Ala Ile Arg Val Ala Leu Asp Glu Ala Arg Met Asn Gly Asp Glu 290 295 300 Ile Asp Tyr Ile Asn Ala His Gly Ser Gly Thr Lys Gln Asn Asp Arg 305 310 315 320 His Glu Thr Ala Ala Val Lys Arg Ile Leu Gly Asp His Ala Tyr Arg 325 330 335 Thr Pro Met Ser Ser Ile Lys Ser Met Val Gly His Ser Leu Gly Ala 340 345 350 Ile Gly Ser Ile Glu Ile Ala Ala Ser Ala Leu Ala Met Glu Tyr Asn 355 360 365 Val Val Pro Pro Thr Ala Asn Leu His Thr Pro Asp Pro Glu Cys Asp 370 375 380 Leu Asp Tyr Val Pro Leu Thr Ala Arg Asp Arg Lys Thr Asp Ala Val 385 390 395 400 Leu Ser Val Gly Ser Gly Phe Gly Gly Phe Gln Ser Ala Val Val Leu 405 410 415 Ala Arg Pro Glu Arg Lys Leu Ala 420 28 1212 DNA Streptomyces murayamaensis ATCC 21414 28 atgacgtcgt ccgtggtggt caccggcctg ggggtggcgt cccccaacgg actcggcatc 60 caggactact gggcggcgac cgtcggtggc aagagcggca tcggccgtat cacccgcttc 120 gacccgtcgt cctacccggc caagctggcc ggcgaggtcc cgggcttcgt cgcggaggac 180 ctgctgccca gccgcctgct cccgcagacc gaccgggtca cccggctggc gctcgtcgcc 240 gccgactggg cgctcgccga cgcgggcatc accccctccg aactcggcga gttcgacatg 300 ggcgtggtga ccgcgagcgc ggccggcggc ttcgagttcg gccagggcga gctccaggcg 360 ctgtggtcca agggcagcca gtacgtctcg gcgtaccagt ccttcgcctg gttctacgcg 420 gtcaacagcg gccagatctc catccgcaac gggatgaagg gccccagcgg cgtggtcgtc 480 agcgaccagg ccggcgggct cgacgcggtg gcgcaggccc ggcggcagat ccgcaagggc 540 accagcgtga tcgtgtccgg cgccatcgac gcctcggtct gcccgtgggg ctgggtggcg 600 cagctggcca gcgaccggct ctccaccagc gacgagccga cccgcgccta tctgccgttc 660 gaccgcgacg cctcgggcta tgtggcgggc gagggcggcg cgatcctgat catggaggac 720 gccgagtcgg cccgcgcccg tggcgcccgt gtctacggcg agatctccgg ctacggctcg 780 accatcgacc cgaaggccgg ctccggccgc ccgccggggc tgcgcaaggc catcgaactc 840 gccctggcgg acgcgggggt cgccccgggt gaggtggacg tggtcttcgc cgacgcggcc 900 gccgaccccg agctcgaccg gcaggaggcc gaggccatca acgccgtgtt cggcacccgc 960 ggcgtgccgg tcaccgctcc caagacgatg accggacggc tctactcggg cgccgccccg 1020 ctggacctgg ccgccgcctt cctcgccatg aaggacggtc tgatcccgcc gaccgtgcac 1080 atcgatccgg ccgccgagta cgacctggat ctggtcaccg gcgagccgcg caccgccgag 1140 gtgcgcaccg cgctggtcgt ggcccgcggc tacggcgggt tcaactccgc ggtggtcgtg 1200 cgcgccgcgt ag 1212 29 403 PRT Streptomyces murayamaensis ATCC 21414 29 Met Thr Ser Ser Val Val Val Thr Gly Leu Gly Val Ala Ser Pro Asn 1 5 10 15 Gly Leu Gly Ile Gln Asp Tyr Trp Ala Ala Thr Val Gly Gly Lys Ser 20 25 30 Gly Ile Gly Arg Ile Thr Arg Phe Asp Pro Ser Ser Tyr Pro Ala Lys 35 40 45 Leu Ala Gly Glu Val Pro Gly Phe Val Ala Glu Asp Leu Leu Pro Ser 50 55 60 Arg Leu Leu Pro Gln Thr Asp Arg Val Thr Arg Leu Ala Leu Val Ala 65 70 75 80 Ala Asp Trp Ala Leu Ala Asp Ala Gly Ile Thr Pro Ser Glu Leu Gly 85 90 95 Glu Phe Asp Met Gly Val Val Thr Ala Ser Ala Ala Gly Gly Phe Glu 100 105 110 Phe Gly Gln Gly Glu Leu Gln Ala Leu Trp Ser Lys Gly Ser Gln Tyr 115 120 125 Val Ser Ala Tyr Gln Ser Phe Ala Trp Phe Tyr Ala Val Asn Ser Gly 130 135 140 Gln Ile Ser Ile Arg Asn Gly Met Lys Gly Pro Ser Gly Val Val Val 145 150 155 160 Ser Asp Gln Ala Gly Gly Leu Asp Ala Val Ala Gln Ala Arg Arg Gln 165 170 175 Ile Arg Lys Gly Thr Ser Val Ile Val Ser Gly Ala Ile Asp Ala Ser 180 185 190 Val Cys Pro Trp Gly Trp Val Ala Gln Leu Ala Ser Asp Arg Leu Ser 195 200 205 Thr Ser Asp Glu Pro Thr Arg Ala Tyr Leu Pro Phe Asp Arg Asp Ala 210 215 220 Ser Gly Tyr Val Ala Gly Glu Gly Gly Ala Ile Leu Ile Met Glu Asp 225 230 235 240 Ala Glu Ser Ala Arg Ala Arg Gly Ala Arg Val Tyr Gly Glu Ile Ser 245 250 255 Gly Tyr Gly Ser Thr Ile Asp Pro Lys Ala Gly Ser Gly Arg Pro Pro 260 265 270 Gly Leu Arg Lys Ala Ile Glu Leu Ala Leu Ala Asp Ala Gly Val Ala 275 280 285 Pro Gly Glu Val Asp Val Val Phe Ala Asp Ala Ala Ala Asp Pro Glu 290 295 300 Leu Asp Arg Gln Glu Ala Glu Ala Ile Asn Ala Val Phe Gly Thr Arg 305 310 315 320 Gly Val Pro Val Thr Ala Pro Lys Thr Met Thr Gly Arg Leu Tyr Ser 325 330 335 Gly Ala Ala Pro Leu Asp Leu Ala Ala Ala Phe Leu Ala Met Lys Asp 340 345 350 Gly Leu Ile Pro Pro Thr Val His Ile Asp Pro Ala Ala Glu Tyr Asp 355 360 365 Leu Asp Leu Val Thr Gly Glu Pro Arg Thr Ala Glu Val Arg Thr Ala 370 375 380 Leu Val Val Ala Arg Gly Tyr Gly Gly Phe Asn Ser Ala Val Val Val 385 390 395 400 Arg Ala Ala 30 267 DNA Streptomyces murayamaensis ATCC 21414 30 atggccacca cgttcaccct cgacgacctc aagcgcatcc tccttgaggc agccggcgcc 60 gacgagggcg tcgacctgga cggcgacatt ctggacaccg agttcgaggt cctgggatac 120 gagtcgctcg ccctgctgga gaccggcggc cgcatcgagc gcgagtacgg catctcgctg 180 gacgacgacg cgctgaccga cgcggtcacc ccgcgcgccc tcatcgaggt cgtcaacgcc 240 cagctgtccg ccgcgtccgc cgcctga 267 31 88 PRT Streptomyces murayamaensis ATCC 21414 31 Met Ala Thr Thr Phe Thr Leu Asp Asp Leu Lys Arg Ile Leu Leu Glu 1 5 10 15 Ala Ala Gly Ala Asp Glu Gly Val Asp Leu Asp Gly Asp Ile Leu Asp 20 25 30 Thr Glu Phe Glu Val Leu Gly Tyr Glu Ser Leu Ala Leu Leu Glu Thr 35 40 45 Gly Gly Arg Ile Glu Arg Glu Tyr Gly Ile Ser Leu Asp Asp Asp Ala 50 55 60 Leu Thr Asp Ala Val Thr Pro Arg Ala Leu Ile Glu Val Val Asn Ala 65 70 75 80 Gln Leu Ser Ala Ala Ser Ala Ala 85 32 786 DNA Streptomyces murayamaensis ATCC 21414 32 atgaccgaga acaccgcacg ggtcgcgctg gtcacgggtg ccacgagcgg catcgggctc 60 tccgtcgccc ggctgctcgg ctcgcagggc cacaaggtct tcatcggcgc gcgcaacgcc 120 gacaacgtcg ccgagacggt caagcagctc cagggcgagg gcctggaggc cgacggctcg 180 gcgctcgacg tcaccgacgc cgccagcgtc aaggccttcg tccaggcggc cgtcgaccgc 240 ttcggcaccg tcgacgtgct ggtgaacaac gccggccgct ccggtggcgg cgtcaccgcc 300 gacatcgagg acgagctgtg ggacgccgtc atcgacacca acctgaacag cgtcttccgg 360 gtcacccgtg aggtcctgaa caccggtggc atgcgccaca aggaccgcgg ccggatcatc 420 aacatcgcct ccaccgcggg caagcagggc gtggtgctcg gcgccccgta ctcggcctcc 480 aagcacggtg tggtcggctt caccaaggcc ctgggcaacg agctcgcgcc caccggcatc 540 acggtcaacg ccgtctgccc cggctacgtc gagacgccga tggcgcagcg cgtgcgccag 600 ggctacgcgg ccgcgtactc cacctccgag gacgcgatcc tggagaagtt ccagtccaag 660 atcccgctcg gccgctactc caccccggac gaggtcgccg gtctggtcgg ctacctcgcc 720 tcggacacgg ccgcgtccat caccgcgcag gcgctcaacg tctgcggcgg cctcggcaac 780 ttctag 786 33 261 PRT Streptomyces murayamaensis ATCC 21414 33 Met Thr Glu Asn Thr Ala Arg Val Ala Leu Val Thr Gly Ala Thr Ser 1 5 10 15 Gly Ile Gly Leu Ser Val Ala Arg Leu Leu Gly Ser Gln Gly His Lys 20 25 30 Val Phe Ile Gly Ala Arg Asn Ala Asp Asn Val Ala Glu Thr Val Lys 35 40 45 Gln Leu Gln Gly Glu Gly Leu Glu Ala Asp Gly Ser Ala Leu Asp Val 50 55 60 Thr Asp Ala Ala Ser Val Lys Ala Phe Val Gln Ala Ala Val Asp Arg 65 70 75 80 Phe Gly Thr Val Asp Val Leu Val Asn Asn Ala Gly Arg Ser Gly Gly 85 90 95 Gly Val Thr Ala Asp Ile Glu Asp Glu Leu Trp Asp Ala Val Ile Asp 100 105 110 Thr Asn Leu Asn Ser Val Phe Arg Val Thr Arg Glu Val Leu Asn Thr 115 120 125 Gly Gly Met Arg His Lys Asp Arg Gly Arg Ile Ile Asn Ile Ala Ser 130 135 140 Thr Ala Gly Lys Gln Gly Val Val Leu Gly Ala Pro Tyr Ser Ala Ser 145 150 155 160 Lys His Gly Val Val Gly Phe Thr Lys Ala Leu Gly Asn Glu Leu Ala 165 170 175 Pro Thr Gly Ile Thr Val Asn Ala Val Cys Pro Gly Tyr Val Glu Thr 180 185 190 Pro Met Ala Gln Arg Val Arg Gln Gly Tyr Ala Ala Ala Tyr Ser Thr 195 200 205 Ser Glu Asp Ala Ile Leu Glu Lys Phe Gln Ser Lys Ile Pro Leu Gly 210 215 220 Arg Tyr Ser Thr Pro Asp Glu Val Ala Gly Leu Val Gly Tyr Leu Ala 225 230 235 240 Ser Asp Thr Ala Ala Ser Ile Thr Ala Gln Ala Leu Asn Val Cys Gly 245 250 255 Gly Leu Gly Asn Phe 260 34 936 DNA Streptomyces murayamaensis ATCC 21414 34 atgacgaccc gcgaggtcga gcacgagatc accatcgagg cccccgccgc cgccgtgtac 60 cggctgctgg cggaggtcac caactggccg cggatcttcc cgccgacgat ctacgtcgac 120 caggtgggcg agcacgacaa ccacgagcgc atccggatct gggccaccgc caacggcgag 180 gccaagaact ggacctcgca ccgtgagctc gaccccgagg cgctgcggat caccttccgc 240 caggaggtca ccacgccgcc ggtcgccgcg atgggcggca cctggatcat cgagaccctg 300 ggcgagacca cctcgcgggt ccggctgctc cacgactacc gggcgatcga cgacgacccc 360 gaggggctgg cctggatcga cgaggcggtc gacaagaaca gccgctcgga gctggccgcg 420 ctgaagcaga acgtcgaact ggcccacgcg accgaggagg tgacgttctc gttcaccgac 480 accgtcatcg tccagggctc gcccaaggac ctgtacgact tcatcaacga ggcgaacctg 540 tggtccgagc ggctgccgca cgtggccgtc gtccggctca ccgaggacac cccggggctg 600 cagaccctgg agatggacac ccgcgccaag gacggctcgg tgcacaccac caagtcgtac 660 cgggtgacct tcccgcacca caagatcgcg tacaagcagg tcacgctgcc cgcgctgatg 720 accctgcaca ccgggatctg gacgttcgag gagacgcccg agggcacggc cgcctcctcg 780 cagcacaccg tcacgctcaa cacggacaac atcgcgaaga tcctcggccc cgaggccacc 840 gtcgcggacg cccgtgagta cgtgcacacc gcgctgtcca ccaacagcac ggcgacgctc 900 aaccacgcca agacgtacgc cgagtcgaag ggctga 936 35 311 PRT Streptomyces murayamaensis ATCC 21414 35 Met Thr Thr Arg Glu Val Glu His Glu Ile Thr Ile Glu Ala Pro Ala 1 5 10 15 Ala Ala Val Tyr Arg Leu Leu Ala Glu Val Thr Asn Trp Pro Arg Ile 20 25 30 Phe Pro Pro Thr Ile Tyr Val Asp Gln Val Gly Glu His Asp Asn His 35 40 45 Glu Arg Ile Arg Ile Trp Ala Thr Ala Asn Gly Glu Ala Lys Asn Trp 50 55 60 Thr Ser His Arg Glu Leu Asp Pro Glu Ala Leu Arg Ile Thr Phe Arg 65 70 75 80 Gln Glu Val Thr Thr Pro Pro Val Ala Ala Met Gly Gly Thr Trp Ile 85 90 95 Ile Glu Thr Leu Gly Glu Thr Thr Ser Arg Val Arg Leu Leu His Asp 100 105 110 Tyr Arg Ala Ile Asp Asp Asp Pro Glu Gly Leu Ala Trp Ile Asp Glu 115 120 125 Ala Val Asp Lys Asn Ser Arg Ser Glu Leu Ala Ala Leu Lys Gln Asn 130 135 140 Val Glu Leu Ala His Ala Thr Glu Glu Val Thr Phe Ser Phe Thr Asp 145 150 155 160 Thr Val Ile Val Gln Gly Ser Pro Lys Asp Leu Tyr Asp Phe Ile Asn 165 170 175 Glu Ala Asn Leu Trp Ser Glu Arg Leu Pro His Val Ala Val Val Arg 180 185 190 Leu Thr Glu Asp Thr Pro Gly Leu Gln Thr Leu Glu Met Asp Thr Arg 195 200 205 Ala Lys Asp Gly Ser Val His Thr Thr Lys Ser Tyr Arg Val Thr Phe 210 215 220 Pro His His Lys Ile Ala Tyr Lys Gln Val Thr Leu Pro Ala Leu Met 225 230 235 240 Thr Leu His Thr Gly Ile Trp Thr Phe Glu Glu Thr Pro Glu Gly Thr 245 250 255 Ala Ala Ser Ser Gln His Thr Val Thr Leu Asn Thr Asp Asn Ile Ala 260 265 270 Lys Ile Leu Gly Pro Glu Ala Thr Val Ala Asp Ala Arg Glu Tyr Val 275 280 285 His Thr Ala Leu Ser Thr Asn Ser Thr Ala Thr Leu Asn His Ala Lys 290 295 300 Thr Tyr Ala Glu Ser Lys Gly 305 310 36 1473 DNA Streptomyces murayamaensis ATCC 21414 36 atgaccccgg accgcctgga cacacaggtc atcgtcgtcg gcgccggccc cgtcgggctt 60 ctgctcgccg gtgagctgcg tcttggcggc gccgacgtgg tcgtactgga acaacgggcc 120 acgcccacca cggagtcgag ggcctccacg ctgcacgccc gcaccatgga gctccttgac 180 agccgcggcc tgctcgacct gttcgggacg ccgccgaacg agccgcgcgg ccacttcggc 240 ggcatcccga tggacctcac gctgcccagc cccttcccgg ggcagtggaa gatgccccag 300 acccggaccg aggcgctgct ccaggagtgg gcgctgtcgc tgggcgcgga catccggcgc 360 ggccacgagc tggtcgccgt gtccgacgag ggcgacttcg tcgaggcccg ggcggccggg 420 ccggagggca cggtcgtggt gcgcgggcgg ttcctcgtcg ggtgcgacgg cgaggagtcg 480 gccgtgcgcc gcctgacggg cgccgagttc ccgggcaacg acgccggccg cgagctgctg 540 cgcgcggacg tggccggtgt caccatcccg ggccgccgct tcgagcggct gcccgccggg 600 ctcgccatcg cggcgacccg cgacggggtg acccgggtga tggtgcacga gttcggctcc 660 caggccgaac cccgcaccgg cgacccggag ttcggcgaga tcgcggcggt ctggaagcgc 720 gtcaccggcg aggacatcag cggcggaacc ccgctgtggg cgaactcgtt cggcgacgcc 780 aaccgccagc tcacgcacta ccgcgacggc cggatcctgt tcgccggcga cgcggcccac 840 cggcagatgc cgatcggcgg ccaggccctc aacctgggcc tccaggacgc cttcaacctg 900 ggctggaagc tggctctgca cctcggcgag tcggcccccg agggcctgct cgacacgtac 960 cacagcgagc ggcacgaggt cggccggcgg gtgctttcca acatcagggc acaggccatg 1020 ctgctgctcg gcggccagga ggtcgagccg ctgcgcgcgg tgctgaccga gctcctgccg 1080 tacgacgacg tccgggcgca cctcgccggg atgatcagcg gcctcgacat ccgttacgac 1140 gtgggcggcc ccgagcaccc gctgctcggc gcacggctgc cggacgccgg tctcaccacc 1200 ggcgaaggcc cgctgagcac cgcccagttg ctgcgcaccg cacgcggtgt gctcctcgac 1260 ctgtccggtg gcagtgcggt gctgtcggac gccgccggct gggcggaccg ggtcaccgct 1320 ctgcccgccg tgccggagaa gggcggcgcc ctcgactcgg tgggcgccgt cctggtccgg 1380 cccgacggcc atgtggcctg ggccggcgcc ccggacaccg acggcgccgg gctgcgggag 1440 gccctggagc gctggttcgg cccctcgcac tga 1473 37 490 PRT Streptomyces murayamaensis ATCC 21414 37 Met Thr Pro Asp Arg Leu Asp Thr Gln Val Ile Val Val Gly Ala Gly 1 5 10 15 Pro Val Gly Leu Leu Leu Ala Gly Glu Leu Arg Leu Gly Gly Ala Asp 20 25 30 Val Val Val Leu Glu Gln Arg Ala Thr Pro Thr Thr Glu Ser Arg Ala 35 40 45 Ser Thr Leu His Ala Arg Thr Met Glu Leu Leu Asp Ser Arg Gly Leu 50 55 60 Leu Asp Leu Phe Gly Thr Pro Pro Asn Glu Pro Arg Gly His Phe Gly 65 70 75 80 Gly Ile Pro Met Asp Leu Thr Leu Pro Ser Pro Phe Pro Gly Gln Trp 85 90 95 Lys Met Pro Gln Thr Arg Thr Glu Ala Leu Leu Gln Glu Trp Ala Leu 100 105 110 Ser Leu Gly Ala Asp Ile Arg Arg Gly His Glu Leu Val Ala Val Ser 115 120 125 Asp Glu Gly Asp Phe Val Glu Ala Arg Ala Ala Gly Pro Glu Gly Thr 130 135 140 Val Val Val Arg Gly Arg Phe Leu Val Gly Cys Asp Gly Glu Glu Ser 145 150 155 160 Ala Val Arg Arg Leu Thr Gly Ala Glu Phe Pro Gly Asn Asp Ala Gly 165 170 175 Arg Glu Leu Leu Arg Ala Asp Val Ala Gly Val Thr Ile Pro Gly Arg 180 185 190 Arg Phe Glu Arg Leu Pro Ala Gly Leu Ala Ile Ala Ala Thr Arg Asp 195 200 205 Gly Val Thr Arg Val Met Val His Glu Phe Gly Ser Gln Ala Glu Pro 210 215 220 Arg Thr Gly Asp Pro Glu Phe Gly Glu Ile Ala Ala Val Trp Lys Arg 225 230 235 240 Val Thr Gly Glu Asp Ile Ser Gly Gly Thr Pro Leu Trp Ala Asn Ser 245 250 255 Phe Gly Asp Ala Asn Arg Gln Leu Thr His Tyr Arg Asp Gly Arg Ile 260 265 270 Leu Phe Ala Gly Asp Ala Ala His Arg Gln Met Pro Ile Gly Gly Gln 275 280 285 Ala Leu Asn Leu Gly Leu Gln Asp Ala Phe Asn Leu Gly Trp Lys Leu 290 295 300 Ala Leu His Leu Gly Glu Ser Ala Pro Glu Gly Leu Leu Asp Thr Tyr 305 310 315 320 His Ser Glu Arg His Glu Val Gly Arg Arg Val Leu Ser Asn Ile Arg 325 330 335 Ala Gln Ala Met Leu Leu Leu Gly Gly Gln Glu Val Glu Pro Leu Arg 340 345 350 Ala Val Leu Thr Glu Leu Leu Pro Tyr Asp Asp Val Arg Ala His Leu 355 360 365 Ala Gly Met Ile Ser Gly Leu Asp Ile Arg Tyr Asp Val Gly Gly Pro 370 375 380 Glu His Pro Leu Leu Gly Ala Arg Leu Pro Asp Ala Gly Leu Thr Thr 385 390 395 400 Gly Glu Gly Pro Leu Ser Thr Ala Gln Leu Leu Arg Thr Ala Arg Gly 405 410 415 Val Leu Leu Asp Leu Ser Gly Gly Ser Ala Val Leu Ser Asp Ala Ala 420 425 430 Gly Trp Ala Asp Arg Val Thr Ala Leu Pro Ala Val Pro Glu Lys Gly 435 440 445 Gly Ala Leu Asp Ser Val Gly Ala Val Leu Val Arg Pro Asp Gly His 450 455 460 Val Ala Trp Ala Gly Ala Pro Asp Thr Asp Gly Ala Gly Leu Arg Glu 465 470 475 480 Ala Leu Glu Arg Trp Phe Gly Pro Ser His 485 490 38 1503 DNA Streptomyces murayamaensis ATCC 21414 38 atggagggga cagccgtgga caccgatgtg atcatcgtcg gcgcgggtcc gaccggcctc 60 atgctcgccg gggaactgcg cctcggcggg gcggacgtcg tcgtcgtcga acggctgacg 120 aagcccaccg gccagtcccg gggcctgggc ttcaccgccc gcgccatgga gatcttcgac 180 cagcgcgggc tgctgccccg gttcggccag ggcgagacgc tggagatcag cccgctcggt 240 cacttcggcg gtgtgcagtt cgactacacc gtcctggagg gcgcccactt cggggcgcgc 300 ggcattcccc agaacatcac cgagacggtc cttgaggagt gggcgaccga gctcggcgtg 360 gacatccggc gcggctggga cttcctggag atagccgacg gctacctcga cggcgacagc 420 gtcgagatca aggtgcagac gcccaactcg gtacggaagc tgcgcgcttc ctacctcgtg 480 ggcgccgacg gcggccgcag cgtggtgcgc gaggcggccg ggttcgactt cccgggcacc 540 tcggccaccc gggcgatgtt cctggccgat gtgaccggct gcaacctcaa gccgcgcttc 600 ctcggtgagc ggctgaacaa cggcatggtg atggcggccc cgctcgccga gggcgtcgac 660 cgcatcatcg tctgcccgga cggcacgccc gcgcgcgcca gcggcgacac ggtcagcttc 720 gaggaggtcg ccgccgcctg gcagtcgatc accggcgagg acatctcgca cggcggcgcc 780 gagtgggtca gcttcttcag cgacgccacc cgccaggcct ccgagtaccg gcgcggccgg 840 gtcctgctgg tcggcgacgc cgcccacatc cacctcccgg ccggcggcca gggcctgagc 900 accggcgtcc aggacgcggc caacctcggc tggaagctgg ccgcggcggt cgccgggacc 960 gcgcccgagg ggctgctcga cacgtaccac ggcgagcgcc accccgtggg tgcccggctg 1020 ctgatgaaca cccgcgccca gggcatggtg ttcctcggcg gacccgaggc cgagccgctg 1080 cgccagctct tcggcgagct catccagtac gacgacgtga agcgccatct cgccgggatc 1140 gtcagtggtc tggacatccg gtacgagctg ggtgacgcgc acccgctggt ggggcgccgg 1200 attccgcctc ggcggctggt gggggcggcg ggggagacca gcaccgtcgc gctgctgcac 1260 gcggcgcggg gtgtgctgct cgacttcgcc gacgacgcgg cggtgcggga cgcggccgcc 1320 gggtggtcgg ggcgcgtcga cgtcgtcacg gcggcgccga agccggtcga cggcggtacc 1380 gatccgctcg cgggtgcggc tgccgtgctc gtacggcccg atggatatgt ggcgtgggcc 1440 gcggacacgg ccgaaggcct tgctccggct cttgagcgct ggttcggtcc ggccggggtg 1500 tga 1503 39 500 PRT Streptomyces murayamaensis ATCC 21414 39 Met Glu Gly Thr Ala Val Asp Thr Asp Val Ile Ile Val Gly Ala Gly 1 5 10 15 Pro Thr Gly Leu Met Leu Ala Gly Glu Leu Arg Leu Gly Gly Ala Asp 20 25 30 Val Val Val Val Glu Arg Leu Thr Lys Pro Thr Gly Gln Ser Arg Gly 35 40 45 Leu Gly Phe Thr Ala Arg Ala Met Glu Ile Phe Asp Gln Arg Gly Leu 50 55 60 Leu Pro Arg Phe Gly Gln Gly Glu Thr Leu Glu Ile Ser Pro Leu Gly 65 70 75 80 His Phe Gly Gly Val Gln Phe Asp Tyr Thr Val Leu Glu Gly Ala His 85 90 95 Phe Gly Ala Arg Gly Ile Pro Gln Asn Ile Thr Glu Thr Val Leu Glu 100 105 110 Glu Trp Ala Thr Glu Leu Gly Val Asp Ile Arg Arg Gly Trp Asp Phe 115 120 125 Leu Glu Ile Ala Asp Gly Tyr Leu Asp Gly Asp Ser Val Glu Ile Lys 130 135 140 Val Gln Thr Pro Asn Ser Val Arg Lys Leu Arg Ala Ser Tyr Leu Val 145 150 155 160 Gly Ala Asp Gly Gly Arg Ser Val Val Arg Glu Ala Ala Gly Phe Asp 165 170 175 Phe Pro Gly Thr Ser Ala Thr Arg Ala Met Phe Leu Ala Asp Val Thr 180 185 190 Gly Cys Asn Leu Lys Pro Arg Phe Leu Gly Glu Arg Leu Asn Asn Gly 195 200 205 Met Val Met Ala Ala Pro Leu Ala Glu Gly Val Asp Arg Ile Ile Val 210 215 220 Cys Pro Asp Gly Thr Pro Ala Arg Ala Ser Gly Asp Thr Val Ser Phe 225 230 235 240 Glu Glu Val Ala Ala Ala Trp Gln Ser Ile Thr Gly Glu Asp Ile Ser 245 250 255 His Gly Gly Ala Glu Trp Val Ser Phe Phe Ser Asp Ala Thr Arg Gln 260 265 270 Ala Ser Glu Tyr Arg Arg Gly Arg Val Leu Leu Val Gly Asp Ala Ala 275 280 285 His Ile His Leu Pro Ala Gly Gly Gln Gly Leu Ser Thr Gly Val Gln 290 295 300 Asp Ala Ala Asn Leu Gly Trp Lys Leu Ala Ala Ala Val Ala Gly Thr 305 310 315 320 Ala Pro Glu Gly Leu Leu Asp Thr Tyr His Gly Glu Arg His Pro Val 325 330 335 Gly Ala Arg Leu Leu Met Asn Thr Arg Ala Gln Gly Met Val Phe Leu 340 345 350 Gly Gly Pro Glu Ala Glu Pro Leu Arg Gln Leu Phe Gly Glu Leu Ile 355 360 365 Gln Tyr Asp Asp Val Lys Arg His Leu Ala Gly Ile Val Ser Gly Leu 370 375 380 Asp Ile Arg Tyr Glu Leu Gly Asp Ala His Pro Leu Val Gly Arg Arg 385 390 395 400 Ile Pro Pro Arg Arg Leu Val Gly Ala Ala Gly Glu Thr Ser Thr Val 405 410 415 Ala Leu Leu His Ala Ala Arg Gly Val Leu Leu Asp Phe Ala Asp Asp 420 425 430 Ala Ala Val Arg Asp Ala Ala Ala Gly Trp Ser Gly Arg Val Asp Val 435 440 445 Val Thr Ala Ala Pro Lys Pro Val Asp Gly Gly Thr Asp Pro Leu Ala 450 455 460 Gly Ala Ala Ala Val Leu Val Arg Pro Asp Gly Tyr Val Ala Trp Ala 465 470 475 480 Ala Asp Thr Ala Glu Gly Leu Ala Pro Ala Leu Glu Arg Trp Phe Gly 485 490 495 Pro Ala Gly Val 500 40 879 DNA Streptomyces murayamaensis ATCC 21414 40 atggaaagca cgctcgcacc gggcgcggtc tcccagggcg ttcgcaggat caccctggac 60 gccgggggag tcacgctgtc cgcgctgctg tgcgagccgg aagggacccc ccgcgccacc 120 gtcgtcgccg tgcacggcgg cgggatgagc gccgggtact tcgacggtca ggcgcacccc 180 gagctgtccc tgctcaccct cggcgcccgg ctcggctaca ccgtgctcgc ggtggaccgg 240 cccggctacg gccgttccgc cgcccagctg ccggacgggc tcaccgtcgc cgagcagacc 300 gaggtgctgc gggccgggat cgacgacttc acctccaagt acccgacggg cgcgggggtg 360 ttgctggtcg cccactcctt cggcggcaag ctcgccctgt cggccgccgc gcactgcacc 420 ggcgacggcc tgctcggcat cgacatctcc ggctgcggcc accgctacgc cgtcaccccg 480 ggcgtgctgc gcaagggcct caagcacatc gcccggcact ggggcccgct gcggctctac 540 ccgccggaca ccttccgcag cagcggctcc ctggtggcgc cgatgccgga gcgcgaggcg 600 agtgaactca agcgctggcc cgagctgttc gcggccctcg cgccgcgcgt gcggatcccg 660 gtccggctca ccttcgccga gcacgagggc tggtggctgc acggcgagca ggacctcgcc 720 gacctcgccg cccagctgac cgcctcgccc cgtatcgtcg tcgaccgcca gccggacgcc 780 ggtcacaaca tcagcctcgg ctgggcggcc cgctcctacc acctgcgcac cctcgcgttc 840 ctggaggact gcatcacgcg ggcgggacgc gatgggtga 879 41 292 PRT Streptomyces murayamaensis ATCC 21414 41 Met Glu Ser Thr Leu Ala Pro Gly Ala Val Ser Gln Gly Val Arg Arg 1 5 10 15 Ile Thr Leu Asp Ala Gly Gly Val Thr Leu Ser Ala Leu Leu Cys Glu 20 25 30 Pro Glu Gly Thr Pro Arg Ala Thr Val Val Ala Val His Gly Gly Gly 35 40 45 Met Ser Ala Gly Tyr Phe Asp Gly Gln Ala His Pro Glu Leu Ser Leu 50 55 60 Leu Thr Leu Gly Ala Arg Leu Gly Tyr Thr Val Leu Ala Val Asp Arg 65 70 75 80 Pro Gly Tyr Gly Arg Ser Ala Ala Gln Leu Pro Asp Gly Leu Thr Val 85 90 95 Ala Glu Gln Thr Glu Val Leu Arg Ala Gly Ile Asp Asp Phe Thr Ser 100 105 110 Lys Tyr Pro Thr Gly Ala Gly Val Leu Leu Val Ala His Ser Phe Gly 115 120 125 Gly Lys Leu Ala Leu Ser Ala Ala Ala His Cys Thr Gly Asp Gly Leu 130 135 140 Leu Gly Ile Asp Ile Ser Gly Cys Gly His Arg Tyr Ala Val Thr Pro 145 150 155 160 Gly Val Leu Arg Lys Gly Leu Lys His Ile Ala Arg His Trp Gly Pro 165 170 175 Leu Arg Leu Tyr Pro Pro Asp Thr Phe Arg Ser Ser Gly Ser Leu Val 180 185 190 Ala Pro Met Pro Glu Arg Glu Ala Ser Glu Leu Lys Arg Trp Pro Glu 195 200 205 Leu Phe Ala Ala Leu Ala Pro Arg Val Arg Ile Pro Val Arg Leu Thr 210 215 220 Phe Ala Glu His Glu Gly Trp Trp Leu His Gly Glu Gln Asp Leu Ala 225 230 235 240 Asp Leu Ala Ala Gln Leu Thr Ala Ser Pro Arg Ile Val Val Asp Arg 245 250 255 Gln Pro Asp Ala Gly His Asn Ile Ser Leu Gly Trp Ala Ala Arg Ser 260 265 270 Tyr His Leu Arg Thr Leu Ala Phe Leu Glu Asp Cys Ile Thr Arg Ala 275 280 285 Gly Arg Asp Gly 290 42 1281 DNA Streptomyces murayamaensis ATCC 21414 42 atgaccagca ctctggcaac ccctttccgt tccctgtccg tacggaactt ccggctgttc 60 gcggccgggc aggtggtctc cgtcgcgggc acctggatga tggtcgtggc ccaggactgg 120 atcgtcctga gcctggccga caactccggt acggcgctgg gcgtggtgac cgcgctgcag 180 ttcaccccgc tgctgctgct caccctgtac ggcgggcgcc tcgccgaccg ctacgacaag 240 cgcttcctgc tgacctgtgc caatctcgcg tccggcgcgc tggctctggt gctcgcgctg 300 ctcgcgttcg cggacgcggt gcagctgtgg cacatctggc tgtgcgcgtt cggcctcggg 360 atggtgaacg ccgtcgaggt gccgacccgg atggcgttcg tcagcgagct ggtcggcccc 420 gaactgctgc ccaacgcctc cgcattgagc gccgcgtact tcaacaccgc ccgggtcgtc 480 ggcccggcgc tggccgggct gctcatcacc ggcttcggca ccggctgggt catgctgttc 540 aactccgtca gctatctggc cacggtggcc gggctgcgga tgatgcggcc ggacgaactg 600 ctgcgcggcg cacggcagga cacccgtccc cgggtgatcg acgggctgcg gtacatccgc 660 agccgccccg atctgaagct gccgctcgcc ctgatcgggg tgatctcgct cgtcgggctc 720 aacttccagc tgacgctgcc gctgtatgcc aaaacggttt tccacgccga cgcggcctcg 780 ttcgggctgc tgaccaccgg cttcgcggcg ggctccctgg tcgccgcgtt cgtcaccacg 840 gcgcgccgcg gccgcccctc cagccgtctg gtggtcgcct cggcgatcgc gttcgcggcc 900 ttggagacgg tggcgggctg ggcgcccaac ttcgcctcgg cgatcgtgct gctctcgctc 960 accggcgggg cgaccatcta cttcgtccag gcggccaacc atcgcgtcca gctcggcagc 1020 gacccgcagt accggggccg ggtgatggcg ctctacacgc tcatcgtcca gggctccacc 1080 ccgctgggat cgctcctcat cggctggctc gccgaacacc tgggcgcccg ctcggggttc 1140 tacgtgggcg gcctggtctc gctggcggcc gccctgacgg cgctggcctt cgaccggcgt 1200 acgggacagg aggcgtccga cgacgtgacg acggcgacga aggccgcgcc cgagggcgag 1260 cccgaggcgg tgagccggtg a 1281 43 426 PRT Streptomyces murayamaensis ATCC 21414 43 Met Thr Ser Thr Leu Ala Thr Pro Phe Arg Ser Leu Ser Val Arg Asn 1 5 10 15 Phe Arg Leu Phe Ala Ala Gly Gln Val Val Ser Val Ala Gly Thr Trp 20 25 30 Met Met Val Val Ala Gln Asp Trp Ile Val Leu Ser Leu Ala Asp Asn 35 40 45 Ser Gly Thr Ala Leu Gly Val Val Thr Ala Leu Gln Phe Thr Pro Leu 50 55 60 Leu Leu Leu Thr Leu Tyr Gly Gly Arg Leu Ala Asp Arg Tyr Asp Lys 65 70 75 80 Arg Phe Leu Leu Thr Cys Ala Asn Leu Ala Ser Gly Ala Leu Ala Leu 85 90 95 Val Leu Ala Leu Leu Ala Phe Ala Asp Ala Val Gln Leu Trp His Ile 100 105 110 Trp Leu Cys Ala Phe Gly Leu Gly Met Val Asn Ala Val Glu Val Pro 115 120 125 Thr Arg Met Ala Phe Val Ser Glu Leu Val Gly Pro Glu Leu Leu Pro 130 135 140 Asn Ala Ser Ala Leu Ser Ala Ala Tyr Phe Asn Thr Ala Arg Val Val 145 150 155 160 Gly Pro Ala Leu Ala Gly Leu Leu Ile Thr Gly Phe Gly Thr Gly Trp 165 170 175 Val Met Leu Phe Asn Ser Val Ser Tyr Leu Ala Thr Val Ala Gly Leu 180 185 190 Arg Met Met Arg Pro Asp Glu Leu Leu Arg Gly Ala Arg Gln Asp Thr 195 200 205 Arg Pro Arg Val Ile Asp Gly Leu Arg Tyr Ile Arg Ser Arg Pro Asp 210 215 220 Leu Lys Leu Pro Leu Ala Leu Ile Gly Val Ile Ser Leu Val Gly Leu 225 230 235 240 Asn Phe Gln Leu Thr Leu Pro Leu Tyr Ala Lys Thr Val Phe His Ala 245 250 255 Asp Ala Ala Ser Phe Gly Leu Leu Thr Thr Gly Phe Ala Ala Gly Ser 260 265 270 Leu Val Ala Ala Phe Val Thr Thr Ala Arg Arg Gly Arg Pro Ser Ser 275 280 285 Arg Leu Val Val Ala Ser Ala Ile Ala Phe Ala Ala Leu Glu Thr Val 290 295 300 Ala Gly Trp Ala Pro Asn Phe Ala Ser Ala Ile Val Leu Leu Ser Leu 305 310 315 320 Thr Gly Gly Ala Thr Ile Tyr Phe Val Gln Ala Ala Asn His Arg Val 325 330 335 Gln Leu Gly Ser Asp Pro Gln Tyr Arg Gly Arg Val Met Ala Leu Tyr 340 345 350 Thr Leu Ile Val Gln Gly Ser Thr Pro Leu Gly Ser Leu Leu Ile Gly 355 360 365 Trp Leu Ala Glu His Leu Gly Ala Arg Ser Gly Phe Tyr Val Gly Gly 370 375 380 Leu Val Ser Leu Ala Ala Ala Leu Thr Ala Leu Ala Phe Asp Arg Arg 385 390 395 400 Thr Gly Gln Glu Ala Ser Asp Asp Val Thr Thr Ala Thr Lys Ala Ala 405 410 415 Pro Glu Gly Glu Pro Glu Ala Val Ser Arg 420 425 44 576 DNA Streptomyces murayamaensis ATCC 21414 44 gtgtgcccgc tgatgcaggc cctggacgag ctggaggcgg cccgcgcggc caccttcgtc 60 cacgacaggg accgccgcca gtacgtggcg gcgcacgcca ccctgcggcg cgtgctcgcc 120 gagtacaccg ggcacgagcc cagccgggtg ccgctcggcc gggccgaagg gccctacggg 180 aagccgcagt tgatcggttc gccggtcccg ctgcacttca acctctcgca cagccacggc 240 ctgatcgcca tcggggtcgc ggcggacccg gtgggcgtcg acgtccagcg cgtcccgtcg 300 cccgaggcgg tcgaggtggt cctgcccagg ctgcatccgc gcgagcgcga ggaactgcgc 360 gctctgcccg catcggagcg cccggaggcg ttcgcgcggc tgtggacccg caaggaggcc 420 tacctcaagg gcctgggcac cggcctcacc cgctcgcccg cggcggacta tctgggcgag 480 acggccgcgg cccgcccggc cggctggacg gtgcgcaacg tgccggtaca gccgggctac 540 gcggccgcgg ccgcgctccg ccaccacccg acctga 576 45 191 PRT Streptomyces murayamaensis ATCC 21414 45 Met Cys Pro Leu Met Gln Ala Leu Asp Glu Leu Glu Ala Ala Arg Ala 1 5 10 15 Ala Thr Phe Val His Asp Arg Asp Arg Arg Gln Tyr Val Ala Ala His 20 25 30 Ala Thr Leu Arg Arg Val Leu Ala Glu Tyr Thr Gly His Glu Pro Ser 35 40 45 Arg Val Pro Leu Gly Arg Ala Glu Gly Pro Tyr Gly Lys Pro Gln Leu 50 55 60 Ile Gly Ser Pro Val Pro Leu His Phe Asn Leu Ser His Ser His Gly 65 70 75 80 Leu Ile Ala Ile Gly Val Ala Ala Asp Pro Val Gly Val Asp Val Gln 85 90 95 Arg Val Pro Ser Pro Glu Ala Val Glu Val Val Leu Pro Arg Leu His 100 105 110 Pro Arg Glu Arg Glu Glu Leu Arg Ala Leu Pro Ala Ser Glu Arg Pro 115 120 125 Glu Ala Phe Ala Arg Leu Trp Thr Arg Lys Glu Ala Tyr Leu Lys Gly 130 135 140 Leu Gly Thr Gly Leu Thr Arg Ser Pro Ala Ala Asp Tyr Leu Gly Glu 145 150 155 160 Thr Ala Ala Ala Arg Pro Ala Gly Trp Thr Val Arg Asn Val Pro Val 165 170 175 Gln Pro Gly Tyr Ala Ala Ala Ala Ala Leu Arg His His Pro Thr 180 185 190 46 1581 DNA Streptomyces murayamaensis ATCC 21414 46 atgccgacca cgccgaccac acagtcctcc gccgaggtct ccgaccggct ggacgaactc 60 agcgaacgca aggaacaggc cgtacgcggt cccagcgaca aggcgaccga ggcgcagcac 120 gccaagggca agctgaccgc acgcgagcgg atcgaactcc tcctggacaa gggcagcttc 180 accgaggtcg agcagctgcg gcggcaccgc gccaccgggt tcggcctgga ggccaagaag 240 ccgtacacgg acggtgtcat caccggctgg ggcacggtcg agggccgtac ggtcttcgtc 300 tacgcccatg acttccgcat cttcggcggc gcgctcggcg aggcccacgc gaccaagatc 360 cacaagatca tggacatggc gctggcggcg ggcgcgccgc tggtctcgct gaacgacggc 420 gcgggcgccc ggatccagga gggcgtctcg gcgctcgccg gttacggcgg catcttccag 480 cgcaacacgc gggcctcggg tgtcatcccg cagatctccg tgatgctcgg cccgtgcgcg 540 ggcggcgcgg cgtactcgcc ggcgctgacc gacttcgtgt tcatggtccg cgagacctcg 600 cagatgttca tcaccggccc ggacgtcgtc caggccgtga cgggcgagga gatcagccag 660 aacggactcg gcggcgccga tgtgcacgcc gggacctcgg gcgtggcgca cttcgcgtac 720 gacgacgagg agagctgcct cgccgaggtg cgctatctgc tctccctgct gccgtccaac 780 aaccgggaga tgccgccgct ggcgcagacc tcggacccgg tggaccgcga gggcaccgcc 840 ctgctcgatc tggtgccggc cgacggcaac cgctcgtacg acgtgcgcgg ggtgatcgag 900 gagctcgtcg acgacggcga gtacatggag atccacgcca actgggcgcc caacctggtg 960 gtggccctgg cccggctgga cggccatgtc gtcggcgtcg tcgccaacca gccgtccgcc 1020 atggccggcg tcctggacat caaggcgagc gagaagggcg cccggttcgt ccagttctgc 1080 gactccttca gcatcccgct gatcaccctc gtcgacgtgc ccgggttcct gccgggcgtc 1140 gaccaggagc acgacggcat catccggcgc ggcgcgaagc tgctctacgc ctactgcaac 1200 gcgaccgtgc ctcgtatctc ggtggtgctg cgcaaggcgt acggcggtgc ctacatcgtg 1260 atggactcgc gttccatcgg agccgacctg tcgttcgcct ggcccaccaa cgagatcgcg 1320 gtgatgggcg ccgagggcgc ggcgaacgtg gtgttccggc gggagatcgc cgcggccgag 1380 gacccggacg cgatgcgcaa gcagaagatc gacgagtaca agaacgagct ggtgcacccc 1440 tacttcgcgg ccgagcgcgg tctggtcgac gacgtcatcg acccgcgcga gacccgctcg 1500 gtgctgtgcc gctcggtcac gatgctcatc gccaaggacg ccgagctgcc ccgccgcaag 1560 cacggcaacc cgccccagta g 1581 47 526 PRT Streptomyces murayamaensis ATCC 21414 47 Met Pro Thr Thr Pro Thr Thr Gln Ser Ser Ala Glu Val Ser Asp Arg 1 5 10 15 Leu Asp Glu Leu Ser Glu Arg Lys Glu Gln Ala Val Arg Gly Pro Ser 20 25 30 Asp Lys Ala Thr Glu Ala Gln His Ala Lys Gly Lys Leu Thr Ala Arg 35 40 45 Glu Arg Ile Glu Leu Leu Leu Asp Lys Gly Ser Phe Thr Glu Val Glu 50 55 60 Gln Leu Arg Arg His Arg Ala Thr Gly Phe Gly Leu Glu Ala Lys Lys 65 70 75 80 Pro Tyr Thr Asp Gly Val Ile Thr Gly Trp Gly Thr Val Glu Gly Arg 85 90 95 Thr Val Phe Val Tyr Ala His Asp Phe Arg Ile Phe Gly Gly Ala Leu 100 105 110 Gly Glu Ala His Ala Thr Lys Ile His Lys Ile Met Asp Met Ala Leu 115 120 125 Ala Ala Gly Ala Pro Leu Val Ser Leu Asn Asp Gly Ala Gly Ala Arg 130 135 140 Ile Gln Glu Gly Val Ser Ala Leu Ala Gly Tyr Gly Gly Ile Phe Gln 145 150 155 160 Arg Asn Thr Arg Ala Ser Gly Val Ile Pro Gln Ile Ser Val Met Leu 165 170 175 Gly Pro Cys Ala Gly Gly Ala Ala Tyr Ser Pro Ala Leu Thr Asp Phe 180 185 190 Val Phe Met Val Arg Glu Thr Ser Gln Met Phe Ile Thr Gly Pro Asp 195 200 205 Val Val Gln Ala Val Thr Gly Glu Glu Ile Ser Gln Asn Gly Leu Gly 210 215 220 Gly Ala Asp Val His Ala Gly Thr Ser Gly Val Ala His Phe Ala Tyr 225 230 235 240 Asp Asp Glu Glu Ser Cys Leu Ala Glu Val Arg Tyr Leu Leu Ser Leu 245 250 255 Leu Pro Ser Asn Asn Arg Glu Met Pro Pro Leu Ala Gln Thr Ser Asp 260 265 270 Pro Val Asp Arg Glu Gly Thr Ala Leu Leu Asp Leu Val Pro Ala Asp 275 280 285 Gly Asn Arg Ser Tyr Asp Val Arg Gly Val Ile Glu Glu Leu Val Asp 290 295 300 Asp Gly Glu Tyr Met Glu Ile His Ala Asn Trp Ala Pro Asn Leu Val 305 310 315 320 Val Ala Leu Ala Arg Leu Asp Gly His Val Val Gly Val Val Ala Asn 325 330 335 Gln Pro Ser Ala Met Ala Gly Val Leu Asp Ile Lys Ala Ser Glu Lys 340 345 350 Gly Ala Arg Phe Val Gln Phe Cys Asp Ser Phe Ser Ile Pro Leu Ile 355 360 365 Thr Leu Val Asp Val Pro Gly Phe Leu Pro Gly Val Asp Gln Glu His 370 375 380 Asp Gly Ile Ile Arg Arg Gly Ala Lys Leu Leu Tyr Ala Tyr Cys Asn 385 390 395 400 Ala Thr Val Pro Arg Ile Ser Val Val Leu Arg Lys Ala Tyr Gly Gly 405 410 415 Ala Tyr Ile Val Met Asp Ser Arg Ser Ile Gly Ala Asp Leu Ser Phe 420 425 430 Ala Trp Pro Thr Asn Glu Ile Ala Val Met Gly Ala Glu Gly Ala Ala 435 440 445 Asn Val Val Phe Arg Arg Glu Ile Ala Ala Ala Glu Asp Pro Asp Ala 450 455 460 Met Arg Lys Gln Lys Ile Asp Glu Tyr Lys Asn Glu Leu Val His Pro 465 470 475 480 Tyr Phe Ala Ala Glu Arg Gly Leu Val Asp Asp Val Ile Asp Pro Arg 485 490 495 Glu Thr Arg Ser Val Leu Cys Arg Ser Val Thr Met Leu Ile Ala Lys 500 505 510 Asp Ala Glu Leu Pro Arg Arg Lys His Gly Asn Pro Pro Gln 515 520 525 48 306 DNA Streptomyces murayamaensis ATCC 21414 48 gtgcacgaca tgagcgagat gacccagttc accgagcccg ccgagcccgc cgccgagtcc 60 gccgggatga ccctggagca ctgccgcgag ctgttgcggg tcgagcgggg caaccccgat 120 ccggaggaac tcgcggcgct ggcggcgctg ttcttcgccc acttctccgc gatcgaggcg 180 cggcgggagg ccgcccgtgt cctgatcccg cggcagcggc gctccgcgag ctggcgccgc 240 accgagcggg cacccggctt cgacggcccg cgcacctggc gcgcgggcgg tcccgcactc 300 gtttga 306 49 101 PRT Streptomyces murayamaensis ATCC 21414 49 Val His Asp Met Ser Glu Met Thr Gln Phe Thr Glu Pro Ala Glu Pro 1 5 10 15 Ala Ala Glu Ser Ala Gly Met Thr Leu Glu His Cys Arg Glu Leu Leu 20 25 30 Arg Val Glu Arg Gly Asn Pro Asp Pro Glu Glu Leu Ala Ala Leu Ala 35 40 45 Ala Leu Phe Phe Ala His Phe Ser Ala Ile Glu Ala Arg Arg Glu Ala 50 55 60 Ala Arg Val Leu Ile Pro Arg Gln Arg Arg Ser Ala Ser Trp Arg Arg 65 70 75 80 Thr Glu Arg Ala Pro Gly Phe Asp Gly Pro Arg Thr Trp Arg Ala Gly 85 90 95 Gly Pro Ala Leu Val 100 50 783 DNA Streptomyces murayamaensis ATCC 21414 50 atgactcaga gttcgtcaga ggcagtgctg gagcctcata tacctgtcca gcgtggtccc 60 ggtggaccac acctgatcga agagggcgtg tcggaagcgg tgcgcagggt ggccggcctc 120 tcgcggggcc ggcggatcct cgtggtcgac agcgacgtcg acggcgcgga gtccctggtg 180 tgccggctgc gcaggcacgg ccacgaggcc atcggcgtga agagcggtag caccgcgctg 240 caggcgtacg aggacgtgga ccttgtcctc ctcgacctcg aactcccgga cctggacggg 300 ctggaggtgt gccgggccat ccgctccgtg agcggcatcc ctgtgatcat cgtcaccgcc 360 cggggctccg agctcgactg tgtgctcggc ctacaggccg gtgcagacga ctatgtggtc 420 aagccctatg gcttccggga attaatggca cggatcgaag ccgtcatgcg tcgcgccagg 480 ttccaaccgc ctgttgccag agagatcttg cacgggcggt tgcgcattga cgtgagctcc 540 cgcgaggtga gcctggacgg ccgcgaggtg gggctgaccc gcaaggaatt cgatctgctc 600 tgcctgctcg cgtcccatcc ggacacggtc attccgcgaa agcgcctgct ccagcaggtc 660 tggggggact cctggtcccg ccgtactgtc gacacccatg tcagcagcct tcgcggaaaa 720 ctcggcgaca gcggctggat cattactgtg cgcggggtcg gtttcaagct gggcaacggg 780 tga 783 51 260 PRT Streptomyces murayamaensis ATCC 21414 51 Met Thr Gln Ser Ser Ser Glu Ala Val Leu Glu Pro His Ile Pro Val 1 5 10 15 Gln Arg Gly Pro Gly Gly Pro His Leu Ile Glu Glu Gly Val Ser Glu 20 25 30 Ala Val Arg Arg Val Ala Gly Leu Ser Arg Gly Arg Arg Ile Leu Val 35 40 45 Val Asp Ser Asp Val Asp Gly Ala Glu Ser Leu Val Cys Arg Leu Arg 50 55 60 Arg His Gly His Glu Ala Ile Gly Val Lys Ser Gly Ser Thr Ala Leu 65 70 75 80 Gln Ala Tyr Glu Asp Val Asp Leu Val Leu Leu Asp Leu Glu Leu Pro 85 90 95 Asp Leu Asp Gly Leu Glu Val Cys Arg Ala Ile Arg Ser Val Ser Gly 100 105 110 Ile Pro Val Ile Ile Val Thr Ala Arg Gly Ser Glu Leu Asp Cys Val 115 120 125 Leu Gly Leu Gln Ala Gly Ala Asp Asp Tyr Val Val Lys Pro Tyr Gly 130 135 140 Phe Arg Glu Leu Met Ala Arg Ile Glu Ala Val Met Arg Arg Ala Arg 145 150 155 160 Phe Gln Pro Pro Val Ala Arg Glu Ile Leu His Gly Arg Leu Arg Ile 165 170 175 Asp Val Ser Ser Arg Glu Val Ser Leu Asp Gly Arg Glu Val Gly Leu 180 185 190 Thr Arg Lys Glu Phe Asp Leu Leu Cys Leu Leu Ala Ser His Pro Asp 195 200 205 Thr Val Ile Pro Arg Lys Arg Leu Leu Gln Gln Val Trp Gly Asp Ser 210 215 220 Trp Ser Arg Arg Thr Val Asp Thr His Val Ser Ser Leu Arg Gly Lys 225 230 235 240 Leu Gly Asp Ser Gly Trp Ile Ile Thr Val Arg Gly Val Gly Phe Lys 245 250 255 Leu Gly Asn Gly 260 52 405 DNA Streptomyces murayamaensis ATCC 21414 52 gtgacctgga cgactgagcg ggtggagggc gccgacctgg acctggaggc ggtcctcgac 60 gtctaccgca gctccgggct cggcgagcgc cgtcccatcg aggacgtgga gcggttcgcc 120 gccatggtcc gcaacgccaa cctcgtggtg gtggcgcggg acgcggaggg caggctcatc 180 ggcatcgccc gcagcatctc cgacttctcc tacgcgacgt acctctcgga catcgcggtg 240 agcggcgact accagcgctc gggcatcggc cgcgcgctca tcgacgccac gcagaaggag 300 gccccgcagg cgaagatcat tctcctgtcg gcgccggcgg cggtggagta ctacccgcac 360 atcggcttca cccagcacaa ctccgcctgg gtgctcaacc cgtag 405 53 134 PRT Streptomyces murayamaensis ATCC 21414 53 Val Thr Trp Thr Thr Glu Arg Val Glu Gly Ala Asp Leu Asp Leu Glu 1 5 10 15 Ala Val Leu Asp Val Tyr Arg Ser Ser Gly Leu Gly Glu Arg Arg Pro 20 25 30 Ile Glu Asp Val Glu Arg Phe Ala Ala Met Val Arg Asn Ala Asn Leu 35 40 45 Val Val Val Ala Arg Asp Ala Glu Gly Arg Leu Ile Gly Ile Ala Arg 50 55 60 Ser Ile Ser Asp Phe Ser Tyr Ala Thr Tyr Leu Ser Asp Ile Ala Val 65 70 75 80 Ser Gly Asp Tyr Gln Arg Ser Gly Ile Gly Arg Ala Leu Ile Asp Ala 85 90 95 Thr Gln Lys Glu Ala Pro Gln Ala Lys Ile Ile Leu Leu Ser Ala Pro 100 105 110 Ala Ala Val Glu Tyr Tyr Pro His Ile Gly Phe Thr Gln His Asn Ser 115 120 125 Ala Trp Val Leu Asn Pro 130 54 1299 DNA Streptomyces murayamaensis ATCC 21414 54 gtgctggccc acatgattcc ccgctatacc ctgcccgcga tggcggacat cttctcggac 60 caggcgcggt acgcgacctg ggtccgggtg gagatcctgg cttccgaggc gcaggcgcgc 120 ctgggacggg tgcccgagga cgcggtcgag gacatgcggc gggccaaggt cccgacgccc 180 gagcgggtgc aggagatcga gcgcgagcgc gaccacgaag tgctctcgtt cctcgccgcg 240 tactgcgagg acatcccgga cgagtcggcc cgctgggtcc acctcggcat gaccagctac 300 gacctcgtcg acacctcgct gggctacaac ctggcccgcg ccaccgacct ggtgatcgcg 360 gccgcggtcg agctgcgcaa ggtcctggtc gaacgggccc tggagcactg ggagacggtc 420 atcgtcggcc gcacccacgg cgtccacgcc gagccgacgt ccttcggcca caagctggcg 480 cagttcgcgt tcgcggtgga ccgctcgatc acccggctgc gcgcggcgcg caaggccgtg 540 gcggtgggca cgatctccgg ctcggtcggc acgtacgcgc tgatcgaccc ctccgtcgag 600 gcgtacgtct gcgaggagct ggacctgggg gtggagccgg ccccgagcca ggtcgtcgcc 660 cgcgaccggc acgcccagct gatccaggcc gtcgccgtgc tcggcgcgag cgtcgagcag 720 atcgccctgg agctgcggct gctgcagcgc accgaggtcc gcgaggtcga ggagcagcgc 780 acctcggcgt accagggctc cagcgccatg ccccacaagc gcaacccgac caccagcgag 840 cgtctgacgg gtctggcccg gctgctgcgc ggttacgcga ccacggccct ggagaacgtg 900 gcgctgtggc acgagcggga tctggcccac cagtcggtgg agcgggtgat cctgccggac 960 gcgctgtcgg tggggcactt ccaggccacg atggcggccg acctggtccg taacctcaag 1020 gtgttcccgg agcggatgcg ggcggggatc gaccagaccg acggtcttgt gttcagctct 1080 gccgtactcg ccgatctgct ggccgacggg gtggagcggg agaaggccta ccgggccgtc 1140 cagtccgccg ccaaccgcac catcgcgacc ggcgagcact tcggggacac gctgcggcag 1200 gagggcatgg acatcggcca gctccgcccg gagcgtttcc tcgtcaacca cggtgtgatt 1260 ctcaagcgat tggagcagct tcgtgacctg gacgactga 1299 55 432 PRT Streptomyces murayamaensis ATCC 21414 55 Val Leu Ala His Met Ile Pro Arg Tyr Thr Leu Pro Ala Met Ala Asp 1 5 10 15 Ile Phe Ser Asp Gln Ala Arg Tyr Ala Thr Trp Val Arg Val Glu Ile 20 25 30 Leu Ala Ser Glu Ala Gln Ala Arg Leu Gly Arg Val Pro Glu Asp Ala 35 40 45 Val Glu Asp Met Arg Arg Ala Lys Val Pro Thr Pro Glu Arg Val Gln 50 55 60 Glu Ile Glu Arg Glu Arg Asp His Glu Val Leu Ser Phe Leu Ala Ala 65 70 75 80 Tyr Cys Glu Asp Ile Pro Asp Glu Ser Ala Arg Trp Val His Leu Gly 85 90 95 Met Thr Ser Tyr Asp Leu Val Asp Thr Ser Leu Gly Tyr Asn Leu Ala 100 105 110 Arg Ala Thr Asp Leu Val Ile Ala Ala Ala Val Glu Leu Arg Lys Val 115 120 125 Leu Val Glu Arg Ala Leu Glu His Trp Glu Thr Val Ile Val Gly Arg 130 135 140 Thr His Gly Val His Ala Glu Pro Thr Ser Phe Gly His Lys Leu Ala 145 150 155 160 Gln Phe Ala Phe Ala Val Asp Arg Ser Ile Thr Arg Leu Arg Ala Ala 165 170 175 Arg Lys Ala Val Ala Val Gly Thr Ile Ser Gly Ser Val Gly Thr Tyr 180 185 190 Ala Leu Ile Asp Pro Ser Val Glu Ala Tyr Val Cys Glu Glu Leu Asp 195 200 205 Leu Gly Val Glu Pro Ala Pro Ser Gln Val Val Ala Arg Asp Arg His 210 215 220 Ala Gln Leu Ile Gln Ala Val Ala Val Leu Gly Ala Ser Val Glu Gln 225 230 235 240 Ile Ala Leu Glu Leu Arg Leu Leu Gln Arg Thr Glu Val Arg Glu Val 245 250 255 Glu Glu Gln Arg Thr Ser Ala Tyr Gln Gly Ser Ser Ala Met Pro His 260 265 270 Lys Arg Asn Pro Thr Thr Ser Glu Arg Leu Thr Gly Leu Ala Arg Leu 275 280 285 Leu Arg Gly Tyr Ala Thr Thr Ala Leu Glu Asn Val Ala Leu Trp His 290 295 300 Glu Arg Asp Leu Ala His Gln Ser Val Glu Arg Val Ile Leu Pro Asp 305 310 315 320 Ala Leu Ser Val Gly His Phe Gln Ala Thr Met Ala Ala Asp Leu Val 325 330 335 Arg Asn Leu Lys Val Phe Pro Glu Arg Met Arg Ala Gly Ile Asp Gln 340 345 350 Thr Asp Gly Leu Val Phe Ser Ser Ala Val Leu Ala Asp Leu Leu Ala 355 360 365 Asp Gly Val Glu Arg Glu Lys Ala Tyr Arg Ala Val Gln Ser Ala Ala 370 375 380 Asn Arg Thr Ile Ala Thr Gly Glu His Phe Gly Asp Thr Leu Arg Gln 385 390 395 400 Glu Gly Met Asp Ile Gly Gln Leu Arg Pro Glu Arg Phe Leu Val Asn 405 410 415 His Gly Val Ile Leu Lys Arg Leu Glu Gln Leu Arg Asp Leu Asp Asp 420 425 430 56 1503 DNA Streptomyces murayamaensis ATCC 21414 56 atgtactccc ggtcgtggtc cagccccttc tccgaggcgg gcggcacagg acgtcccgcg 60 ttcgtcaccg agttcggcct gtggaccgac gaacaggccg ctgcggccga gcagatcgag 120 gcctcgctcg acgagatcga cctggtccgc ctcgccttcg ccgacccgca cgggctggcc 180 cgctccaaga cgctgaccgt ggacgcgttc cgctcggtcc tgcgcaacgg catggacttc 240 agctcgggcc cgttcatctt cgacaccggc cacgcggccg ccctggactt cctcgccgac 300 ccgggcgtcg gcgtcgacga gatcgcgggc gcgggcagct tcgtgctggt cccggacccg 360 ctgacgttcc aggtgctccc ccacgaggga ccgcgcaccg cgtgggtgct cggtgacgag 420 tatctgcgcg acggctcccc gcacccgctc tccgcgcgga acgtgctgcg ccaggtcgtc 480 gcccggtacg cggcccgcga cctcaccccg gtgctcggcc tggaggtcga gtggtacctg 540 acccgcaagc tcgcgggtcc gcccgggaac gcgggcaacg gcttcggcct ccagggcgcg 600 gcccccaagg tcgaggcgat gaactcgggc taccagttca acctggacgc caactacgac 660 tcggtggccc acttcaccag cccgctggcg atgaagctgc tcgaactcgg cctgccgctg 720 cgctcgatcg agcacgagtc gggcccgggc cagatcgaga cgaccttcaa cccgatgcac 780 gcgctggaca ccgccgacgc gatgctcctg ttccgcaccg tggtcaagca gaccgccgcg 840 cgccagggct accacgcctc cttcatggcg ctgccccgcg tcgacagctt cgacccgtgc 900 ggctggcatc tgcaccagtc ggtgatggac agcacgaacg ggcgcaacct cttcgcggcc 960 gacggcggcg gcatctcgga ccagggcaag gcgtacatcg acgggctgct ctcccgcgcc 1020 cgcgacctgt gtctgctctc ggtccccacc gtcaacggct accgccgcat gggcgcggac 1080 ttctcgctct cgccgacccg tctcggctgg agctacgagg accgcagcgc gatgatccgg 1140 gtggtcggcg gcggcgccgg cacgcacatc gagaaccggg tgggcgagcc caccgccaac 1200 ccgtacctca acatcgccgc ccagctctcc gccgggttcg acggcatggc caccgaggtc 1260 ggcgcgagca cgcgggagag cggcgaggag tcatacgaga cgctgccgca ggacctcggc 1320 gaggcgctgg aggccttccg ggccggtcag gccgccgaac tgctcggcaa gccgctggcc 1380 gccaccctgg ccaagctgaa ggagagcgag ctgtcccgct acgaggcctg gcgcgcggcc 1440 gagcggcccg ccgacggcca ggtcaccgag tgggagcagc gcgaatactt cgaggccttc 1500 tga 1503 57 500 PRT Streptomyces murayamaensis ATCC 21414 57 Met Tyr Ser Arg Ser Trp Ser Ser Pro Phe Ser Glu Ala Gly Gly Thr 1 5 10 15 Gly Arg Pro Ala Phe Val Thr Glu Phe Gly Leu Trp Thr Asp Glu Gln 20 25 30 Ala Ala Ala Ala Glu Gln Ile Glu Ala Ser Leu Asp Glu Ile Asp Leu 35 40 45 Val Arg Leu Ala Phe Ala Asp Pro His Gly Leu Ala Arg Ser Lys Thr 50 55 60 Leu Thr Val Asp Ala Phe Arg Ser Val Leu Arg Asn Gly Met Asp Phe 65 70 75 80 Ser Ser Gly Pro Phe Ile Phe Asp Thr Gly His Ala Ala Ala Leu Asp 85 90 95 Phe Leu Ala Asp Pro Gly Val Gly Val Asp Glu Ile Ala Gly Ala Gly 100 105 110 Ser Phe Val Leu Val Pro Asp Pro Leu Thr Phe Gln Val Leu Pro His 115 120 125 Glu Gly Pro Arg Thr Ala Trp Val Leu Gly Asp Glu Tyr Leu Arg Asp 130 135 140 Gly Ser Pro His Pro Leu Ser Ala Arg Asn Val Leu Arg Gln Val Val 145 150 155 160 Ala Arg Tyr Ala Ala Arg Asp Leu Thr Pro Val Leu Gly Leu Glu Val 165 170 175 Glu Trp Tyr Leu Thr Arg Lys Leu Ala Gly Pro Pro Gly Asn Ala Gly 180 185 190 Asn Gly Phe Gly Leu Gln Gly Ala Ala Pro Lys Val Glu Ala Met Asn 195 200 205 Ser Gly Tyr Gln Phe Asn Leu Asp Ala Asn Tyr Asp Ser Val Ala His 210 215 220 Phe Thr Ser Pro Leu Ala Met Lys Leu Leu Glu Leu Gly Leu Pro Leu 225 230 235 240 Arg Ser Ile Glu His Glu Ser Gly Pro Gly Gln Ile Glu Thr Thr Phe 245 250 255 Asn Pro Met His Ala Leu Asp Thr Ala Asp Ala Met Leu Leu Phe Arg 260 265 270 Thr Val Val Lys Gln Thr Ala Ala Arg Gln Gly Tyr His Ala Ser Phe 275 280 285 Met Ala Leu Pro Arg Val Asp Ser Phe Asp Pro Cys Gly Trp His Leu 290 295 300 His Gln Ser Val Met Asp Ser Thr Asn Gly Arg Asn Leu Phe Ala Ala 305 310 315 320 Asp Gly Gly Gly Ile Ser Asp Gln Gly Lys Ala Tyr Ile Asp Gly Leu 325 330 335 Leu Ser Arg Ala Arg Asp Leu Cys Leu Leu Ser Val Pro Thr Val Asn 340 345 350 Gly Tyr Arg Arg Met Gly Ala Asp Phe Ser Leu Ser Pro Thr Arg Leu 355 360 365 Gly Trp Ser Tyr Glu Asp Arg Ser Ala Met Ile Arg Val Val Gly Gly 370 375 380 Gly Ala Gly Thr His Ile Glu Asn Arg Val Gly Glu Pro Thr Ala Asn 385 390 395 400 Pro Tyr Leu Asn Ile Ala Ala Gln Leu Ser Ala Gly Phe Asp Gly Met 405 410 415 Ala Thr Glu Val Gly Ala Ser Thr Arg Glu Ser Gly Glu Glu Ser Tyr 420 425 430 Glu Thr Leu Pro Gln Asp Leu Gly Glu Ala Leu Glu Ala Phe Arg Ala 435 440 445 Gly Gln Ala Ala Glu Leu Leu Gly Lys Pro Leu Ala Ala Thr Leu Ala 450 455 460 Lys Leu Lys Glu Ser Glu Leu Ser Arg Tyr Glu Ala Trp Arg Ala Ala 465 470 475 480 Glu Arg Pro Ala Asp Gly Gln Val Thr Glu Trp Glu Gln Arg Glu Tyr 485 490 495 Phe Glu Ala Phe 500 58 1386 DNA Streptomyces murayamaensis ATCC 21414 58 ttgacctcag cgtccattgg cgacatacgc gacctcctcg cccggggaga gctgtccgcc 60 gccgaccatg tgcagtcggt cctcaccgcg atccagaaga ccgacatcga gctcggcgcc 120 ttcgtctcgg tcgcgggcga cgaggccgtg cgggaggccg aactggccga cgcccggatc 180 cgcgaggagg gcccggccgt cttcgaccgg cagccgctgc tcgggatcac ggtctcggtg 240 aaggacctca tccagaccgg ggacctgccc actgcccgtg ggtccctcct ggagaaccgg 300 cggccccggg ccgacgcgcc ctcggtcgcg cggctgcggg ccgccggggc catcgtcatc 360 ggcaagacca cgacgtcgga gtacgggtgg agcgcctcca cggtgagccg ggtggccccg 420 cccacccgta acccgtggga tctggaactc tccgccggcg gctccagcgg cggcgccgcg 480 gccgcggtcg cggcggggct cggctcgggg gcgctcggca ccgacggcgc gggctcgatc 540 cgtatcccgt cggcgttctg cggtgtggtc ggctacaagc cgtcgttcgc caaggtgccg 600 tatgtgcccg cctgcgccga ccggctctcc caccaggggc cgatcgcgcg caccgtgccg 660 gacgtcatcg agctcgcctc ggtgatcacc ggcgggcatc cgcaggaccc ggactcgatg 720 ctcggcgtgc atgaactgcc ccgccagcgg cggcggttgc gcatcggctg gatcgagttc 780 ccgggcacct cgccggaggt ccgccgggtc agcgagcagg gtctggacgc gctcgccgcg 840 caggggcacc gcgtcgagcg gatcgaggtg ccgttccgcg acccgtatcc ggcgctcgtc 900 gacatcctcg ccgcgagcga cgcggcgggt acctcgcccg ccgacgagga gtggtgcgac 960 ccgggccgcc tcgcgatcgt gcggcacggc cgcacgctca gcgcggccac cgtgatgcgg 1020 gccgaggagg tgcgtctggc gctgcgcacc acactgcacc agatcttcga ccggtacgac 1080 ctgctcgcga tggccaccgt gcccatcgag ccgatcgatc cccacgcgat cggccctgac 1140 tgggccagcc gtccggagga cctgctctgg ctggcgtgga cacccgccgc gtatcccttc 1200 aatatgactg gccagccggc cgtttcgctc ccggccggac tcacccgcgc cggtctcccg 1260 gtggggctcc aactcgtggg ccccttcggc gcggacgatc tggtcctgtc cgccgcacgc 1320 cgtctggagg cggacctcgg gccgctgccg gccgcaccgg accgagtaac cgaaaggatc 1380 ctgtaa 1386 59 461 PRT Streptomyces murayamaensis ATCC 21414 59 Met Thr Ser Ala Ser Ile Gly Asp Ile Arg Asp Leu Leu Ala Arg Gly 1 5 10 15 Glu Leu Ser Ala Ala Asp His Val Gln Ser Val Leu Thr Ala Ile Gln 20 25 30 Lys Thr Asp Ile Glu Leu Gly Ala Phe Val Ser Val Ala Gly Asp Glu 35 40 45 Ala Val Arg Glu Ala Glu Leu Ala Asp Ala Arg Ile Arg Glu Glu Gly 50 55 60 Pro Ala Val Phe Asp Arg Gln Pro Leu Leu Gly Ile Thr Val Ser Val 65 70 75 80 Lys Asp Leu Ile Gln Thr Gly Asp Leu Pro Thr Ala Arg Gly Ser Leu 85 90 95 Leu Glu Asn Arg Arg Pro Arg Ala Asp Ala Pro Ser Val Ala Arg Leu 100 105 110 Arg Ala Ala Gly Ala Ile Val Ile Gly Lys Thr Thr Thr Ser Glu Tyr 115 120 125 Gly Trp Ser Ala Ser Thr Val Ser Arg Val Ala Pro Pro Thr Arg Asn 130 135 140 Pro Trp Asp Leu Glu Leu Ser Ala Gly Gly Ser Ser Gly Gly Ala Ala 145 150 155 160 Ala Ala Val Ala Ala Gly Leu Gly Ser Gly Ala Leu Gly Thr Asp Gly 165 170 175 Ala Gly Ser Ile Arg Ile Pro Ser Ala Phe Cys Gly Val Val Gly Tyr 180 185 190 Lys Pro Ser Phe Ala Lys Val Pro Tyr Val Pro Ala Cys Ala Asp Arg 195 200 205 Leu Ser His Gln Gly Pro Ile Ala Arg Thr Val Pro Asp Val Ile Glu 210 215 220 Leu Ala Ser Val Ile Thr Gly Gly His Pro Gln Asp Pro Asp Ser Met 225 230 235 240 Leu Gly Val His Glu Leu Pro Arg Gln Arg Arg Arg Leu Arg Ile Gly 245 250 255 Trp Ile Glu Phe Pro Gly Thr Ser Pro Glu Val Arg Arg Val Ser Glu 260 265 270 Gln Gly Leu Asp Ala Leu Ala Ala Gln Gly His Arg Val Glu Arg Ile 275 280 285 Glu Val Pro Phe Arg Asp Pro Tyr Pro Ala Leu Val Asp Ile Leu Ala 290 295 300 Ala Ser Asp Ala Ala Gly Thr Ser Pro Ala Asp Glu Glu Trp Cys Asp 305 310 315 320 Pro Gly Arg Leu Ala Ile Val Arg His Gly Arg Thr Leu Ser Ala Ala 325 330 335 Thr Val Met Arg Ala Glu Glu Val Arg Leu Ala Leu Arg Thr Thr Leu 340 345 350 His Gln Ile Phe Asp Arg Tyr Asp Leu Leu Ala Met Ala Thr Val Pro 355 360 365 Ile Glu Pro Ile Asp Pro His Ala Ile Gly Pro Asp Trp Ala Ser Arg 370 375 380 Pro Glu Asp Leu Leu Trp Leu Ala Trp Thr Pro Ala Ala Tyr Pro Phe 385 390 395 400 Asn Met Thr Gly Gln Pro Ala Val Ser Leu Pro Ala Gly Leu Thr Arg 405 410 415 Ala Gly Leu Pro Val Gly Leu Gln Leu Val Gly Pro Phe Gly Ala Asp 420 425 430 Asp Leu Val Leu Ser Ala Ala Arg Arg Leu Glu Ala Asp Leu Gly Pro 435 440 445 Leu Pro Ala Ala Pro Asp Arg Val Thr Glu Arg Ile Leu 450 455 460 60 2058 DNA Streptomyces murayamaensis ATCC 21414 60 atgtcgccaa tggacgctga ggtcaacgga gcagctcctc gtcagaacgg ggtgggccgc 60 cggtcacgag acctgctgcg gctgcttggc gcgcgccgcc gcggcctgga ccgacttgag 120 gtgccactcg gagtcgaagg cggtgacctc gatctcctcg cccgcggcca ccagcgcggc 180 ggcggcgctc atggcgccgg cgatgaaccc cgaggtgcgg tgcgcggcga gcaggtcgga 240 ctcgtcgaac ggggtgccgt cgcagcgcag cagacgcagg tccatgaacc cgttgaacct 300 ctggcccagc acctcgaccg actgcgggct gcggatgctg aaccgcacct tcgacgccac 360 atggccgtgg tggtgctggt cggagtagaa ggcgacgtcg gggatggtcg gcgggatgaa 420 gtggtcgcgc tccaccacgg cgggcacctt gggcaggttc ccggcgatga agtgccagga 480 gttgtactgc atgcgggacg acatcgccca ggcgttgtcg gccagttgca gcaccgagtc 540 ctcgtagtgg cgcttggccg acggggcggg caccacgcag cagaagaagt cggtgatgtc 600 ccacttggtg atctcggcgt agctctgctc ccgcagggcg cgcatcagtt cggggatcga 660 acgcatgccc cggctcatgg cgaagtcggc ctcgaagacc tccgtcgccc cggccaccgt 720 ctcgtacacc agggcctcaa gtccggtacc gaactcgccg tacggccggg cgagccagga 780 gggggacgcg gccaggctcg cgcggagctc ggcgaaggtg gcgccggtga ccgggagacg 840 ctcgctcagc agggcggcga gctccgcctc gcgctgctgc gacttctccc cgtacggacc 900 ggccaggcgc tcgatcttgt gcatcagcgc gccgtggatc tcgcggtaga gctgggcgtt 960 ggggatgaca tggcccatgc ggcgctcgcg cagcgccatg gcgagggcgt tcagcgcctc 1020 gacgcggtgc gtgggagcgg gcgggacgag ctcgccgccg gggaccgcgt tgtagttgcc 1080 gcgggtgcgc tccagcatgt acgcgatgtg atccagcgtc agctgggtgc cgttggcctc 1140 ctcgatgcgc ccggcgcccg cggagcgcac cagcagcgtg aggcagacga ccatcaccgc 1200 gtcgtggtcc gaccactgct ccatggagac gcccatcaga cggctgaacg tctcgttggg 1260 gtggcccgcc cacagcgtct tgccgatgac gttgttggtc tcgcggaagt tggtgtagag 1320 cttcccctcc tggtgcagca cgaagggggc ggtccgcagc gcggactccc gcagcatctc 1380 caggagttcg tcacgggcct gggtgccgag cgccgccagc cactggcggc agtcgacgac 1440 ctggtcggcg aagcgggcgg ccgcgcggtc gacctcgctc tcgtagtcga gcaggtcctg 1500 cgccgaccac ggcacgctca tgacgccctc gaccagcttc tcctcgtcct ccaacggccc 1560 ctgcgagggc acgcggacga cgatgcggcc ggtcgtggtc aggcccagct cgccgaggaa 1620 cgcggggcgc tccttgacgt cgcgcacggg cgtcggcagg ttctcctcgc gccacgagat 1680 gccgcagagc accttgagcg cggcctcgtc ggcggtgcgc agggcgcgca gctggacctc 1740 ggcggggacg tggccgtcca gggtgagcag ggcgttcacc gcgccgcgca ggtccggggc 1800 cgcggtcgcg cgctcccagg cgcgcttgag cagagtgggg aaaccggcct cctcgtcttt 1860 gaggcggtcc ggcttcggcg tggccccggc caccgcgccc tggcggctcg gccggcggct 1920 ctgccgcttc ttggcgttga tggcccggcg ggaggtgccg ttgcgctcgg cggaacttgt 1980 catgacacac cctcagcggt aagcccgatg tgcttccaca tctcgtcggt cgtgggcgtc 2040 cagtcctcgt cgacgtag 2058 61 685 PRT Streptomyces murayamaensis ATCC 21414 61 Met Ser Pro Met Asp Ala Glu Val Asn Gly Ala Ala Pro Arg Gln Asn 1 5 10 15 Gly Val Gly Arg Arg Ser Arg Asp Leu Leu Arg Leu Leu Gly Ala Arg 20 25 30 Arg Arg Gly Leu Asp Arg Leu Glu Val Pro Leu Gly Val Glu Gly Gly 35 40 45 Asp Leu Asp Leu Leu Ala Arg Gly His Gln Arg Gly Gly Gly Ala His 50 55 60 Gly Ala Gly Asp Glu Pro Arg Gly Ala Val Arg Gly Glu Gln Val Gly 65 70 75 80 Leu Val Glu Arg Gly Ala Val Ala Ala Gln Gln Thr Gln Val His Glu 85 90 95 Pro Val Glu Pro Leu Ala Gln His Leu Asp Arg Leu Arg Ala Ala Asp 100 105 110 Ala Glu Pro His Leu Arg Arg His Met Ala Val Val Val Leu Val Gly 115 120 125 Val Glu Gly Asp Val Gly Asp Gly Arg Arg Asp Glu Val Val Ala Leu 130 135 140 His His Gly Gly His Leu Gly Gln Val Pro Gly Asp Glu Val Pro Gly 145 150 155 160 Val Val Leu His Ala Gly Arg His Arg Pro Gly Val Val Gly Gln Leu 165 170 175 Gln His Arg Val Leu Val Val Ala Leu Gly Arg Arg Gly Gly His His 180 185 190 Ala Ala Glu Glu Val Gly Asp Val Pro Leu Gly Asp Leu Gly Val Ala 195 200 205 Leu Leu Pro Gln Gly Ala His Gln Phe Gly Asp Arg Thr His Ala Pro 210 215 220 Ala His Gly Glu Val Gly Leu Glu Asp Leu Arg Arg Pro Gly His Arg 225 230 235 240 Leu Val His Gln Gly Leu Lys Ser Gly Thr Glu Leu Ala Val Arg Pro 245 250 255 Gly Glu Pro Gly Gly Gly Arg Gly Gln Ala Arg Ala Glu Leu Gly Glu 260 265 270 Gly Gly Ala Gly Asp Arg Glu Thr Leu Ala Gln Gln Gly Gly Glu Leu 275 280 285 Arg Leu Ala Leu Leu Arg Leu Leu Pro Val Arg Thr Gly Gln Ala Leu 290 295 300 Asp Leu Val His Gln Arg Ala Val Asp Leu Ala Val Glu Leu Gly Val 305 310 315 320 Gly Asp Asp Met Ala His Ala Ala Leu Ala Gln Arg His Gly Glu Gly 325 330 335 Val Gln Arg Leu Asp Ala Val Arg Gly Ser Gly Arg Asp Glu Leu Ala 340 345 350 Ala Gly Asp Arg Val Val Val Ala Ala Gly Ala Leu Gln His Val Arg 355 360 365 Asp Val Ile Gln Arg Gln Leu Gly Ala Val Gly Leu Leu Asp Ala Pro 370 375 380 Gly Ala Arg Gly Ala His Gln Gln Arg Glu Ala Asp Asp His His Arg 385 390 395 400 Val Val Val Arg Pro Leu Leu His Gly Asp Ala His Gln Thr Ala Glu 405 410 415 Arg Leu Val Gly Val Ala Arg Pro Gln Arg Leu Ala Asp Asp Val Val 420 425 430 Gly Leu Ala Glu Val Gly Val Glu Leu Pro Leu Leu Val Gln His Glu 435 440 445 Gly Gly Gly Pro Gln Arg Gly Leu Pro Gln His Leu Gln Glu Phe Val 450 455 460 Thr Gly Leu Gly Ala Glu Arg Arg Gln Pro Leu Ala Ala Val Asp Asp 465 470 475 480 Leu Val Gly Glu Ala Gly Gly Arg Ala Val Asp Leu Ala Leu Val Val 485 490 495 Glu Gln Val Leu Arg Arg Pro Arg His Ala His Asp Ala Leu Asp Gln 500 505 510 Leu Leu Leu Val Leu Gln Arg Pro Leu Arg Gly His Ala Asp Asp Asp 515 520 525 Ala Ala Gly Arg Gly Gln Ala Gln Leu Ala Glu Glu Arg Gly Ala Leu 530 535 540 Leu Asp Val Ala His Gly Arg Arg Gln Val Leu Leu Ala Pro Arg Asp 545 550 555 560 Ala Ala Glu His Leu Glu Arg Gly Leu Val Gly Gly Ala Gln Gly Ala 565 570 575 Gln Leu Asp Leu Gly Gly Asp Val Ala Val Gln Gly Glu Gln Gly Val 580 585 590 His Arg Ala Ala Gln Val Arg Gly Arg Gly Arg Ala Leu Pro Gly Ala 595 600 605 Leu Glu Gln Ser Gly Glu Thr Gly Leu Leu Val Phe Glu Ala Val Arg 610 615 620 Leu Arg Arg Gly Pro Gly His Arg Ala Leu Ala Ala Arg Pro Ala Ala 625 630 635 640 Leu Pro Leu Leu Gly Val Asp Gly Pro Ala Gly Gly Ala Val Ala Leu 645 650 655 Gly Gly Thr Cys His Asp Thr Pro Ser Ala Val Ser Pro Met Cys Phe 660 665 670 His Ile Ser Ser Val Val Gly Val Gln Ser Ser Ser Thr 675 680 685 62 402 DNA Streptomyces murayamaensis ATCC 21414 62 atgctctctt accgtggcac gagcgaaaca ggacaagagg ggggccgaat gcccacgaac 60 acttcggacg actcgctgga cgagacagtg gaaggctcgg tgtccgggcg cgacaagctg 120 atcgccgagc ggacccgcag cgaaacgtgg aagaagccgc cacgccgtat cgagcgcgcg 180 gagtgcatca cctgcgacac ctgcctgcgt gcctgcccgc ccgagttcaa cgcgatcttc 240 gacaacggac tcgacgtcgt catcatcccc gaactgtgct ccggctgccc caagtgcgtc 300 ctggagtgcc cggtcgactg catctacgtc gacgaggact ggacgcccac gaccgacgag 360 atgtggaagc acatcgggct taccgctgag ggtgtgtcat ga 402 63 133 PRT Streptomyces murayamaensis ATCC 21414 63 Met Leu Ser Tyr Arg Gly Thr Ser Glu Thr Gly Gln Glu Gly Gly Arg 1 5 10 15 Met Pro Thr Asn Thr Ser Asp Asp Ser Leu Asp Glu Thr Val Glu Gly 20 25 30 Ser Val Ser Gly Arg Asp Lys Leu Ile Ala Glu Arg Thr Arg Ser Glu 35 40 45 Thr Trp Lys Lys Pro Pro Arg Arg Ile Glu Arg Ala Glu Cys Ile Thr 50 55 60 Cys Asp Thr Cys Leu Arg Ala Cys Pro Pro Glu Phe Asn Ala Ile Phe 65 70 75 80 Asp Asn Gly Leu Asp Val Val Ile Ile Pro Glu Leu Cys Ser Gly Cys 85 90 95 Pro Lys Cys Val Leu Glu Cys Pro Val Asp Cys Ile Tyr Val Asp Glu 100 105 110 Asp Trp Thr Pro Thr Thr Asp Glu Met Trp Lys His Ile Gly Leu Thr 115 120 125 Ala Glu Gly Val Ser 130 64 642 DNA Streptomyces murayamaensis ATCC 21414 64 ttggatctgg ccgacccggt cccggccgaa ctggccgcca aactcgcctc gatgggcccc 60 gcgcacgagg aggtgctggc ggactcggtg ggcctcgccc tccttgtcgt cctggagacg 120 ctggacccgg ccgagcggat ggcgttcgtc ctgcacgatc tgttcggcct cccctatgac 180 gaggtggcgc cgatcgtggg gaccggcgcc gaggaggcgt gcgagctggc cgaccgggcc 240 cgggcgcggg tgcggcgggt cgatccgctg ccggacgacg gtacgacgcg gctgcgccgg 300 atcgtcgacg cgttcctgac cgcctcgcgc ggcggcgact tcgccaccct gaccgcgctg 360 ctcgccccgg acgtggtgct ccgcgccgac ccggaggcgg tggcggtggg ggcgccgacg 420 gaggtgcggg gcgcgggctc ggtggcggac gcgttctcgg ggcgcgccaa gtacgccaag 480 ctggcgctgg tcgacggcgt cgtcggggcg gtgtgggcgc cgcgcgggcg gccgagggtc 540 gtcttcgggt tcaccgtcgt ggacgagaag atcaccggga tcgacatgcg ggccgcgccc 600 gagcggctgg accggctcga tctgacgatc ctgaacgact ga 642 65 213 PRT Streptomyces murayamaensis ATCC 21414 65 Met Asp Leu Ala Asp Pro Val Pro Ala Glu Leu Ala Ala Lys Leu Ala 1 5 10 15 Ser Met Gly Pro Ala His Glu Glu Val Leu Ala Asp Ser Val Gly Leu 20 25 30 Ala Leu Leu Val Val Leu Glu Thr Leu Asp Pro Ala Glu Arg Met Ala 35 40 45 Phe Val Leu His Asp Leu Phe Gly Leu Pro Tyr Asp Glu Val Ala Pro 50 55 60 Ile Val Gly Thr Gly Ala Glu Glu Ala Cys Glu Leu Ala Asp Arg Ala 65 70 75 80 Arg Ala Arg Val Arg Arg Val Asp Pro Leu Pro Asp Asp Gly Thr Thr 85 90 95 Arg Leu Arg Arg Ile Val Asp Ala Phe Leu Thr Ala Ser Arg Gly Gly 100 105 110 Asp Phe Ala Thr Leu Thr Ala Leu Leu Ala Pro Asp Val Val Leu Arg 115 120 125 Ala Asp Pro Glu Ala Val Ala Val Gly Ala Pro Thr Glu Val Arg Gly 130 135 140 Ala Gly Ser Val Ala Asp Ala Phe Ser Gly Arg Ala Lys Tyr Ala Lys 145 150 155 160 Leu Ala Leu Val Asp Gly Val Val Gly Ala Val Trp Ala Pro Arg Gly 165 170 175 Arg Pro Arg Val Val Phe Gly Phe Thr Val Val Asp Glu Lys Ile Thr 180 185 190 Gly Ile Asp Met Arg Ala Ala Pro Glu Arg Leu Asp Arg Leu Asp Leu 195 200 205 Thr Ile Leu Asn Asp 210 

What is claimed is:
 1. An isolated polyketide, wherein the polyketide comprises a kinamycin comprising least one saccharide moiety.
 2. The polyketide of claim 1, wherein the saccharide comprises a polysaccharide.
 3. The polyketide of claim 1, wherein the saccharide comprises a 2, 6 dideoxysugar.
 4. The polyketide of claim 3, wherein the 2, 6 dideoxysugar comprises a digitose.
 5. The polyketide of claim 4, wherein the digitose comprises an L-digitose.
 6. The polyketide of claim 1, wherein the saccharide comprises an olivose.
 7. The polyketide of claim 1, wherein the saccharide comprises a lactose, a galactose, a glucose or a fructose.
 8. The polyketide of claim 1, wherein the polyketide comprises a type II polyketide.
 9. The polyketide of claim 8, wherein the type II polyketide comprises a kinamycin.
 10. The polyketide of claim 9, wherein the kinamycin comprises an aglycone kinamycin.
 11. An isolated kinamycin molecule, wherein the kinamycin molecule comprises at least one saccharide moiety.
 12. A pharmaceutical composition comprising a polyketide, wherein the polyketide comprises a kinamycin comprising at least one saccharide moiety, and a pharmaceutically acceptable carrier.
 13. A pharmaceutical composition comprising a kinamycin, wherein the kinamycin comprises at least one saccharide moiety, and a pharmaceutically acceptable carrier.
 14. The pharmaceutical composition of claim 12 or claim 13, wherein the pharmaceutically acceptable carrier comprises a solid or a liquid.
 15. The pharmaceutical composition of claim 12 or claim 13, wherein the saccharide comprises a polysaccharide.
 16. The pharmaceutical composition of claim 12 or claim 13, wherein the saccharide comprises a 2, 6 dideoxysugar.
 17. The pharmaceutical composition of claim 16, wherein the 2, 6 dideoxysugar comprises a digitose.
 18. The pharmaceutical composition of claim 17, wherein the digitose comprises an L-digitose.
 19. The pharmaceutical composition of claim 12 or claim 13, wherein the saccharide comprises an olivose.
 20. The pharmaceutical composition of claim 12 or claim 13, wherein the polyketide comprises a type II polyketide.
 21. The pharmaceutical composition of claim 13, wherein the kinamycin is an aglycone kinamycin.
 22. A polyketide comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated polyketide comprising a glycosylated kinamycin.
 23. The polyketide of claim 22, further comprising isolating the glycosylated kinamycin.
 24. The polyketide of claim 22, wherein the polyketide comprises a type II polyketide.
 25. The polyketide of claim 22, wherein the glycosylation comprises a saccharide.
 26. The polyketide of claim 25, wherein the saccharide further comprises a polysaccharide.
 27. The polyketide of claim 25, wherein the saccharide comprises a 2, 6 dideoxysugar.
 28. The polyketide of claim 26, wherein the 2, 6 dideoxysugar comprises a digitose.
 29. The polyketide of claim 28, wherein the digitose comprises an L-digitose.
 30. The polyketide of claim 25, wherein the saccharide comprises an olivose.
 31. The polyketide of claim 25, wherein the saccharide comprises a lactose, a galactose, a glucose or a fructose.
 32. The polyketide of claim 22, wherein the kinamycin is an aglycone kinamycin.
 33. The polyketide of claim 22, wherein the Streptococcus sp. of step (b) is selected from the group consisting of S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus and S. violaceoruber.
 34. The polyketide of claim 22, wherein the Dactylosporangium sp. of step (b) is a Dactylosporangium sp. ATCC
 53693. 35. An isolated glycosylated kinamycin made by a process comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin.
 36. A method for making a composition comprising a glycosylated kinamycin comprising the following steps: (a) providing a nucleic acid comprising a Streptococcus murayamaensis nucleic acid sequence comprising an insert deposited as ATCC accession no. ______; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; (c) inserting the nucleic acid into the Streptococcus sp. of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin.
 37. The method of claim 36, further comprising isolating the glycosylated kinamycin.
 38. The method of claim 36, wherein the polyketide comprises a type II polyketide.
 39. The method of claim 36, wherein the glycosylation comprises a saccharide.
 40. The method of claim 39, wherein the saccharide further comprises a polysaccharide.
 41. The method of claim 39, wherein the saccharide comprises a 2, 6 dideoxysugar.
 42. The method of claim 41, wherein the 2, 6 dideoxysugar comprises a digitose.
 43. The method of claim 42, wherein the digitose comprises an L-digitose.
 44. The method of claim 39, wherein the saccharide comprises an olivose.
 45. The method of claim 39, wherein the saccharide comprises a lactose, a galactose, a glucose or a fructose.
 46. The method of claim 36, wherein the kinamycin is an aglycone kinamycin.
 47. The method of claim 36, wherein the Streptococcus sp. of step (b) is selected from the group consisting of S. peuceticus, S. griseus, S. peuceticus var. caesius, S. nogalater, S. galilaeus, S. argillaceus, S. atroolivaceus, S. olivoreticuli, S. cyanogenus, S. globisporus, S. fradiae, Actinomadura hibisca, S. olivaceus and S. violaceoruber.
 48. The method of claim 36, wherein the Dactylosporangium sp. of step (b) is a Dactylosporangium sp. ATCC
 53693. 49. An isolated composition comprising a compound having a general formula as set forth as DS2 in FIG.
 3. 50. An isolated composition comprising a compound having a general formula as set forth as DS1a in FIG.
 3. 51. The isolated composition of claim 48 or claim 49, further comprising a saccharide.
 52. The isolated composition of claim 51, wherein the saccharide comprises a 2, 6 dideoxysugar.
 53. The method of claim 52, wherein the 2, 6 dideoxysugar comprises a digitose.
 54. The method of claim 53, wherein the digitose comprises an L-digitose.
 55. The method of claim 51, wherein the saccharide comprises an olivose.
 56. The method of claim 51, wherein the saccharide comprises a lactose, a galactose, a glucose or a fructose.
 57. An isolated composition comprising a compound having a general formula as set forth as DS1 in FIG.
 3. 58. An isolated or recombinant nucleic acid comprising a nucleic acid sequence having 95% sequence identity to SEQ ID NO:1, wherein the nucleic acid, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus.
 59. An isolated or recombinant nucleic acid comprising a nucleic acid sequence having a sequence as set forth in SEQ ID NO:1, wherein the nucleic acid, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus.
 60. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:2, wherein the sequence identity is at least 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:2; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:2; or (d) encoding a polypeptide as set forth in SEQ ID NO:3.
 61. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:3, wherein the sequence identity is at least 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:3; or (c) encoded by a nucleic acid as set forth in claim
 60. 62. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:4, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:4; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:4; or (d) encoding a polypeptide as set forth in SEQ ID NO:5.
 63. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:5, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:5; or (c) encoded by a nucleic acid as set forth in claim
 62. 64. An isolated or recombinant nucleic acid comprising-a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:6, wherein the sequence identity is at least 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:6; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:6; or (d) encoding a polypeptide as set forth in SEQ ID NO:7.
 65. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:7, wherein the sequence identity is at least 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:7; or (c) encoded by a nucleic acid as set forth in claim
 64. 66. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:8, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:8; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:8; or (d) encoding a polypeptide as set forth in SEQ ID NO:9.
 67. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:9, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:9; or (c) encoded by a nucleic acid as set forth in claim
 66. 68. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:10, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:10; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:10; or (d) encoding a polypeptide as set forth in SEQ ID NO:11.
 69. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:11, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:11; or (c) encoded by a nucleic acid as set forth in claim
 68. 70. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:12, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:12; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:12; or (d) encoding a polypeptide as set forth in SEQ ID NO:13.
 71. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:13, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:13; or (c) encoded by a nucleic acid as set forth in claim
 70. 72. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:14, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:14; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:14; or (d) encoding a polypeptide as set forth in SEQ ID NO:15.
 73. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:15, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:15; or (c) encoded by a nucleic acid as set forth in claim
 72. 74. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:16, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:16; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:16; or (d) encoding a polypeptide as set forth in SEQ ID NO:17.
 75. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:17, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:17; or (c) encoded by a nucleic acid as set forth in claim
 74. 76. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:18, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:18; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:18; or (d) encoding a polypeptide as set forth in SEQ ID NO:19.
 77. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:19, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:19; or (c) encoded by a nucleic acid as set forth in claim
 76. 78. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:20, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:20; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:20; or (d) encoding a polypeptide as set forth in SEQ ID NO:21.
 79. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:21, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:21; or (c) encoded by a nucleic acid as set forth in claim
 78. 80. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:22, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:22; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:22; or (d) encoding a polypeptide as set forth in SEQ ID NO:23.
 81. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:23, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%, and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:23; or (c) encoded by a nucleic acid as set forth in claim
 80. 82. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:24, wherein the sequence identity is at least 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:24; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:24; or (d) encoding a polypeptide as set forth in SEQ ID NO:25.
 83. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:25, wherein the sequence identity is at least 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:25; or (c) encoded by a nucleic acid as set forth in claim
 82. 84. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:26, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:26; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:26; or (d) encoding a polypeptide as set forth in SEQ ID NO:27.
 85. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:27, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:27; or (c) encoded by a nucleic acid as set forth in claim
 84. 86. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:28, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:28; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:28; or (d) encoding a polypeptide as set forth in SEQ ID NO:29.
 87. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:29, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:29; or (c) encoded by a nucleic acid as set forth in claim
 86. 88. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:30, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:30; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:30; or (d) encoding a polypeptide as set forth in SEQ ID NO:31.
 89. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:31, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:31; or (c) encoded by a nucleic acid as set forth in claim
 88. 90. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:32, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:32; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:32; or (d) encoding a polypeptide as set forth in SEQ ID NO:33.
 91. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:33, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:33; or (c) encoded by a nucleic acid as set forth in claim
 90. 92. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:34, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:34; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:34; or (d) encoding a polypeptide as set forth in SEQ ID NO:35.
 93. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:35, wherein the sequence identity is at least 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:35; or (c) encoded by a nucleic acid as set forth in claim
 92. 94. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:36, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:36; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:36; or (d) encoding a polypeptide as set forth in SEQ ID NO:37.
 95. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:37, wherein the sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:37; or (c) encoded by a nucleic acid as set forth in claim
 94. 96. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:38, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:38; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:38; or (d) encoding a polypeptide as set forth in SEQ ID NO:39.
 97. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:39, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:39; or (c) encoded by a nucleic acid as set forth in claim
 96. 98. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:40, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:40; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:40; or (d) encoding a polypeptide as set forth in SEQ ID NO:41.
 99. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:41, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:41; or (c) encoded by a nucleic acid as set forth in claim
 98. 100. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:42, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:42; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:42; or (d) encoding a polypeptide as set forth in SEQ ID NO:43.
 101. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:43, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:43; or (c) encoded by a nucleic acid as set forth in claim
 100. 102. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:44, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:44; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:44; or (d) encoding a polypeptide as set forth in SEQ ID NO:45.
 103. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:45, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:45; or (c) encoded by a nucleic acid as set forth in claim
 102. 104. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:46, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:46; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:46; or (d) encoding a polypeptide as set forth in SEQ ID NO:47.
 105. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:47, wherein the sequence identity is at least 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:47; or (c) encoded by a nucleic acid as set forth in claim
 104. 106. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:48, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:48; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:48; or (d) encoding a polypeptide as set forth in SEQ ID NO:49.
 107. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:49, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:49; or (c) encoded by a nucleic acid as set forth in claim
 106. 108. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:50, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:50; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:50; or (d) encoding a polypeptide as set forth in SEQ ID NO:51.
 109. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:51, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:51; or (c) encoded by a nucleic acid as set forth in claim
 108. 110. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:52, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:52; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:52; or (d) encoding a polypeptide as set forth in SEQ ID NO:53.
 111. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:53, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:53; or (c) encoded by a nucleic acid as set forth in claim
 110. 112. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:54, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:54; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:54; or (d) encoding a polypeptide as set forth in SEQ ID NO:55.
 113. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:55, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:55; or (c) encoded by a nucleic acid as set forth in claim
 112. 114. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:56, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:56; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:56; or (d) encoding a polypeptide as set forth in SEQ ID NO:57.
 115. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:57, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:57; or (c) encoded by a nucleic acid as set forth in claim
 114. 116. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:58, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:58; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:58; or (d) encoding a polypeptide as set forth in SEQ ID NO:59.
 117. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:59, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:59; or (c) encoded by a nucleic acid as set forth in claim
 116. 118. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:60, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:60; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:60; or (d) encoding a polypeptide as set forth in SEQ ID NO:61.
 119. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:61, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:61; or (c) encoded by a nucleic acid as set forth in claim
 118. 120. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:62, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:62; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:62; or (d) encoding a polypeptide as set forth in SEQ ID NO:63.
 121. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:63, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:63; or (c) encoded by a nucleic acid as set forth in claim
 120. 122. An isolated or recombinant nucleic acid comprising a nucleic acid sequence (a) having a sequence identity to SEQ ID NO:64, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:64; (c) that hybridizes under stringent conditions to a sequence comprising SEQ ID NO:64; or (d) encoding a polypeptide as set forth in SEQ ID NO:65.
 123. An isolated or recombinant polypeptide comprising a sequence (a) having a sequence identity to SEQ ID NO:65, wherein the sequence identity is at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% and the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (b) having a sequence as set forth in SEQ ID NO:65; or (c) encoded by a nucleic acid as set forth in claim
 122. 124. A polyketide comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a plurality of nucleic acid coding sequences, wherein the nucleic acid coding sequences have at least 95% sequence identity to SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO: 26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO: 48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62 and SEQ ID NO:64, wherein the plurality of nucleic acid coding sequences, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated polyketide comprising a glycosylated kinamycin.
 125. A method for making a glycosylated kinamycin comprising the following steps: (a) providing a plurality of nucleic acid coding sequences, wherein the nucleic acid coding sequences have at least 95% sequence identity to SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO: 26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO: 48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62 and SEQ ID NO:64, wherein the plurality of nucleic acid coding sequences, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the nucleic acid into the bacillus of step (b) or contacting the nucleic acid with the intracellular extract of step (b) under conditions wherein the nucleic acid is transcribed into transcription products and the transcription products are translated into polypeptides, thereby making a glycosylated kinamycin.
 126. A polyketide comprising a glycosylated kinamycin made by a process comprising the following steps: (a) providing a plurality of polypeptides, wherein the polypeptide sequences have at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO: 31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO: 53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63 and SEQ ID NO:65, wherein the plurality of polypeptides, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the polypeptides of step (a) into the bacillus of step (b) or contacting the polypeptides of step (a) with the intracellular extract of step (b) under conditions allowing synthesis of a glycosylated kinamycin.
 127. A method for making a glycosylated kinamycin comprising the following steps: (a) providing a plurality of polypeptides, wherein the polypeptide sequences have at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO: 31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO: 53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63 and SEQ ID NO:65, wherein the plurality of polypeptides, when expressed in a Streptococcus, results in the synthesis of a kinamycin molecule in the Streptococcus; (b) providing (i) a Streptococcus sp. or a Dactylosporangium sp. bacillus, or (ii) an intracellular extract of a Streptococcus sp. or a Dactylosporangium sp.; and (c) inserting the polypeptides of step (a) into the bacillus of step (b) or contacting the polypeptides of step (a) with the intracellular extract of step (b) under conditions allowing synthesis of a glycosylated kinamycin.
 128. An isolated or recombinant antibody capable of specifically binding to a polypeptide, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO: 13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO: 35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO: 57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63 and SEQ ID NO:65. 